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ABSTRACT 
Granulocyte macrophage colony stimulating factor (GM-CSF) is a potent regulator of 
haemopoiesis and is vital for immune function. GM-CSF is rapidly, but transiently activated 
in response to T cell activating signals. It is now well established that activation of the GM-
CSF gene in T cells is accompanied by distinct changes in chromatin structure across the 
promoter region. The aim of this thesis was to investigate these chromatin remodelling events 
and their association with gene transcription. 
Analysis of GM-CSF promoter accessibility and transcription in response to various 
pharmacological stimulations demonstrated that the processes of transcription and promoter 
chromatin remodelling were distinct, with each requiring different factors and signals. While 
chromatin remodelling was found to be dependent on factors activated downstream of PKC 
signalling, transcription required both PKC and calcium signalling pathways. Nuclear 
activation of the NF-KB transcription factor, c-Rel was strongly correlated with chromatin 
remodelling events. In contrast NFAT transcription factors were demonstrated to be required 
for GM-CSF transcription but not chromatin remodelling. In addition, remodelling of the 
GM-CSF promoter was found to be relatively stable in contrast to the more transient profile 
observed for transcription. 
The ATPase component of the SWI/SNF chromatin remodelling complex has 
previously been shown to associate with the GM-CSF promoter in vitro. To determine 
whether Brgl was involved in activation of the GM-CSF gene in vivo, T cells were 
transfected with an ATPase defective Brgl mutant construct. Analysis of these cells 
demonstrated that efficient activation of the GM-CSF gene is dependent on Brgl. 
Surprisingly, chromatin immunoprecipitation experiments revealed that Brgl is bound to the 
GM-CSF promoter in resting T cells and is depleted concomitant with chromatin 
remodelling. These data lead to the hypothesis that Brgl is involved in forming a basal 
chromatin state that is transcriptionally competent. In support of this, Brgl is not bound to 
the GM-CSF promoter in B cells, which do not express GM-CSF. However a competent 
chromatin environment can be created in these cells by increasing histone acetylation levels. 
Data presented here are consistent with a model in which the basal state of the GM-CSF 
promoter is maintained in a transcriptionally competent state in resting T cells via histone 
acetylation and Brg I recruitment. Such a chromatin environment may ensure that GM-CSF 
can be activated rapidly in response to T cell activation signals. Microarray analysis was 
subsequently used to identify genes which may be similarly poised to respond to T cell 
XIII 
activation signals by the constitutive recruitment of Brgl. A number of cytokine genes were 
identified as Brgl targets. One of these, Interferon gamma (IFNy) was found to share a 
similar activation profile to GM-CSF and data presented here suggests it may be regulated by 
a common mechanism. As observed for GM-CSF, Brgl is constitutively poised at the WNy 
promoter in resting EL-4 T cells and lost from the promoter concomitant with gene 
activation. 
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CHAPTER 1. 
INTRODUCTION 
1.1 IMMUNE GENE REGULATION 
The immune system is a complex network of cells, tissues and organs which 
provide host defense against invading pathogens. Capable of providing remarkable 
surveillance, the immune system helps to fight bacterial and viral infections and eradicate 
cancerous body cells. The innate immune system includes cells which provide the initial 
line of defense against infection and helps to detect and eliminate invading pathogens 
before infection can take hold. Adaptive immunity occurs once immune cells gain the 
ability to recognize a pathogen and allows the immune system to mount an even stronger 
attack. The primary response to infection is inflammation which results in chemokine 
mediated recruitment of innate immune cells to the site of injury or infection (reviewed in 
Schluger and Rom, 1997). These cells move from capillaries into infected tissue to 
scavenge bacteria and cellular debris and help to prevent the spread of infection. A range of 
cell types derived from myeloid and lymphoid lineages help to mediate the immune 
response including T cells, B cells, macrophages, neutrophils, mast cells, granulocytic and 
dendritic cells. Helper T cells, also known as CD4 positive (CD4+) T cells, aid in both 
cellular and humoral immunity. They help to trigger antibody production by B cells and 
activate other T cells and macrophages. CD8 positive (CD8+) T cells, also known as 
cytotoxic T cells, can differentiate into killer T cells which attack and destroy infected 
cells. Infection stimulates the differentiation and proliferation of immune cells by 
triggering changes in gene expression programs and cytokine profiles. The swift responses 
characteristic of the immune system, rely on the rapid and co-ordinate activation and 
silencing of various genes (reviewed in Holloway et al, 2002). The activation of these 
immune genes helps to protect the organism from disease, however when the regulation of 
these genes is compromised, the ability to defend against infection and disease is 
weakened. Therefore, understanding the precise mechanisms underlying immune gene 
regulation is vital. 
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1.1.1 T CELL ACTIVATION 
T cell activation plays a central role in cell mediated immunity. During infection, 
antigens are taken up by antigen presenting cells (APCs) which process and present them to 
T cells. APCs (including macrophages, B cells and dendritic cells) present the processed 
antigen bound to major histocompatibility complex (MFIC) antigens. These self-antigens 
aid T cells in the recognition of foreign antigens (reviewed in Stefanova et al, 2003). T cell 
activation is a complex process requiring two signals, which are occupancy of the T cell 
receptor (TCR) and interaction with costimulatory ligands on the APC. When a T cell 
comes in contact with an APC, the TCR is stimulated along with the co-stimulatory 
molecule. The TCR recognises and binds to antigen fragments presented together with 
MHC molecules (reviewed in van der Merwe and Davis, 2003). The second signal is 
provided by stimulation of the costimulatory molecule which augments TCR activation. 
The main costimulatory molecules are CD2, LFA-1 and CD28 which bind the LFA-3, 
ICAM-1 and B7 ligands respectively (reviewed in Wingren et al, 1995). A specialized 
junction formed between the APC and T cell is stabilized by costimulators and helps to 
sustain and amplify signalling from the TCR (reviewed in Acuto and Cantrell, 2000). 
T cell stimulation triggers an intracellular cascade of signalling which leads to the 
nuclear translocation of numerous transcriptional activators required for activating immune 
genes. TCR activation and stimulation of the costimulatory molecule initiate signalling 
cascades by activating protein tyrosine kinases (reviewed in Acuto and Cantrell, 2000). The 
tyrosine kinases regulate the metabolism of inositol phospholipids via the Ras and Rho 
family of GTPases. Changes in inositol phospholipid metabolism directly influence 
calcium levels and the activity of numerous serine/threonine lcinases including PKC and 
phosphatidyl inosito1-3 kinase (PI3K). The TCR controls the production of inositol 1, 4, 5 
triphosphate (IP3) and diacylglycerol (DAG) through the hydrolysis of phosphatidylinositol 
(4, 5) biphosphate (PIP2) (reviewed in Gupta, 1989). Therefore these tyrosine kinases help 
to regulate the intracellular levels of calcium and the activity of protein kinase C (PKC; 
Figure 1.1) which plays a significant role in immune responses (reviewed in Tan and 
Parker, 2003). These signalling cascades ultimately result in the activation of an array of 
cytokine genes which help trigger the proliferation and differentiation of cells required for 
an immune response. 
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Figure 1.1. Overview of the signalling pathways leading to cytokine gene 
expression following TCR ligation and CD28 stimulation. 
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1.1.2 CYTOKINES 
Activated T cells produce an array of cytokines which relay signals between cells 
within the immune system. These small protein hormones play an important role in the 
development of the immune system and the immune response. The types of cytokines 
produced depend on the cell type, stimulus and the environment and can enhance or inhibit 
cellular functions such as cell growth and differentiation (Lotem et al, 1991; Gasson, 
1991). Most cytokines act locally in a paracrine manner and stimulate the proliferation of 
progenitor blood cells in the bone marrow. Cytokine expression is controlled primarily at 
the level of transcription. The genes encoding cytokines are often highly inducible and are 
rapidly switched on and off during an immune response. Cytolcine genes are often silent or 
expressed at very low levels in resting cells, however following immune stimulation, 
expression is induced to high levels for a short period of time following which levels return 
to basal (reviewed in Holloway et al, 2002). 
Cytokine gene expression is restricted to particular cell types and often only 
expressed following exposure to a specific set of signals. While some cytokines are widely 
expressed across a range of cell types, certain cytokines are restricted to a single cell type. 
Restricted cytokine expression profiles are observed in differentiated Th 1 and Th2 cells. 
Naïve T cells are capable of differentiating into two distinct subtypes, Th 1 and Th2 cells 
which are characterized by distinct patterns of cytokine gene expression. Thl cells produce 
IFN-y and are involved in protecting against intracellular bacterial and viral infections. Th2 
cells express IL-4, IL-5 and IL-13 to fight extracellular parasites. The types of cytokines 
produced therefore depend on the stimulus. 
1.2 	GRANULOCYTE-MACROPHAGE 	COLONY- 
STIMULATING FACTOR (GM-CSF) 
Granulocyte-macrophage colony-stimulating factor (GM-CSF or CSF2) is a 22 lcDa 
glycoprotein consisting of 127 amino acids derived from a 144 amino acid precursor. It was 
first purified from mouse lung conditioned medium almost 30 years ago (Burgess et al, 
1977) and identified as a factor which could stimulate cell proliferation from immature 
bone-marrow derived progenitors (reviewed in Gasson, 1991). GM-CSF is a cytokine 
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involved in regulating the differentiation, maturation and survival of inflammatory cells. It 
plays a role in host defense and homeostatic maintenance of myelopoiesis. Compared to 
other cytokines, GM-CSF is relatively widely expressed. Following immune stimulation a 
wide range of cell types including Th 1 and Th2 cells, macrophages, fibroblasts and 
endothelial cells secrete GM-CSF (reviewed in Gasson et al, 1990). Specific high affinity 
receptors are found on the surface of target cells which include multipotential haemopoietic 
stem cells, mature neutrophils, monocytes and macrophages. The major progeny of 
haemopoietic progenitor cells stimulated by GM-CSF are granulocytes and macrophages. 
In vitro research has shown that GM-CSF stimulates the growth and differentiation of GM 
lineage cells from bone marrow progenitor cells (Burgess et al, 1977). In vivo studies 
indicate that GM-CSF is predominantly involved in the recruitment and activation of 
myeloid lineage cells at sites of inflammation (Mock and English, 1990). 
The role of GM-CSF in immune regulation has been highlighted by studies 
involving GM-CSF knockout mice. While the GM-CSF/- mouse is viable with no 
abnormalities in haemopoiesis for up to 12 weeks, lung development is abnormal as is the 
accumulation of surfactant and protein in the alveolar spaces, suggesting that GM-CSF has 
a role in pulmonary homeostasis (Stanley et al, 1994). In addition the response to infection 
is significantly reduced in GM-CSF deficient mice demonstrating that this cytokine is 
critical for proper immune function (Lieschke et al, 1994; Zhan et al, 1998). Transgenic 
mice overexpressing GM-CSF have enlarged livers and spleens and increased numbers of 
macrophages and granulocytes (Burke et al, 2004) providing further evidence of a role for 
GM-CSF in regulating haemopoesis. 
Aberrant expression of GM-CSF has been linked to a number of disease states 
including asthma (Stanley et al, 1994), atopy (Cousins et al, 1996), rheumatoid arthritis 
(Campbell et al, 1997) and myeloid leukemias (Young et al, 1987). Myeloid leukemias are 
clonal neoplasms of the granulocyte-macrophage precursor cells. This type of leukemia is 
thought to arise from the over-expression of GM-CSF via the action of viral or cellular 
oncogenes (Metcalf, 1985). GM-CSF has also been suggested as a tumor marker due to its 
critical role in regulating haemopoetic growth and differentiation (reviewed in Mroczko 
and Szmitkowski, 2004). In asthma it is thought GM-CSF plays a role in establishing the 
level of surfactant in the lungs (Stanley et al, 1994) and inflammation of the synovial fluid 
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in the arthritic joint is exacerbated by GM-CSF (reviewed in Feldmann et al, 1996). 
1.2.1 REGULATION OF GM-CSF 
GM-CSF expression is regulated primarily at the level of transcription (Chan et al, 
1986). The rapid induction of GM-CSF gene expression following immune stimulation 
involves the activation and nuclear translocation of a range of transcription factors which 
bind to regulatory regions of the GM-CSF gene. The human GM-CSF gene is located on 
chromosome 5q31.1 (Miyatake et al, 1985). The murine equivalent is located on sub-band 
B1 on chromosome 11 (Barlow et al, 1987). Both the murine and human genes are 
approximately 2.5kb in length and comprise 4 exons and 3 introns (Miyatake et al, 1985). 
Expression of the GM-CSF gene is controlled by the proximal promoter comprising of the 
first 120 bp upstream of the transcription start site and an enhancer located a further 3 kb 
upstream of the human promoter (Cockerill et al, 1993) and 2 kb upstream of the mouse 
promoter (Osborne et al, 1995). Both the promoter and enhancer elements are required for 
the induction of GM-CSF gene expression. The GM-CSF gene in mice and humans is 
highly conserved with their promoters sharing approximately 90% sequence homology 
(Miyatake et al, 1985). However sequence analysis of cloned human and murine GM-CSF 
cDNA revealed only a 54% homology in the protein coding region (Wong et al, 1985) 
suggesting that while the gene products may differ, they are regulated in a similar fashion. 
The GM-CSF promoter has been relatively well defined. It contains an array of 
transcription factor binding sites including the CD28 response region (CD28RR) and 
conserved lymphokine element 0 (CLEO). It contains binding sites for NFAT, NF-KB, SP1, 
Ets, CBF and AP1 transcription factors (Dunn et al, 1994;-Wang et al, 1994; Himes et al, 
1996; Cockerill et al, 1996; Schreck and Baeuerle, 1990; Shang et al, 1999) as outlined in 
Figure 1.2. The CD28RR consists of the CK-1 region (also termed the CD28RE), a 10bp 
element which responds specifically to signals delivered to T cells via the CD28 surface 
receptor, and an adjacent NF-KB and a Sp 1 binding site. The CK-1 region is a variant NF-
KB site which binds Rel A homodimers and c-Rel containing complexes (Himes et al, 
1996). The CLEO is shared between a number of cytokine genes including GM-CSF, IL-4 
and IL-5. This element binds NFAT, Ets and AP-1 transcription factors (Masuda et al, 
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1993). 
Studies in transgenic mice and cell lines determined that the GM-CSF enhancer is 
essential for the highly inducible activation of the human GM-CSF gene (Cockerill et al, 
1999). The GM-CSF enhancer element is approximately 400bp in mice (Osborne et al, 
1995) and 716bp in humans (Cockerill et al, 1993). It contains binding sites for Spl, 
AML1, CBF, AP1 transcription factors and four NFAT binding sites (Cockerill et al, 1993; 
Cockerill et al, 1995; Cockerill et al, 1996). 
1.2.2 Factors involved in transcriptional activation of the GM-
CSF promoter 
1.2.2.1 NFAT 
The nuclear factor of activated T cells (NFAT) family of transcription factors 
regulates expression of a number of cytolcine genes. Members include NFATc 1 (NFATc), 
NFATc2 (NFATp), NFATn, NFATc3 (NFAT4 or NFATx) and NFATc4 (NFAT3), all of 
which share a conserved DNA binding domain. These factors are activated via the calcium 
dependent protein phosphatase, calcineurin following TCR ligation (Jain et al, 1993; Luo et 
al, 1996). In resting T cells, NFAT proteins can be found in the cytoplasm in a 
phosphorylated form with low affinity for DNA. T cell activation results in increased 
intracellular calcium levels. This leads to the dephosphorylation of NFAT by the calcium-
dependent phosphatase, calcineurin and their subsequent nuclear translocation (Beals et al, 
1997). While NFATp is constitutively expressed, NFATc is newly synthesized in response 
to T cell activating signals (Chuvpilo et al, 1999). 
The involvement of NFAT in GM-CSF expression has been studied in considerable 
detail and subsequently its role in activating GM-CSF expression is well established. Using 
the electrophoretic mobility shift assay (EMSA) recombinant NFATp proteins were found 
to bind to the CD28RR of a GM-CSF promoter probe (Shang et al, 1999). However, 
reporter assays involving the cotransfection of Jurkat T cells with an NFATp construct and 
a construct containing two copies of the CD28RR attached to a luciferase reporter 
demonstrated that NFATp alone is not capable of activating this region. NFATp can 
however cooperate with signals which mimic T cell activation to enhance transcription 
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Figure 1.2. Schematic representation of transcription factor binding sites 
across the GM-CSF promoter. 
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from this element (Shang et al, 1999). NFAT has also been shown to bind to the CLEO 
region of the GM-CSF promoter (Tsuboi et al, 1994). Furthermore, it is clear that NFAT 
members play an important role in GM-CSF induction as inhibition of NFAT activation 
using the immunosuppressant Cyclosporin A prevents GM-CSF transcriptional activation 
(Cockerill et al, 1993). 
1.2.2.2 NF-KB 
The NF-KB family of transcription factors is responsible for mediating immune and 
inflammatory responses by coordinating the expression of an array of immune genes. There 
are five mammalian NF-KB/Rel family members; p65 (Rel A), c-Rel, RelB, p50 (NF-KB 1) 
and p52 (NF-KB2) (reviewed in Baldwin, 1996). The NF-KB family members share the Rel 
homology domain consisting of approximately 300 amino acids. NF-KB binds as homo and 
heterodimers to decameric sequence motifs within promoter and enhancer elements. While 
all members bind to DNA only the Rel A, c-Re! and Rel B factors have carboxy-terminal 
transactivation functions (Verma et al, 1995). Many target genes produce proteins which 
are quickly expressed in immune and inflammatory responses. NF-KB transcription factors 
are rapidly activated in response to a number of stimuli and thus are involved in rapid gene 
induction. NF-KB exists in the cytoplasm of resting cells bound to its inhibitory protein 
partner IfcB which masks its nuclear localisation signal to sequester NF-KB in the 
cytoplasm (Antonsson et al, 2003). Numerous extracellular signals, including T cell 
activation, activate the Itc13 lcinase complex which phosphorylates serine residues on the 
inhibitory IKB targeting it for ubiquitination and degradation. NF-KB is then free to 
translocate into the nucleus (reviewed in Baldwin, 1996). NF-KB proteins are activated in 
two waves following T cell stimulation with levels of Rel A and p50 peaking within 30 
minutes. Levels of c-Rel and Rel B accumulate during the second wave of activation, 
peaking at approximately 6 hours following T cell activation (Kalli et al, 1998). 
NF-KB binds at two sites in the CD28RR of the GM-CSF promoter (at positions -82 
to -91 and -98 to -108) as determined by EMSA (Schreck and Baeuerle, 1990). These sites 
are referred to as the CK-1 element and the classical NF-KB/Spl site. Following on from 
this, the NF-KB family members c-Rel and Rel A were found to bind to the CK-1 element 
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and were reported as being vital for the activity of the CD28RR in vitro (Himes et al, 
1996). Previous work has also identified the NF-KB/Spl region of the CD28RR in the GM-
CSF promoter as critical for GM-CSF induction in primary T cells (Cakouros et al, 2001). 
GM-CSF transcription was inhibited in transgenic mice carrying the human GM-CSF 
transgene with an NF-KB/Sp 1 mutation. This mutation exhibited an effect only when 
integrated into chromosomal DNA, either in transgenic mice or stably transfected cell lines 
while reporter expression was unaffected in cells transiently transfected with the mutant 
NF-KB/Sp 1 construct. These data suggest that the NF-KB/Spl region of the GM-CSF 
promoter plays an important role in the activation of the GM-CSF gene in a chromatin 
context. 
1.3 CHROMATIN 
1.3.1 CHROMATIN STRUCTURE 
Within the eukaryotic nucleus DNA is assembled into a DNA-protein complex 
called chromatin. The concept that DNA is organized into small repeating units was 
proposed more than thirty years ago by Hewish and Burgoyne (1973) when they found that 
a DNA ladder was produced when chromatin was digested. These repeating units called 
nucleosomes were subsequently found to consist of DNA associated with an octamer of 
histone proteins, consisting of two copies each of histones H2A, H2B, H3 and H4 (Thomas 
and Kornberg, 1975). The structure of the nucleosome core particle was resolved many 
years later by X-ray crystallography (Luger et al, 1997) and showed 147 base pairs of DNA 
helix super-coiled around the histone octamer, contacting the histone proteins with 
approximately two turns aligned with grooves between the histone proteins. Neighboring 
nucleosomes are then linked by short segments of DNA of variable length referred to as 
linker DNA (Morris, 1976). The four core histones (H2A, H2B, H3 and H4) are small, 
proteins which consist of a highly conserved histone fold domain (Zhong et al, 1983) and a 
less conserved N-terminal tail. The histone fold domains mediate histone-histone and 
histone-DNA interactions which are involved in formation of the core nucleosome structure 
(reviewed in Luger and Richmond, 1998). The amino-terminal tails have random coil 
segments extending out of the nucleosome core and while not involved in the formation of 
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the nucleosome structure facilitate the assembly of nucleosomes into higher order 
chromatin structures (reviewed in Peterson and Laniel, 2004). These higher order structures 
are then stabilized by linker histone H1, which is structurally unrelated to the core histones 
(reviewed in Lu and Hansen, 2003). Nucleosomal arrays are coiled together to form a 30 
nm chromatin filament, which is then further condensed to form the interphase 
chromosomes or the more highly compacted metaphase chromosomes. 
1.3.2 REGULATION OF GENE EXPRESSION 
While the role of chromatin in packaging DNA into the confines of the nucleus has 
long been established (Eikbush and Moudrianakis, 1978), a second equally important role it 
plays in gene regulation has emerged only more recently (reviewed in Struhl, 1999). The 
assembly of DNA into nucleosomes is generally considered inhibitory to the binding of 
transcription factors. For example, in the case of the yeast PHO5 promoter the Pho4 
transcription factor can bind to the active promoter yet is unable to bind to the repressed 
promoter (Venter et al, 1994). It has long been known that more tightly compacted 
chromatin structures form a repressive transcriptional environment (Wasylyk and 
Chambon, 1980). For example, on a global scale chromatin within the cell nucleus can be 
classified as the more condensed heterochromatin, which is generally gene poor and 
inhibitory to gene transcription and euchromatin which corresponds to more relaxed 
chromatin domains associated with actively transcribed regions of the genome (reviewed in 
Yasuhara and Wakimoto, 2006). However even within these classifications it is now clear 
that chromatin is highly dynamic and can change in both structure and composition in 
response to cellular signals. Furthermore, it is clear that such changes are often required to 
facilitate gene activation. There are two general mechanisms by which changes in 
chromatin can occur broadly classified as histone modification and chromatin remodelling. 
1.3.3 HISTONE MODIFYING COMPLEXES 
Chromatin structure can be altered directly or indirectly through covalent 
modifications to the N-terminal tails of the core histone proteins (reviewed in Turner, 
2000). Intense study over the last decade has uncovered a vast number of sites in the N- 
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terminal tails of histones which can be subjected to a variety of post translational 
modifications. These include acetylation, methylation, phosphorylation, or ubiquitylation 
(Alfrey et al, 1964; Stevely and Stocken, 1966; Henry et al, 2003). 
While the addition of acetyl and phosphate groups to histone proteins can change 
the charge of the protein and alter chromatin by electrostatic means, such changes are 
unlikely to alter nucleosome structure although they may influence higher order chromatin 
packaging (Shogren-Knaak et al, 2006). However the major mechanism by which the tail 
modifications are thought to act is by facilitating interactions with non-histone proteins 
(Jenuwein and Allis, 2001). While most study has focused on modifications to histone 
tails, with the use of mass spectroscopy in studying histones it has become clear that 
residues outside of the N-terminal tail can also be modified (reviewed in Mersfelder and 
Parthun, 2006). Initial work demonstrated that lysine 79 on histone H3 within the core 
domain could be methylated in yeast (Ng et al, 2002) and since then a number of other core 
modifications have been identified. Unlike modifications to the histone tails, these core 
modifications are thought to influence the structure of the nucleosome. 
The modification of histone proteins is carried out by enzymes which catalyze the 
addition and removal of covalent groups. Interestingly, many of these histone modifying 
proteins such as histone acetyltransferases (HATs), histone deacetylases (HDACs), histone 
methyltransferases and kinases were initially identified as transcriptional activators and 
repressors (reviewed in Nar et al, 2001). These enzymes have been shown to play a central 
role in modifying histones to alter chromatin structure. For example, the coactivator CREB 
binding protein (CBP) was one of the first HATs identified and reported to have intrinsic 
acetyltransferase activity (Bannister and Kouzarides, 1996) while in contrast class I, II and 
III histone deacetylases are found in corepressor complexes (reviewed in Verdin et al, 
2003). 
Initially histone modifications were considered to disrupt chromatin stability 
however it is emerging that the major mechanism by which the tail modifications function 
is by acting as docking sites for non-histone proteins which are able to modify chromatin 
structure and function (reviewed in de la Cruz et al, 2005). There is now evidence that 
specific histone marks can be recognized and bound by particular proteins and this has 
given rise to the histone code hypothesis. This hypothesis suggests that just as DNA 
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provides the code for every mRNA and protein required by an organism, the code present 
in histone modifications acts as a means of adding to the information held within the 
genetic code by stipulating when genes should be turned on or off (Jenuwein and Allis, 
2001). Thus, site specific and domain wide histone modifications help to dictate the 
transcriptional potential of a gene by tagging genes with activating or repressive marks. 
Acetylation of histone proteins is generally associated with gene activation in euchromatic 
domains while heterochromatin corresponds with transcriptionally repressed, deacetylated 
chromatin environment (reviewed in Kornberg and Lorch, 1999). The acetylation of lysine 
residues on H3 and H4 are associated with active genes while methylation of H3-K9 and 
H3-K27 is linked to repression (Zhang and Reinberg, 2001). Therefore certain methylating 
marks are associated with activation while others are linked to repression. 
The code established by various histone marks is recognized by particular proteins. 
Chromodomains are common domains found in numerous regulators of chromatin 
structure. These domains have been found to interact with histones, DNA and RNA. 
Heterochromatin protein 1 (HP1) directs the binding of other proteins to regulate chromatin 
structure and transcription. The chromodomain of HP1 recognizes methylation of lysine 9 
in histone H3 (Nielsen et al, 2002). Bromodomains, present in a number of HAT co-
activators, have been shown to act as acetyl-lysine-binding domains (Dhalluin et al, 1999) 
and are likely to be important in the assembly and activity of multiprotein complexes 
during transcriptional activation. 
In addition to the covalent modification of histone proteins, the core histone 
proteins can also be altered by the inclusion of histone variants (reviewed in Hake and 
Allis, 2006). Recently several H3 variants were identified as having either repressive marks 
(H3.2) or activating marks (H3.3) while the histone variant H3.1 contained both activating 
and repressive marks (Hake et al, 2006). The histone variant H2A.Z is often associated 
with regions of chromatin which have potential to be actively transcribed (Allis et al, 1986) 
and is considered to stop the spreading of silenced chromatin (Meneghini et al, 2003). 
1.3.4 CHROMATIN REMODELLING 
Chromatin remodelling refers to any detectable change in either a single 
nucleosome or chromatin domain. Chromatin remodelling may therefore involve global or 
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localized changes and can be detected using a number of different assays which rely on 
changes to DNA accessibility using endonucleases. The complexes involved in remodelling 
chromatin have been identified in a wide range of organisms from yeast to humans 
(Peterson and Herskowitz, 1992; Kwon et al, 1994) indicating the inherent importance of 
chromatin remodelling complexes in transcription of the eukaryotic genome. These 
chromatin remodelling complexes are large multi-subunit protein complexes which use the 
energy from ATP hydrolysis to move histones by disrupting the DNA-histone bonds 
(reviewed in Becker and Horz, 2002). A number of ATP dependent chromatin remodeling 
complexes have been identified including the ISWI, Mi-2 and SWI/SNF complexes 
(reviewed in Vignali et al, 2000). The SWI/SNF complex is the most widely studied ATP 
dependent chromatin remodelling complex and is well conserved from yeast to humans 
(Kwon et al, 1994). SWI/SNF was first discovered in yeast as having DNA dependent 
ATPase activity (Laurent et al, 1993). Its name hails from its function in activating 
particular genes involved in mating type switching and sucrose non-fermenting 
metabolism. It comprises 10-15 subunits, with a combined molecular mass of 
approximately 2 MDa. The ATPase component of the mammalian SWI/SNF complex, 
Brg 1 or Brm, is central to its function. Other Brgl/Brm associated factors (BAFs) are 
found within SWI/SNF and are important in regulating the interaction between SWI/SNF 
and other factors. For example BAF57 mediates the interaction of SWI/SNF with estrogen 
and androgen receptors (Belandia et al, 2002). 
Histone loss and nucleosome sliding have both been proposed as mechanisms by 
which SWI/SNF drives the displacement of nucleosomes from gene regulatory regions. 
Previous in vitro work demonstrated that SWI/SNF can displace histone octamers from one 
piece of DNA to another (Lorch et al, 1999). Nucleosome sliding was first demonstrated in 
vitro with the detection of short range nucleosome mobility in response to the action of the 
ATP dependent GAGA factor remodelling complex (Varga-Weisz et al, 1995). SWI/SNF 
has also been shown to slide nucleosomes to an acceptor site on the same molecule of DNA 
in vitro (Whitehouse et al, 1999). There is also evidence to support both mechanisms in 
vivo. Histone loss was demonstrated in vivo at the yeast PI105 and PHO8 promoters 
(Reinke and Horz, 2003; Adkins et al, 2004). By embedding the PHO5 promoter within a 
small plasmid which limits the ability for nucleosome sliding, Korber et al (2004) 
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demonstrated that histone loss at the PHO5 promoter is most likely due to histone eviction 
in trans rather than nucleosome sliding. The nucleosome transfer observed at the PHO5 
and PHO8 promoters requires the histone chaperone, Asfl (Korber et al, 2006). Histone 
chaperones aid the displacement of nucleosomes through the disassembly of the histone 
octamer (Walter et al, 1995). Nucleosome sliding has been demonstrated in vivo by 
Lomvardas and Thanos (2001) who showed that the nucleosome encompassing the IFN-13 
promoter slides in response to virus infection. Thus, it appears that different nucleosome 
remodelling mechanisms may operate at different genes. 
The SWI/SNF complex lacks DNA sequence specific binding and is therefore 
thought to be recruited to specific promoter and enhancer regions via interactions with 
specific transcription factors and histone modifications. This is supported by evidence in 
which components of the SWI/SNF complex interact with a variety of activators and 
factors which bind to specific DNA sites (Nie et al, 2000; Zhao et al, 2005). BAF250 has 
been shown to directly bind to the beta-globin locus and in addition, it is capable of 
interacting with the glucocorticoid receptor thereby conferring binding specificity to the 
SWI/SNF complex (Nie et al, 2000). Thus, BAF250 has been suggested to recruit the 
complex to gene regulatory elements by directly binding DNA or interacting with other 
sequence specific transcription factors. In vitro work has demonstrated that SWI/SNF 
interacts with the transcription factor EKLF and the recruitment of the SWI/SNF complex 
to the beta-globin promoter is via an interaction with this transcription factor (Lee et al, 
1999; Brown et al, 2002). The SWI/SNF complex has also been found to associate with the 
RNA polymerase II holoenzyme (Wilson et al, 1996). Recent reports have shown that RNA 
polymerase II is associated with the mediator complex, CBP and other proteins suggesting 
that the holoenzyme can be recruited as a unit to promoter regions therefore supporting the 
role of Brgl in helping to initiate gene transcription. 
It is becoming clear that ATP dependent remodelling complexes act cooperatively 
along side histone modifying proteins. Histone marks and the recruitment of chromatin 
remodelling activities help define whether or not a particular gene will be activated or not. 
Acetylated histones have been found to stabilize SWI/SNF association (Hassan et al, 2002) 
and this is due to the interaction of the bromodomain present in the ATPase subunit of the 
SWI/SNF complex with acetylated histones. Conversely, the HDAC Rpd3, causes 
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transcriptional repression by inhibiting the recruitment of SWI/SNF (Deckert and Struhl, 
2002). SWUSNF is recruited to the IFN-13 promoter by prior acetylation of lysine 8 on 
histone H4 (Agalioti et al, 2002) and to the myogenin promoter following hyperacetylation 
of H4 (de la Sema et al, 2005). This facilitated by bromodomains within the complex 
acting as acetyl-lysine-binding domains (Dhalluin et al, 1999). 
Although BAF complexes comprise multiple subunits it is now evident that only 
four of these are essential in vitro for the complete known range of activities (Narlikar et al, 
2002). Of particular interest, Brgl alone was found to be capable of increasing accessibility 
to a nucleosome which is unable to slide due to the position of neighboring nucleosomes 
(Fan et al, 2003). Other components of the SWI/SNF complex may exert their role by 
interacting with targets and co-activators or controlling the extent of the remodelling. It is 
also possible that they possess other important roles yet to be identified. 
1.3.5 BRG1 
The SWI/SNF complex in mammalian cells has two different catalytic subunits; 
Brahma (Brm, also called SNF2cc or Smarca2) and Brahma related gene 1 (Brgl, also 
known as Snf213 or Smarca4). Brm and Brgl are the ATPase components of the SWUSNF 
complex and therefore central to its function. Disruption of Brm increases cellular 
proliferation (Reyes et al, 1998) while the targeted deletion of Brgl in mice is embryonic 
lethal (Bultman et al, 2000) with the embryo dying during the pen-implantation stage. The 
heterozygote survives but develops exancephaly and tumors (Bultman et al 2000). 
While the genes encoding Brgl and Brm share 70% sequence homology, the two 
proteins differ in some of their activities and properties. While showing some functional 
redundancy in some cases, both Brgl and Brm have been found to interact with the Rb 
protein to suppress the cancerous phenotype displayed in tumor lines (Strobeck et al, 
2002). However these proteins display distinct tissue and developmentally specific patterns 
of expression. Work carried out by Reisman et al (2005) demonstrated the differential 
expression of the Brgl and Brm components of the SWI/SNF complex. While Brgl was 
found predominantly in tissues undergoing self renewal, Brm was consistently present in 
tissues such as brain, liver and endothelial which undergo limited proliferation. In addition, 
the non-conserved regions of Brgl and Brm allow binding to specific transcription factors 
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or co-activators permitting recruitment to different gene promoters and enhancers. In 
support of this Brg 1 has been found to bind zinc finger proteins via its unique N-terminal 
domain while Brm lacks this capability (Kadam and Emerson, 2003). 
Loss of Brgl has also been associated with increased DNA methylation. Banine et 
al (2005) demonstrated that the CD44 and E-cadherin promoters are hypermethylated in 
non-expressing SW13 and C33A cell lines which are deficient in Brg 1 and Brm. The 
restoration of Brgl function in these cells resulted in the demethylation of the CD44 and E-
cadherin promoter. This study suggests that the loss of Brgl may result in increased DNA 
methylation in some cases. Therefore the loss of SWI/SNF mediated transcription is a 
possible mechanism to increase DNA methylation in cancer cells. In addition they found 
that the dominant negative Brgl and Brm proteins still interact with the promoters of these 
genes however transcription is inhibited. Thus while the ATPase domain is essential for 
transcriptional activity, recruitment to promoter regions is regulated by a different domain. 
1.3.6 CHROMATIN REMODELLING IN THE IMMUNE 
SYSTEM 
The rapid and precisely controlled expression of a range of genes, including 
cytolcines, in response to immune and inflammatory signals is critical for the orchestration 
of an effective and appropriate immune response. Data accumulated over the last decade 
has begun to reveal the critical role that chromatin plays in facilitating activation of these 
genes (reviewed in Smale and Fisher, 2002). It is now becoming clear that the activation of 
genes in a chromatin context involves a complex interplay between transcription factors, 
chromatin modifiers and chromatin remodellers. 
Initial work demonstrated the appearance of inducible DNase I hypersensitive sites 
in gene regulatory regions. The appearance of these sites was thought to represent changes 
in accessibility brought about by changes in chromatin structure. Early studies examined 
the position and appearance of DNase I hypersensitive sites across the IFN-13 gene upon 
induction. Inducible DNase I hypersensitive sites were detected 100, 430 and 580bp 
upstream of the transcription start site indicating changes in chromatin structure during 
IFN-f3 activation (Higashi, 1985). Since these earlier studies, the accessibility of hundreds 
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of genes has been mapped to varying levels. Inducible DNase I hypersensitive sites have 
been detected in a number of immune gene promoters and enhancer elements 
demonstrating that transcriptional induction of genes such as GM-CSF, IL-2, IL-13 and IL-
4 is associated with changes in chromatin structure (Cockerill et al, 1993; Ward et al, 1998; 
Takemoto et al, 1998). 
Basal chromatin environment is now considered to play a vital role in regulating 
immune gene expression. For example, the appearance of DNase I hypersensitive sites is 
associated with cytokine gene expression programs in Thl versus Th2 cells (Agarwal and 
Rao, 1998). Following TCR ligation naive T cells differentiate into two distinct T helper 
(Th) subsets, Th 1 and Th2 cells. Thl cells are capable of producing IFN-y while Th2 cells 
are capable of producing IL-4. Differentiated Thl and Th2 cells show differences in 
chromatin structure and DNA methylation status at these particular gene loci. Avni and 
colleagues (2002) showed that culturing naive T cells in polarizing conditions created a 
selective pattern of histone acetylation on the IL-4 and IFN-y genes. Chromatin 
immunoprecipitation revealed that the IL-4 locus is hyperacetylated in Th2 cells (Avni et 
al, 2002; Yamashita et al, 2004; Grogan et al, 2003) while the IFN-y promoter is 
hyperacetylated in Th 1 cells (Avni et al, 2002) with acetylation status strongly correlated 
with gene expression. In addtition DNA methylation of the IFN-y and IL-4 promoters in 
Th 1 versus Th2 cells has been correlated with gene expression. While the IFN-y promoter 
is hypomethylated in Th0 and Th 1 cells, it undergoes hypermethylation during Th2 
differentiation (Winders et al, 2004). Conversely, the 5' region of the IL-4 locus is 
hypermethylated in naive T cells and undergoes extensive demethylation during Th2 
differentiation (Lee et al, 2002). 
While these studies demonstrate that histone modifications play an important role in 
immune gene regulation, numerous studies have also demonstrated that changes in 
nucleosome structure accompany the induction of cytokine gene transcription (Cockerill et 
al, 1993; Rao et al, 2001; Weinmann et al, 1999). Activation of the IL-2 gene in EL-4 and 
primary T cells is accompanied by changes in chromatin structure restricted to the first 
300bp covering the proximal promoter (Rao et al, 2001). Increased accessibility is detected 
within the first 2 hours of T cell activation and maintained for at least 16 hours post-
stimulation. In addition the kinetics of remodelling preceded transcription of the IL-2 gene. 
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Similarly rapid and selective remodelling is observed at the IL-12 p40 promoter 
(Weinmann et al, 1999) with nucleosome remodelling detected within one hour of 
macrophage activation with LPS. 
The precise manner in which signals, transcription factors, chromatin remodellers 
and the transcriptional machinery interact to drive remodelling and transcription has only 
been elucidated for a handful of eukaryotic genes (Agalioti et al, 2000; de la Serna et al, 
2005). One of the best defined activation profiles is that of the IFN-13 gene which is 
activated in response to viral infection. A nucleosome positioned over the TATA box and 
start site of transcription is remodelled following a series of ordered recruitment events 
(Yie et al, 1999; Agalioti et al, 2000; Lomvardas and Thanos, 2001; Agalioti et al, 2002). 
Agalioti et al (2000) found that following infection, an enhanceosome is assembled at the 
nucleosome free enhancer region of the IFN-13 gene. The enhanceosome directs the ordered 
recruitment of factors required for chromatin remodelling and transcription with the HAT, 
GCN5 initially recruited to the enhancer region followed by the CBP/PolII holoenzyme 
complex. Histone acetylation by GCN5 then acts as a signal for CBP mediated SWI/SNF 
recruitment. SWI/SNF then remodels the nucleosome covering the transcriptional start site 
and transcription of the IFN-13 gene is then activated by the recruitment of THID. 
Activation of the genes encoding the cytokines GM-CSF, IL-2 and IL-12 is also 
likely to be dependent on the recruitment of chromatin modifying activities as the 
transcription factor binding sites in the promoter regions of these genes are covered by 
nucleosomes (Weinmann et al, 1999; Rao et al, 2001; Holloway et al, 2003). However it is 
possible that these genes activate in a similar manner to the yeast PHO5 promoter which is 
activated in the presence of low phosphate. The binding of Pho4, a key PHO5 activator, is 
inhibited by nucleosomes encompassing the PHO5 promoter region. While Pho4 can bind 
to the active promoter it is unable to bind to the repressed promoter (Venter et al, 1994). 
Svaren et al (1994) showed that deletion of the Pho4 activation domain prevented 
remodelling of the nucleosome encompassing the PHO5 promoter suggesting it recruited 
remodelling activities. This was confirmed in later work by Barbaric et al (2003), who 
demonstrated that Pho4 was required for the recruitment of the histone acetyltransferase 
complex, SAGA. Histones are then lost from the promoter at a rate determined by 
SWI/SNF recruitment (Gaudreau et al, 1997). 
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1.3.7 GM-CSF ACTIVATION IN A CHROMATIN CONTEXT 
There is substantial evidence that chromatin remodelling plays a vital role in 
regulation of the GM-CSF gene. The discovery of an inducible DNase I hypersensitive site 
in the GM-CSF enhancer following T cell stimulation provided the first evidence that the 
chromatin structure of the GM-CSF gene is altered following immune stimulation 
(Cockerill et al, 1993). Further investigations revealed that the appearance of this site was 
restricted to cells capable of GM-CSF expression, therefore highlighting the importance of 
chromatin remodelling in GM-CSF activation (Cockerill et al, 1999). The NFAT family of 
transcription factors were implicated in GM-CSF enhancer remodelling as treatment of 
Jurkat T cells with cyclosporin A prevented the appearance of the DNase I hypersensitive 
site (Cockerill et al, 1993). Using DNase footprinting Johnson et al (2004) recently 
demonstrated that GM-CSF enhancer core elements are spanned by two adjacent 
nucleosomes. Following T cell activation remodelling is not restricted to the enhancer 
region, but rather spans a 3 kb domain. NFAT dependent chromatin remodelling at the 
GM-CSF enhancer was also confirmed by site directed mutagenesis, with mutations in 
NFAT binding sites preventing GM-CSF enhancer remodelling (Johnson et al, 2004). 
The detection of an inducible DNase I hypersensitive site at the GM-CSF promoter 
following T cell stimulation suggested the chromatin structure of the promoter is also 
altered during T cell activation (Cockerill et al, 1999). Carrying on from this, Holloway et 
al (2003) mapped accessibility across the GM-CSF promoter region and demonstrated that 
a single nucleosome is positioned across the resting GM-CSF promoter between -174 and 
+24. Following T cell stimulation this nucleosome is rapidly and selectively remodelled. 
Mutation of the NF-K13/Sp1 site within the GM-CSF promoter has been shown to limit 
remodelling in primary mouse lymphocytes (Cakouros et al, 2001). Further evidence of a 
role for NF-tc13 in GM-CSF promoter remodelling was provided by Holloway et al, (2003) 
who demonstrated that the stable expression of an IKI3a, mutant construct, which prevents 
NF-K13 nuclear translocation, inhibited GM-CSF promoter chromatin remodelling events. 
Most recently, Chen et al (2005) demonstrated that the increase in GM-CSF promoter 
accessibility following T cell activation is due to histone loss. However, the mechanism 
behind the loss of histones from the GM-CSF promoter following T cell stimulation and 
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the signals and factors involved in this process remain to be elucidated, and this is the focus 
of the studies outlined in this thesis. 
1.4 RESEARCH PROJECT AIMS 
The aim of this study was to identify the role of signals and factors activated 
following T cell stimulation in regulating chromatin remodelling and transcription of the 
murine GM-CSF promoter. The specific aims were to: 
1) Identify the signals, factors and kinetics involved in increasing accessibility to the GM-
CSF promoter 
2) Determine the role of Brgl in activating the GM-CSF gene 
3) Determine whether other genes are activated in a similar manner. 
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CHAPTER 2. 
MATERIALS AND METHODS 
2.1.1 Cell culture 
Murine EL-4 T cells (ATCC) were cultured in RPMI 1640 medium (Gibco()) 
supplemented with 10% FCS (JRH Biosciences), 2mM L-glutamine (JRH Biosciences), 
100U/m1 penicillin and 1001..tg/m1 streptomycin (JRH Biosciences). The murine A-20 B cell 
line (provided by Prof. Lyn Corcoran, WEHI) was grown in DMEM (Gibco(D) 
supplemented with 10% FCS (JRH Biosciences), 2mM L-glutamine (JRH Biosciences), 
100U/m1 penicillin, 100i,tg/m1 streptomycin (JRH Biosciences) and 0.05mM p-
mercaptoethanol (Sigma-Aldrich). Cultures were incubated at 37 °C and 5% CO2 in 
humidified air. EL-4 T cells and A-20 B cells were maintained at a density between 2x10 5 
and 5x105 cells/m1 by addition of fresh medium every 24 to 48 hours. 
2.1.2 Freezing cells 
Cells (50m1 at 5x105 cells/m1) were centrifuged at 500g for 5 minutes. The 
supernatant was removed and the cells were resuspended in 2.5ml of culture medium. 
DMSO (500111) was added to 2m1 of medium then added slowly to the cells. The cell 
suspension was aliquoted between 5 cryovials, wrapped in cotton wool to allow gradual 
freezing and stored at -80°C or the vapour phase of liquid nitrogen. 
2.1.3 Thawing cells 
Frozen stocks of EL-4 T cells or A-20 B cells were thawed in a water bath at 37 °C. 
The cell suspension was then transferred to a 15m1 Falcon tube along with 10m1 of culture 
medium and centrifuged at 500g for 5 minutes. The supernatant, containing DMSO was 
then discarded. The pelleted cells were resuspended in lml of media which was transferred 
to a 25cm2 culture flask with another 9m1 of medium. The cells were then cultured at 37 °C 
and 5% CO2in humidified air (section 2.1.1). 
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2.1.4 Stimulation of cultured cells 
Table 2.1. Reagents used to treat EL-4 T cells and A-20 B cells. 
Stimuli Stock concentration Treatment 
Phorbol myristate acetate 
(PMA/P; Boehringer Mannheim) 
1mg/m1 in DMSO 2Ong/m1 for various 
times as indicated 
Calcium ionophore A23187 
(I, Sigma-Aldrich) 
10mM in DMSO 111M for various 
times as indicated 
Cyclohexamide 
(CHX; Calbiochem) 
100mg/m1 in ethanol 1012g/m1 for 30 minutes 
Cyclosporin A 
(CsA; Calbiochem) 
100 mg/ml in ethanol 5Ong/m1 for 30 minutes 
Ro-32-0432 
(Roche Pharmaceuticals) 
10mM in DMSO 101.IM for 1 hour 
Trichostatin A 
(TSA; Sigma-Aldrich) 
Img/m1 in DMSO 200ng/m1 for 4/16 hours 
In some experiments stimuli were withdrawn from EL-4 T following treatment. In this case 
cells were treated with P/I for 2 hours, before pelleting cells at 500g, washing cells twice in 
- fresh RPMI medium before resuspending in RPMI medium free of stimuli. 
2.2 Analysis of RNA by real-time PCR 
Cytolcine mRNA levels in EL-4 T cells and A-20 B cells were determined by real-
time PCR according to the following protocols. 
• 
2.2.1 Isolation of RNA 
Total RNA was isolated from 5x10 5 -1x106 cells. Following centrifugation at 700g at 
room temperature, the pelleted cells were lysed by the addition of 500111 of Tri-reagent 
(Sigma) with repeated pipetting. The cell lysates were then transferred to eppendorf tubes 
and incubated at room temperature for 5 minutes. Chloroform (1001.11) was added to each 
sample tube which was then shaken vigorously for approximately 15 seconds. The samples 
were incubated at room temperature for 10 minutes. Samples were then centrifuged at 
12000g for 15 minutes at 4°C. The upper aqueous phase was transferred to new eppendorf 
tubes, to which 300111 of isopropanol was added. Each tube was gently inverted several 
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times and then placed at —80 °C for 30 minutes to overnight to precipitate the RNA. The 
samples were centrifuged at 13000g for 10 to 30 minutes at 4 °C and the supernatant 
removed. The pellets were washed with 75% ethanol and air dried for several minutes. 
MilliQ water (201.t1 to 501.11 depending on pellet size) was added to each pellet which was 
then vortexed and heated at 60°C for several minutes on a heating block. The RNA was 
snap frozen in liquid nitrogen and stored at —80 °C. 
2.2.2 Quantitation of RNA 
Isolated RNA was diluted 1 in 20 with MilliQ water and absorbance readings were 
determined using the BioRad SmartSpec 3000TM  spectrophotometer. Absorbance at 260, 
280 and 320 nm was measured for each sample. RNA was quantified according to the 
formula 1 O.D. at 260nm = 40.01.1g/m1. RNA quality was assessed by agarose gel 
electrophoresis. RNA (500ng) and 2.5gg of Lambda molecular weight marker (New 
England Biolabs) were separated on a 1% agarose gel in 1xTAE (refer to section 2.9.1) at 
100V for 1 hour before staining with ethidium bromide. 
2.2.3 cDNA synthesis 
RNA (0.514 to 114) was added to an eppendorf tube along with 21./1 of 5x first 
strand buffer (Invitrogen) and 1111 of 1U/111 DNase (Sigma). MilliQ water was added to a 
total volume of lOptl. This reaction was then incubated at 37 °C for 30 minutes and the 
DNase then inactivated at 75 °C for 5 minutes. Another 21.11 of first strand buffer was added 
to each tube along with 1xl of 1ps/111 oligodT (Sigma) and 3.5g1 of MilliQ water. This 
reaction was incubated at 70 °C for 10 minutes and then cooled on ice. A 2111 aliquot of 
0.1M DTT (Invitrogen), 1111 of 10mM dNTPs (Promega) and 0.5g1 of Superscript reverse 
transcriptase (Invitrogen) was added to each reaction. This mixture was incubated at 42 °C 
for 50 minutes and then the enzyme inactivated at 70°C for 15 minutes. The cDNA was 
stored at —20°C. 
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2.2.4 Real-time PCR 
2.2.4.1 Primers 
The primer sequences used in the amplification of target cDNA are outlined in the table 
below. 
Table 2.2 Primers used in the quantification of cytokine mRNA by real-time PCR. 
Name Sequence (5' to 3') Amplicon (bp) Reference 
mGM+II Forward primer AAGGTCCTGAGGAGGATGTG 140 Holloway 
et al, 2003 mGM+II Reverse primer GAGGTTCAGGGCTTCTTTGA 
mM-CSF Forward primer CGAGTCAACAGAGCAACCAA 236 
mM-CSF Reverse primer TGCTTCCTGGGTCAAAAATC 
mIL-4 Forward primer TCAACCCCCAGCTAGTTGTC 177 
mIL-4 Reverse primer TG1TCTTCGTTGCTGTGAGG 
mIL-5 Forward primer ATGGAGATTCCCATGAGCAC 177 
mIL-5 Reverse primer CCCACGGACAGTTTGATTCT 
mIFNy Forward primer GCTTTGCAGCTCTTCCTCAT 162 
mIFNy Reverse primer GTCACCATCC ITITGCCAGT 
mGAPDH Forward primer AAGTATGATGACATCAAGAAGGTGGT 67 
mGAPDH Reverse primer AGCCCAGGATGCCCTTTAGT 
All primers were supplied by Sigma. 
2.2.4.2 SYBR green real-time PCR 
cDNA was diluted lOng/1.11 with MilliQ water and 5p1 (50ng) was used in each 
reaction. A PCR was prepared containing 12.5p1 Qiagen QuantiTect SYBR green master 
mix, 1.5p1 forward primer (5gM), 1.5111 reverse primer (5pM) and 4.5g1 MilliQ water to 
give a total reaction volume of 25p1. A no template control (NTC) was prepared for each 
primer set to detect any contaminating DNA. This reaction replaced 51.11 of cDNA with 5p1 
of MilliQ water. The Rotor-gene 2000 real-time PCR machine (Corbett Research, 
Australia) was used for the amplification of cDNA. The optimized PCR cycle conditions 
were; 95 °C for 15 minutes (hold); 95 °C for 15 seconds, 60°C for 60 seconds (30-45 cycles, 
acquiring to channel 1); 60 °C to 95 °C increasing 1 °C every 5 seconds (melt). Reactions 
were prepared in an area designated "PCR only" to reduce the occurrence of 
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contamination. Melt analysis was used to assess the presence of a single PCR species and 
this was verified by separating PCR products on a 2% agarose gel in lx TAE (section 
2.9.1) at 100V for 40 minutes. Molecular weight marker (2.51ag of 100 bp ladder from New 
England BioLabs) was also electrophoresed on each gel. PCR products were visualized 
using ethidium bromide. 
Standard curves for each primer set were used to quantify cytokine mRNA levels 
and glyceraldehyde phosphate dehydrogenase (GAPDH) expression was used for 
normalization of data. A mouse GAPDH PCR plasmid containing a 67bp fragment of the 
mouse GAPDH gene was prepared by cloning the PCR product formed using the GAPDH 
primers into the PCR® 2.1 vector (Section 2.5). This plasmid was used in the construction 
of a GAPDH standard curve. The mouse GM-CSF construct, AOGM provided by Dr. P 
Cockerill (Osborne et al, 1995) was used for construction of the GM-CSF standard curve. 
The mM-CSF, mIL-4 and mIL-5 standard curves were generated using serial dilutions of 
quantified gel extracted PCR product. 
2.2.4.3 Gel extraction of PCR product 
PCR products were extracted from 2% agarose gels using the Qiagen Gel 
Extraction kit according to the manufacturers' protocol. Briefly, the DNA fragment was 
excised from the gel and weighed before adding 3 volumes of buffer QG. The sample was 
then incubated at 50 °C for 10 minutes with occasional vortexing. Isopropanol (1 gel 
volume) was then added to the sample and mixed by inversion. The sample was then 
applied to the MinElute column and centrifuged for 1 minute. The flow-through was 
discarded and the column washed with 750g1 of buffer PE by centrifuging again for 1 
minute. The flow-through was discarded and the sample centrifuged for 1 minute at 
10,000g. The column was then transferred to a fresh eppendorf tube and 10m1 of MilliQ 
water applied to the membrane. The sample was incubated for 1 minute at room 
temperature before centrifuging once again for 1 minute. 
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2.3 Chromatin Accessibility by real-time PCR (CHART PCR) 
Accessibility of regions of cytokine genes to MNase and restriction enzymes was 
determined by CHART-PCR (Rao et al, 2001) according to the following protocols. 
2.3.1 Isolation of nuclei 
Nuclei were isolated from EL-4 T cells and A-20 B cells as described previously 
(Schreiber et al, 1989). The entire protocol was carried out in the cold room at 4 °C. Briefly, 
cells (2x106) were pelleted at 500g for 5 minutes. The media was aspirated and cells 
washed in ice cold PBS (ICN Biomedicals). The supernatant was removed and the pellet 
was resuspended in 0.5m1 of nuclei buffer (10mM Tris, pH 7.5, 10mM NaC1, 3mM MgC12, 
0.1mM EDTA, 0.5% Igepal, 16.5nM Spermine (Sigma-Aldrich) and 0.321aM Spermidine 
(Sigma-Aldrich)) and transferred to eppendorf tubes, using cut pipette tips to prevent cell 
lysis. The cells were incubated for 5 minutes on ice and then centrifuged at 700g for 4 
minutes. The supernatant was discarded and the nuclei were resuspended in 400m1 of nuclei 
wash buffer (10mM Tris pH 7.5, 50mM NaC1, 10mM MgC12, 0.2mM EDTA, 0.2mM 
EGTA, 18nM Spermine and 0.32pM Spermidine). The nuclei were then centrifuged at 
700g for 4 minutes. The wash buffer was removed and the nuclei were gently resuspended 
in 250p1 of restriction enzyme buffer diluted 1:10 with MilliQ water (New England Biolabs 
buffer 2) or 200111 of MNase buffer (10mM Tris pH 7.5, 15mM NaC1, 60mM KC1, 18nM 
spermine and 0.32gM spermidine) supplemented with the following protease inhibitors; 
Aprotinin (214/m1; Calbiochem), Leupeptin (114/m1; Calbiochem) and PMSF (100gM; 
Sigma-Aldrich). 
2.3.2 Restriction digest 
For each treatment, 97111 aliquots of EL-4 nuclei resuspended in restriction enzyme 
buffer were transferred to two eppendorf tubes. Hinfl (150 units; New England Biolabs) 
was added to one sample (as determined empirically) and the other sample was left 
untreated. Both samples were incubated at 37 °C for 30 minutes with occasional flicking to 
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resuspend nuclei. Samples were then removed from the heating block and 100111 of PBS 
added to each sample and DNA isolated immediately (Section 2.3.4). 
2.3.3 MNase digest 
EL-4 or A-20 nuclei resuspended in MNase buffer (94111) were transferred to 
eppendorf tubes containing 11.11 of ice cold CaCl 2 (0.1M). MNase (5U/ Boehringer) was 
then added to one tube and the other was left untreated. Both samples were then incubated 
at room temperature for 5 minutes before adding 20p1 stop buffer (0.1M EDTA, pH8 and 
50mM EGTA, pH 8) and placing on ice. A further 801.11 of MNase buffer was added and 
DNA isolated immediately (Section 2.3.4). 
2.3.4 DNA isolation 
DNA was isolated from cell nuclei using the Qiagen QIAamp DNA blood mini kit 
according to the manufacturers' instructions. Briefly, 20111 of Qiagen protease was added to 
each cell nuclei sample along with 4g1 of RNase (Roche; 10mg/m1 in 0.01M sodium 
acetate, pH 5.2) and 200111 of buffer AL. The samples were then vortexed for 15 seconds, 
incubated at 56 °C for 10 minutes and then centrifuged briefly. Ethanol (200g1) was added 
to each sample and pulse vortexed for 15 seconds. The samples were then centrifuged 
briefly. The contents in each eppendorf tube were then applied to QIAamp spin columns. 
The tubes were centrifuged at 8000g for 1 minute. The filtrate was discarded and the 
column was placed in a new collection tube. Buffer AW1 (500g1) was carefully applied to 
each column. The spin columns were then centrifuged at 8000g for 1 minute. The filtrate 
was again discarded and the column was placed in a fresh collection tube. Buffer AW2 
(500111) was then carefully applied to each column. The samples were centrifuged at 
13000g for 3 minutes. The collection tube was discarded and the spin column was placed in 
a 1.5m1 microcentrifuge tube. Buffer AE (200111) was then applied to each column and 
incubated at room temperature for 5 minutes. The tubes were then centrifuged at 8000g for 
1 minute. The spin column was discarded and the flow through containing DNA was stored 
at -20°C. 
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2.3.5 Quantification of DNA 
Prior to PCR amplification the concentration of DNA was determined using a 
spectrophotometer. Isolated DNA was diluted 1:20 with MilliQ water and absorbance 
readings determined using the BioRad SmartSpec 3000 1m spectrophotometer. Absorbance 
at 260, 280 and 320nm was measured for each sample. DNA was quantified according to 
the formula 1 0.D. at 260nm=50pg/ml. DNA quality was assessed by agarose gel 
electrophoresis. DNA (50Ong) and 2.5pg of the Lambda molecular weight marker (New 
England Biolabs) were separated on a 1% agarose gel in 1xTAE (section 2.9.1) at 100V for 
1 hour before staining with ethidium bromide. 
2.3.6 Real-time PCR of CHART samples 
2.3.6.1 Primers 
The primers used in the amplification of genomic DNA in the CHART assay are outlined 
below. 
Table 2.3. Primers used in the quantification of genomic DNA by real-time PCR. 
Name Sequence (5' to 3') Amplicon (bp) Reference 
mGM-I Forward primer GCCTGACAACCTGGGGGAAG 116 Holloway 
et al, 2003 mGM-I Reverse primer TGATTAATGGTGACCACAGAACTC 
mGM+I Forward primer GAGTTCTGTGGTCACCATTAATCA 147 Holloway 
et al, 2003 mGM+I Reverse primer CACATCCTCCTCAGGACCT'T 
mGM-V Forward primer TGGAATGAGCCACCAGAGTA 75 Holloway 
et al, 2003 mGM-V Reverse primer GGCTCTTGCTTCCATAGCAC 
nnIL-4E Forward primer GCACCAGGGCACTTAAACAT 158 
mIL-4E Reverse primer CTGTGCAGTGCCACAATGAT 
mIL-5p Forward primer ACCCTGAGTTTCAGGACTCG 94 Wang 
et al, 2006 mIL-5p Reverse primer TCCCCAAGCAATTTATTCTCTC 
mIFN-yp Forward primer AACATGCCACAAAACCATAGC 156 
mIFN-yp Reverse primer CACCTCTCTGGCTTCCAGTT 
All primers were supplied by Sigma. 
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2.3.6.2 Real-time PCR 
DNA was diluted to lOng4t1 for real-time PCR amplification. A PCR was prepared 
containing 12.4t1 SYBR, 1.4d forward primer (511M), 1.5111 reverse primer (511M), and 
4.5111 MilliQ water to which 5p1 (50ng) of DNA was added to give a total reaction volume 
of 25111. A NTC reaction was set up for each primer set which included 5111 of MilliQ water 
in place of DNA. Amplification of DNA was performed by and detected with the Rotor-
gene 2000 real-time PCR machine (Corbett Research, Australia). The PCR conditions 
were; 95 °C for 15 minutes seconds (hold); 95°C for 15 seconds followed by 60°C for 60 
seconds (35-45 cycles, acquiring to channel 1); 60 °C to 95 °C increasing by 1 °C every 5 
seconds (melt). Reactions were set up in an area designated "PCR only" to reduce 
contamination. Melt analysis was used to assess the presence of a single PCR species and 
this was verified by separating PCR products on a 2% agarose gel in lx TAE (section 
2.9.1) at 100V for 40 minutes. Molecular weight marker (2.51.1g of 100 bp ladder from New 
England BioLabs) was also electrophoresed on each gel. Electrophoresed PCR products 
were visualized with ethidium bromide. PCR products were quantified using standard 
curves for each primer set. Accessibility was determined by correlating the Ct values from 
the amplification plots to a standard curve for each primer set and was expressed as a 
percentage of undigested genomic DNA for each primer set. 
The mouse GM-CSF construct, AOGM was used for construction of the mGM-I, 
mGM+I and mGM-V standard curves. The IFNyp, IL-4p and IL-5p standard curves were 
generated separately using quantified and serially diluted gel extracted PCR product 
(section 2.2.4.3). 
2.4 Analysis of nuclear proteins 
Nuclear levels of various transcription factors in EL-4 T cells were determined 
according to the following protocols. 
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2.4.1 Preparation of nuclear extracts 
Nuclear extracts were prepared as described previously (Schreiber et al, 1989). 
Cells (5x105 cells/nil) were centrifuged at 500g for 5 minutes. The supernatant was 
removed and the pellet washed in PBS. Cell pellets were resuspended in 1.25 ml buffer A 
(10mM Tris pH 7.4, 10mM NaCl, 3mM MgC12, 0.1mM EDTA pH 8 and 0.5% Igepal) and 
transferred to eppendorf tubes. The samples were then incubated on ice for 5 minutes and 
centrifuged at 700g for 5 minutes. The supernatant was removed and the pellets were 
resuspended in 1.25m1 of buffer A minus Igepal. The tubes were then centrifuged at 700g 
for 5 minutes. The supernatant containing the cytoplasmic extracts was removed and 
transferred to a new eppendorf tube. The pelleted nuclei were resuspended in 2411 of buffer 
C (400mM NaC1, 7.5mM MgC12, 0.2mM EDTA pH 8 and 1mM DTT with protease 
inhibitors added just prior to use; aprotinin (10m.g/m1), leupeptin (51.1,g/m1) and PMSF 
(5001.1M). The nuclei were then incubated in buffer C for 15 minutes on ice then 
centrifuged at 13000g for 5 minutes. The supernatant containing the nuclear proteins was 
then transferred to a new eppendorf tube. The nuclear extracts were stored at -80 °C. 
2.4.2 Quantification of protein 
Protein concentrations of nuclear extracts were determined using the Bradford 
protein assay (Bradford, 1976) using bovine serum albumin (BSA) as the protein standard. 
Serial dilutions of BSA were prepared from 1.0 to 0.1mg/m1 for construction of a standard 
curve. Nuclear extracts were diluted 1:10. Bradford dye reagent (BioRad) was prepared by 
filtering 1 part dye to 4 parts water through filter paper (Whatman, Number 1). The dye 
reagent (1m1) was added to 10[11 of the standards and samples. The standards and samples 
were vortexed and incubated at room temperature for 5 minutes. Absorbance was measured 
at 595nm using the BioRad SmartSpec 3000TM  spectrophotometer. The concentration of the 
nuclear extracts was determined from the BSA standard curve. 
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2.4.3 Separation and transfer of nuclear proteins 
2.4.3.1 SDS PAGE and Western Blotting 
Nuclear extracts (3-1514) were added to an equal volume of 2x sample buffer 
(section 2.9.2) and heated at 95°C for 5 minutes. A 12.5% acrylamide gel was poured and 
assembled in a gel apparatus (BioRad). The tank was filled with lx SDS PAGE running 
buffer (section 2.9.2). The samples were then loaded onto the gel along with 51.1,1 of 
Multimark® multi-coloured standard (Invitrogen). The samples were electrophoresed at 
125V for 90 minutes. The gel was removed from its cassette and placed into the transfer 
apparatus (BioRad). The chambers were filled with Western transfer buffer (section 2.9.2) 
and proteins were transferred to a nitrocellulose membrane (Micro Filtration Systems) at 
20V for 18 hours at 4°C. 
The membrane was placed in blocking solution (section 2.9.2) and incubated on a 
platform shaker at room temperature for 1 hour. Following this the membrane was sealed in 
plastic with the appropriate primary antibody (Table 2.4) diluted with lx TNT (section 
2.9.2) and incubated for another hour at room temperature on a shaker. The membrane was 
washed three times in lx TNT (10 minutes per wash) and sealed in plastic along with the 
appropriate secondary antibody dilution in lx TNT. The membrane was incubated in this 
secondary antibody solution for 1 hour at room temperature on a shaker then washed 
another three times (10 minutes per wash) in lx TNT. The membrane was then sealed in 
plastic and incubated for 5 minutes in 2.5ml of Pierce SuperSignal 0 West Pico Luminol 
enhancer solution and 2.5ml of stable peroxide solution (Pierce). The solution was removed 
and the membrane was exposed to high performance autoradiography film (Amersham 
Pharmacia Biotech) for 1 minute. The film was then agitated in developer (Kodak) for 1 
minute, rinsed in water and placed in fixing solution (Ilford) for 1 minute. Shorter or longer 
exposures were carried out as required. 
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Table 2.4. Antibodies used in the analysis of proteins in EL-4 T cells. 
Primary Antibody Concentration Secondary Antibody Concentration 
Anti—p65 (Rel A) 1:1000 Goat anti-rabbit 1:1000 
Anti-c-Rel 1:1000 Goat anti-rabbit 1:1000 
Anti-Spl 1:1000 Goat anti-rabbit 1:1000 
Anti NFATp 1:1000 Rabbit anti-mouse 1:1000 
Anti -NFATc 1:1000 Rabbit anti-mouse 1:1000 
Anti-HA 1:1000 Goat anti-rabbit 1:1000 
Anti-Brgl 1:1000 Goat anti-rabbit 1:1000 
All primary antibodies were provided by Santa Cruz Biotechnology. Peroxidase-conjugated 
secondary antibodies were provided by Dako. 
2.4.3.2 Stripping and Reprobing Blots 
Antibodies were removed from blots to enable reprobing for analysis of additional 
proteins. Blots were incubated at 65 °C in stripping buffer (section 2.9.2) for 30 minutes 
with shaking, followed by three washes (10 minutes per wash) in lx TNT. The membrane 
was then placed in blocking solution for 1 hour. The remainder of the protocol was carried 
out as described in section 2.4.3.1. 
2.5 Cloning 
2.5.1 Ligation 
PCR product was ligated into the appropriate vector by combining fresh PCR 
product, 1111 of 10x ligation buffer (Invitrogen), 2111 PCR® 2.1 vector (50ng total; 
Invitrogen), 1 pi T4 DNA ligase (New England Biolabs) and MilliQ water to a total volume 
of 101,11. The ligation reaction was then incubated for a minimum of 4 hours at 14°C. 
2.5.2 Preparation of competent cells 
L-broth (100m1; section 2.9.1) was inoculated with lml of a saturated MC1061 
E.Coli culture and incubated with shaking at 37°C. The optical density of the cells was then 
measured at 650nm using the BioRad SmartSpec 3000Tm spectrophotometer. Once the 
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bacterial culture had reached an 0.D650 of 0.4 to 0.5 the culture was transferred to 
centrifuge tubes and centrifuged at 7000g for 5 minutes. The bacterial pellet was then 
resuspended in 20m1 of ice cold 50mM CaC12 and incubated on ice for 30 minutes. The 
cells were then pelleted at 7000g for 5 minutes and resuspended in 3m1 ice cold 50mM 
CaC12. 
2.5.3 Transformation of competent cells 
A 200111 aliquot of the freshly prepared competent cells was used for each 
transformation. A 21.11 aliquot of the ligation reaction was pipetted into the competent cells 
and mixed well prior to incubating on ice for 30 minutes. The cells were then heat shocked 
at 42°C for 30 seconds and placed on ice. SOC medium (250111; section 2.9.1) was added to 
each sample and the vials placed on a shaking platform at 37°C for 1 hour at 225rpm. 
Transformed cells (10-200g1) were then spread on LB agar plates (section 2.9.1) containing 
antibiotic. The plates were inverted and incubated at 37 °C for 18 hours before incubating at 
4°C for 3 hours to allow colour development. A single colony was then inoculated into 2m1 
of L-broth containing the appropriate antibiotics for further propagation and preparation of 
stocks. Glycerol stocks of transformed bacterial cultures were prepared by adding 850111 
bacterial culture to 150111 of sterile glycerol in an eppendorf tube. Stocks were stored at - 
80°C. 
2.6 Transfection of EL-4 T cells 
EL-4 T cells were transfected with plasmids targeting NFAT or Brg 1 action 
according to the following protocols. 
2.6.1 Plasmids 
The mutant Brg 1 construct, pBJ5-brg 1 K/R and the pBJ5 plasmid were provided by 
Dr G. Crabtree (Khavari et al, 1993). The pEGFP-VIVIT and pEGFP plasmids were 
provided by Dr. A. Rao (Aramburu et al, 1999). The KKII plasmid used for magnetically 
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activated cell sorting was provided with the MACSelect kit (Miltenyi Biotech). Plasmids 
were propagated in MC1061 E.Coli cells. 
2.6.2 Plasmid purification 
Plasmids were isolated either by alkaline lysis/CsC12 purification or using the 
Qiagen Midi prep kit. In each case, glycerol stocks of MC1061 cells, transformed with the 
relevant plasmids, were inoculated in 2m1 of L-broth containing either ampicillin 
(10011g/m1) or kanamycin (1001..tg/m1) depending on the resistance provided by the plasmid. 
The starter cultures were incubated at 37 °C in a shaking incubator for 6 to 8 hours before 
transferring to larger (100-400m1) cultures (containing antibiotics) for overnight 
incubation. 
2.6.2.1 Plasmid preparation by alkaline lysis 
The pEGFP and pEGFP-VIVIT plasmids were isolated by alkaline lysis and 
subsequent cesium chloride (CsC12) purification, essentially as described previously 
(Sambrook and Russel, 2001). Bacterial cultures grown overnight were transferred to 
500m1 centrifuge bottles and bacteria pelleted at 3200g for 15 minutes at 4 °C. The 
supernatant was removed and the pellet resuspended in 8m1 alkaline lysis buffer 1 (50mM 
glucose, 25mM Tris HC1 pH 7.4, 10mM EDTA pH 8) with repeated pipetting and 
transferred to sorvall tubes. Lysozyme (80mg) was then added to each sample and 
incubated at room temperature for 5 minutes. Freshly prepared lysis buffer 2 (16m1; 0.2M 
NaOH, 1% SDS) was then added and the samples inverted several times before incubating 
on ice for 10 minutes. Ice cold buffer 3 (12m1; 5M ICAc, pH 4.8) was then added to each 
sample and mixed by inverting several times. The lysate was incubated on ice for another 
10 minutes before centrifuging at 17000g for 20 minutes at 4°C. The supernatant was then 
transferred to a new tube and 0.6 volumes of isopropanol was added and mixed well before 
incubating at room temperature for 30 minutes. The samples were then centrifuged at 
12000g for 15 minutes at room temperature and the pellets resuspended in 1 ml TE 
(100mM Tris pH 7.4, 10mM EDTA pH 8). RNase (Roche; 1001.tg/m1) was then added to 
each sample and incubated at 37 °C for 30 minutes. TE (9m1) and CsC12 (10.9g) was added 
35 
to each sample. Ethidium bromide (5mg) was added and the centrifuge tubes balanced and 
sealed. The tubes were then centrifuged at 120,000g for 40 hours in the Beckman L8-70M 
Ultracentrifuge. The plasmid bands were extracted using a 5m1 syringe and transferred to 
50m1 falcon tubes. Ethidium bromide was removed by extracting several times with an 
equal volume of MilliQ saturated butanol. Once the lower DNA phase was colourless, 2 
volumes of water was added along with 0.1 volume of 3M sodium acetate (pH 6.5) and 2.5 
volumes ethanol (100%). The DNA was then precipitated at -20°C for 6 hours before 
transferring to sorval tubes and pelleting at 12000g for 15 minutes. The pellet was then 
washed in 70% ethanol and resuspended in 4001A1 TE. DNA was then reprecipitated by 
adding 40p1 3M sodium acetate (pH 6.5) and lml ethanol before incubation at -20 °C for 48 
hours. The plasmid DNA was then pelleted at 13000g for 15 minutes. The pellet was 
washed in 70% ethanol and allowed to air dry before resuspending in 200111 TE. The DNA 
was then quantitated by measuring absorbance at A260 (section 2.3.5), the plasmid stock 
diluted to 1p,g4t1 and stored at -20°C. 
2.6.2.2 Plasmid purification using the Qiagen Midi Prep kit 
Plasmid DNA was extracted from MC1061 E.Coli bacterial cultures transformed 
with the pBJ5, pBJ5-brg1K/R and KKII plasmids using the Qiagen midiprep kit according 
to the manufacturers' instructions, with some modification as outlined below. 
Overnight bacterial cultures (400m1) were pelleted at 6000g for 15 minutes at 4 °C. 
Pellets were resuspended in 20m1 of buffer P1 to which 20m1 of buffer P2 was added 
before inverting several times. Lysates were incubated at room temperature for 5 minutes, 
20m1 of chilled buffer P3 added and samples mixed by inverting several times before 
incubating on ice for 30 minutes. Samples were then centrifuged at 20000g for 30 minutes 
at 4°C following which the supernatant was removed and centrifuged again at 20000g for 
15 minutes. The supernatant was transferred to a fresh tube and DNA was precipitated by 
adding 0.7 volumes of isopropanol. After inverting to mix, samples were centrifuged at 
15000g for 30 minutes at 4°C. The supernatant was then carefully removed and the pellet 
resuspended in 500p1 TE and RNase treated (1001...tg/m1) for 30 minutes at 37 °C. Samples 
were then phenol/chloroform extracted and ethanol/NaAc precipitated (section 2.9.3). DNA 
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was resuspended in 500111 TE and 4.5ml of buffer QBT was added. The columns (Qiagen-
tip 100) were equilibrated by washing with 4m1 of buffer QBT and allowed to empty by 
gravity flow. The DNA solution was then applied to the column and emptied by gravity 
flow. The column was washed twice with 10m1 of buffer QC and plasmid DNA was eluted 
with 5m1 of buffer QF into a glass sorvall tube. Isopropanol (3.5m1) was added to 
precipitate the DNA. Samples were mixed before centrifuging at 15000g for 30 minutes at 
4°C. The pellet was washed in 70% ethanol, air dried for 10 minutes then resuspended in 
40011,1 TE. Plasmid DNA was then reprecipitated and resuspended in a smaller volume 
before quantitation by spectrophotometry reading at A260  (Section 2.3.5) and diluting to 
Plasmid stocks were stored at -20 °C. 
2.6.3 Electroporation of EL-4 T cells 
EL-4 T cells were co-transfected by electroporation with 814 of either pBJ5, pBJ5- 
brg1K/R, pEGFP or pEGFP-VWIT plasmids along with 314 of the K KII selection plasmid 
in 4mm cuvettes using the BioRad Gene Pulser X cell. Briefly, EL-4 T cells at a density of 
5x105 cells/ml were pelleted at 1000g for 5 minutes. The supernatant was removed and the 
cells resuspended in RPMI containing 20% FCS at 1.5x10 7 cells/ml. Plasmid DNA was 
then added to the side of each cuvette (BioRad) followed by the addition of 300W of the 
cell suspension. Cells were then electroporated at 270V with a capacitance of 974tF. 
RPMI medium (1m1) was then added to each cuvette and the cells left to recover for 5 
minutes. The transfected cells were then transferred to 75cm2 culture flasks containing the 
appropriate amount of medium (5m1 per electroporation) and returned to the incubator for 
24 hours. 
2.6.4 Magnetic labelling and, sorting of transfected cells 
Transfected cells were enriched 24 hours post transfection using the MACSelect 
magnetically activated cell sorting kit (Miltenyi Biotech) according to the manufacturers' 
instructions. Transfected cells (2x107) were pelleted at 200g for 5 minutes and resuspended 
in lml PBS supplemented with 5mM EDTA pH 8. The cell suspension was then layered 
over 2m1 of FCS in a 15ml Falcon tube before pelleting once again at 200g for 5 minutes to 
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remove dead cells. The cell pellet was resuspended in 3201.,t1 degassed PBE (PBS 
containing 5mM EDTA and 0.5% BSA) per 107 cells and 80111 of MACSelect K KII 
microbeads were added. The cells and beads were mixed well and incubated at 4 °C for 15 
minutes, with occasional flicking. The cell suspensions were made up to 2m1 with PBE. 
Two MS/RS + columns (Miltenyi Biotech) were set up in the magnetic separation apparatus 
and washed with 500111 PBE. The magnetically labelled cells were then applied to the 
columns in 4x 5001A1 aliquots (half over each column). The columns were then washed 
twice with 5001A1 PBE before removing from the magnetic field and placing into a 15m1 
Falcon tube. RPM! medium (500ptl) was then added to the column and the plunger used to 
force cells through. Cells were then transferred to 6 well culture plates at a density of 5x10 5 
cells/ml. 
2.7 Chromatin Immunoprecipitation (ChIP) 
ChIP analysis of Brg 1 binding was performed according to the Upstate protocol 
(http://www.upstate.com/misc/protocol)  with some modifications. EL-4 T cells or A-20 B 
cells (15ml at 5x10 5 cells/nil) were incubated in RPM! or DMEM respectively containing 
1% formaldehyde for 15 minutes with shaking at room temperature to crosslink chromatin. 
Crosslinlcing was stopped by adding glycine to a final concentration of 0.125M and 
incubating for 10 minutes with shaking. Cells were collected after two PBS washes 
(supplemented with 214/m1 Aprotinin, 114/m1 Leupeptin and 1001AM PMSF) at 500g for 4 
minutes. Cells (2x106) were resuspended in 250111 lysis buffer (1% SDS, 10mM EDTA, 
50mM Tris HC1 pH 8.1 supplemented with protease inhibitors). Following incubation on 
ice for 10 minutes samples were sonicated five times with 30 second pulses at output 2 
(Microson XL 2000) to generate DNA fragments ranging from 200 to 1000bp. Samples 
were diluted to 1.25m1 with IP dilution buffer (1.2mM EDTA pH8, 0.1% SDS, 1% Triton 
X, 16.7mM Tris HC1 pH 8.1, 167mM NaC1) and pre-cleared with 60111 salmon sperm 
DNA/Protein A agarose (Upstate) for 30 minutes at 4 °C. The protein A agarose was 
pelleted by centrifuging at 500g for 1 minute and 1001A1 of the supernatant removed for the 
total input. The remaining supernatant was aliquoted as either a no antibody control or 
immunoprecipitated with 114 of Brg-1 antibody (Santa Cruz Biotechnology) overnight at 
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4°C with rotation. Immune complexes were recovered by incubation at 4 °C for one hour 
with 60p1 salmon sperm DNA/Protein A agarose. Samples were washed for 3 minutes on 
the rotary wheel at 4°C followed by pelleting at 500g for 1 minute. Immune complexes 
were washed once in low salt buffer (2mM EDTA, 0.1% SDS, 1% Triton X, 20mM Tris 
HC1 pH 8.1, 150mM NaCl), high salt buffer (2mM EDTA, 0.1% SDS, 1% Triton X, 20mM 
Tris HC1 pH 8.1, 500mM NaCl) and LiC1 buffer (1mM EDTA, 10mM Tris HC1 pH 8.1, 
250mM LiC1, 1% Igepal, 1% deoxycholate) and washed twice with TE (1mM EDTA pH 8, 
10mM Tris HCI pH 8.1). All wash buffers were supplemented with protease inhibitors. 
Chromatin was eluted by adding 200g1 of elution buffer (1% SDS, 0.1M NaHCO3) and 
incubating at room temperature for 1 hour on the rotary wheel. Protein A agarose was 
pelleted by centrifuging at 500g for 1 minute and the supernatant containing chromatin 
removed. The elution step was repeated and supernatants combined to give 4001.41 total 
volume. Crosslinks were reversed with 0.2M NaC1 overnight at 65 °C. DNA was then 
purified by phenol/chloroform extraction and ethanol/NaAc precipitation (section 2.9.3). 
DNA was resuspended in 501.11 of MilliQ water and amplified by real-time PCR using 
primer sets outlined in Table 2.5. 
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Table 2.5. Primers used in real-time PCR analysis of ChIP samples. 
Name Sequence (5' to 3') Amplicon 
(bp) 
Reference 
mGM-I Forward primer GCCTGACAACCTGGGGGAAG 116 Holloway 
et al, 2003 mGM-I Reverse primer TGATTAATGGTGACCACAGAACTC 
mGM+I Forward primer GAGTTCTGTGGTCACCATTAATCA 147 Holloway 
et al, 2003 mGM+I Reverse primer CACATCCTCCTCAGGACCTT 
mGM-V Forward primer TGGAATGAGCCACCAGAGTA 75 Holloway 
et al, 2003 mGM-V Reverse primer GGCTCTTGCTTCCATAGCAC 
m1L-4E Forward primer GCACCAGGGCACTTAAACAT 158 
m1L-4E Reverse primer CTGTGCAGTGCCACAATGAT 
mIL-5p Forward primer ACCCTGAGTTTCAGGACTCG 94 Wang 
et al, 2006 mIL-5p Reverse primer TCCCCAAGCAATTTATTCTCTC 
m1FN-yp Forward primer AACATGCCACAAAACCATAGC 156 
mIFN-yp Reverse primer CACCTCTCTGGCTTCCAGTT 
mGM-3' Forward primer ATTTGGGCATAGGTGGAGTG 89 
mGM-3' Reverse primer CCTCGATTTCACCTCCCTTT 
mGM-5' Forward primer GAGCTTCTGGAGAGGGAGGT 60 
mGM-5' Reverse primer TCCCAGGCTTAGTCTGTTGC 
mGAPDH Forward primer AAGTATGATGACATCAAGAAGGTGGT 67 Brettingham-
Moore et al, 2005 mGAPDH Reverse primer AGCCCAGGATGCCCTTTAGT 
All primers were supplied by Sigma. Real-time PCR was carried out as described in section 
2.3.6.2. Brgl recruitment was determined as the percentage of immunoprecipitated sample, 
minus the "No Antibody" control, compared to the total input. 
2.8 Microarrays 
The expression of T cell genes in response to the introduction of an ATPase 
defective Brgl mutant construct (pBJ5-brg1K/R) was determined by microarray analysis 
according to the following protocols. 
2.8.1 Sample preparation from Brgl mutant cells 
EL-4 T cells co-transfected with either the pBJ5 or pBJ5brg1K/R and K KII 
plasmids were sorted for transfected cells (section 2.6.3 and 2.6.4) then either left untreated 
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or stimulated for 6 hours in the presence of P/I as described in sections 2.1.4. Total RNA 
was isolated as described in section 2.2.1. 
2.8.2 RNA quality assessment 
The quality of the RNA to be used in the microarray experiments was assessed 
using the Agilent 2100 BioAnalyzer which determines sample integrity and the 
NanoDrop@ which determines sample concentration and purity. cRNA was prepared and 
microarrays hybridized with Dr. Kaiman Peng at the Biomolecular Resource Facility, John 
Curtin School of Medical Research at the Australian National University, according to the 
recommended Affymetrix protocols as outlined below. 
2.8.3 First strand cDNA synthesis 
RNA (3[1g) was made up to a total volume of 8ial with MilliQ water. RNA along 
with 2111 PolyA RNA control (Invitrogen Life Technologies) and 2111 T7-(dT)24 oligomer 
(Affymetrix) were combined into 100g1 PCR tubes. The reaction components were mixed 
and incubated at 70°C for 10 minutes before cooling at 4°C for 2 minutes. To each sample 
4111 of 5x first strand reaction mix (Invitrogen Life Technologies), 2pi 0.1 M DTT 
(Invitrogen Life Technologies) and 11.11 10mM dNTPs was added along with 1111 
Superscript II (Invitrogen Life Technologies). The reactions were incubated at 42°C for 1 
hour before cooling for 2 minutes at 4°C. 
2.8.4 Second strand cDNA synthesis 
Following first strand cDNA synthesis, 91p1 DEPC treated water, 30111 5x second 
strand reaction (Invitrogen Life Technologies), 3i,t1 10mM dNTPs (Invitrogen Life 
Technologies), 1111 10U4t1 E. coli DNA ligase (Invitrogen Life Technologies), 4[E1 10U4t1 
E. coli DNA polymerase I (Invitrogen Life Technologies) and 1121 2U/111 E. coli RNase H 
(Invitrogen Life Technologies) were added to each sample. Each sample was then 
incubated at 16°C for 2 hours. T4 DNA polymerase (2R1; Invitrogen Life Technologies) 
was then added and the samples incubated at 16 °C for a further 5 minutes. Following this 
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10i.t1 of 0.5M EDTA was added. Double stranded cDNA was purified using phase lock gel 
GeneChip sample clean up modules (Affymetrix). 
2.8.5 Synthesis of Biotin labelled cRNA 
In Vitro Transcription (IVT) and biotin labelling of cRNA was carried out using the 
BioArray HighYield RNA transcript labelling kit (Affymetrix). Briefly, template cDNA 
(12111) was transferred to an RNase free microfuge tube along with 811,1 RNase free water, 
followed by 12R1 labelling NTP mix (Affymetrix), 4g1 10x IVT labelling buffer 
(Affymetrix) and 4111 IVT labelling enzyme mix (Affymetrix). The reactions were 
incubated at 37°C for 16 hours. 
2.8.6 Purification and quantification of cRNA 
Unincorporated NTPs were removed from the cRNA using the Genechip sample 
clean up module (Affymetrix). IVT reactions were made up to 10041 with RNase free 
water and mixed by vortexing for 3 seconds. IVT cRNA binding buffer (350111; Qiagen) 
was added and vortexed, followed by 250111 of 100% ethanol which was mixed by 
pipetting. The sample was then applied to the IVT cRNA clean up spin column which was 
then centrifuged for 15 seconds at 8000g. The flow through was discarded and IVT cRNA 
wash buffer (50041; Qiagen) was added to each column followed by centrifugation at 
8000g for 15 seconds before discarding the flow through. This step was repeated using 
500111 of 80% ethanol. The spin column was then centrifuged at maximum speed for 5 
minutes before discarding the collection tube and its contents. RNase free water (35111) was 
pipetted directly onto the membrane before centrifuging at 13000g for 1 minute and the 
eluate collected in a new collection tube. Another 3411 of RNase free water was added to 
the column and the eluate collected by centrifugation at 13000g for 1 minute. The 
concentration and purity of the cRNA was determined using the NanoDrop®. 
2.8.7 Fragmentation of cRNA 
Fragmentation reactions were set up using 2014 cRNA along with 6.41.11 5x 
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Fragmentation buffer (Affymetrix) and RNase free water to a total volume of 321A1. cRNA 
was then incubated at 94°C for 35 minutes. A small aliquot of non fragmented and 
fragmented cRNA was analyzed using the BioAnalyzer (Agilent) to determine 
concentration and purity. Samples were stored at -20 °C before hybridization. 
2.8.8 Target hybridization 
A hybridization mixture was prepared containing 1511g fragmented cRNA, 50pM 
control oligonucleotide B2 (Affymetrix), lx eukaryotic hybridization buffer (Affymetrix), 
100pM DMSO, 1.5/5/25/100pM controls (bioB, bioC, bioD, cre; Affymetrix), 0.1mg/m1 
herring sperm DNA (Affymetrix) in a total volume of 300111. 
cRNA hybridization cocktails were initially hybridized to Affymetrix Test3 arrays 
to ensure sample quality before proceeding onto the Mouse Genome 430 2.0 GeneChips ® . 
The arrays were equilibrated to room temperature and the hybridization cocktails were 
heated at 99°C for 5 minutes then 45 °C for 5 minutes. The hybridization cocktails were 
then centrifuged at 13000g for 5 minutes to remove insoluble material. The array was wet 
with lx hybridization buffer (Affymetrix) by pipetting through one of the septa, and 
incubated in the hybridization oven for 10 minutes with rotation at 45 °C. Buffer solution 
was then removed from the array chamber and the chamber filled with 80g1 of the 
hybridization cocktail. The arrays were then placed in the hybridization oven at 45 °C and 
rotated at 60rpm for 16 hours. 
2.8.9 Washing and staining the arrays 
Arrays were washed and scanned using the GeneChip° Operating System (GCOS, 
Affymetrix). Arrays were removed from the hybridization oven and the hybridization 
cocktail removed. The array was then filled with 1001.11 of non stringent wash buffer after 
equilibrating to room temperature. The following dye and antibody solutions were prepared 
and 6001.11 of each placed into eppendorfs and fitted to the fluidics station. 
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SAPE Stain solution 
2x MES stain buffer (Affymetrix) 600111 
50mg/m1 acetylated BSA (Affymetrix) 48g1 
1mg/m1 SAPE 	(Affymetrix) 12111 
ddH20 540111 
Total volume 1200A1 
Antibody solution 
2x MES stain buffer (Affymetrix) 3001.11 
50mg/m1 acetylated BSA (Affymetrix) 24111 
10mg/m1 goat IgG (Affymetrix) 61.11 
0.5mg/m1 biotinylated antibody (Affymetrix) 3.6111 
ddH20 266.4g1 
Total volume 600111 
After washing the lines in the fluidics station and placing the wash and stain solutions in 
the station, the arrays were fitted to the station and the wash and dye steps carried out 
according to the program set. The arrays were then scanned using the Affymetrix 
GeneChip@ Scanner 3000. 
2.9 General Techniques 
2.9.1 General reagents 
TAE buffer (50x) 
24.2g Tris base 
10111 0.5M EDTA 
5.7 ml Glacial acetic acid 
Distilled water to 100mIs 
pH to 7.0 using acetic acid 
Agarose gel loading buffer 
0.25g sucrose 
12.5111 0.5M EDTA 
125R1 10% SDS 
0.25% BPB 
MilliQ water to lml 
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L-Broth 
5g tryptone 
2.5g yeast extract 
2.5g NaCl 
200 1115M NaOH 
MilliQ water to 500 ml 
1.5g agar 
LB agar plates 
lg tryptone 
0.5g yeast extract 
0.5g NaC1 
MilliQ water to 100m1 
401115M NaOH 
SOC medium 
20g tryptone 
5g yeast extract 
0.5g NaC1 
2.5m1 1M KC1 
MilliQ water to 1000m1 
pH to 7 with NaOH 
20m1 sterile glycerol 
2.9.2 Reagents for SDS PAGE and western blotting 
10x SDS-PAGE running buffer 
14.5g Tris base 
72g Glycine 
5g SDS 
To 500m1 with distilled water 
Distilled water tolOml 
13-mercaptoethanol (10%) added before use. 
2x Sample buffer 
0.5M Tris HC1, pH 6.8 
Glycerol 
10% SDS 
0.1% BPB 
2.5 ml 
2.0 ml 
4.0 ml 
0.5 ml 
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SDS-PAGE Upper buffer 
30g Tris Base 
2g SDS 
pH to 6.8 with HC1 
Distilled water to 500m1 
SDS-PAGE Running gel 
2m1 lower buffer 
3.4ml 30% acrylamide 
20111 10% APS 
10g1 TEMED 
2.7m1 distilled water  
SDS-PAGE Lower buffer 
91g Tris Base 
2g SDS 
pH to 8.8 with HC1 
Distilled water to 500m1 
SDS-PAGE Stacking gel 
0.7m1 Upper buffer 
0.4m1 30% acrylamide 
15g1 10% APS 
5g1 TEMED 
1.5m1 distilled water 
Western transfer buffer 
2.4g Tris 
11.2g Glycine 
200m1 Methanol 
1.0g SDS 
Distilled water to 1000m1  
10x TNT, pH 8 
12.11g Tris 
87.6g NaC1 
5m1 Tween 
Distilled water to 1000m1 
Blocking solution 
Western blocking reagent (Roche) diluted 1:10 with lx TNT 
Stripping buffer 
6.25m1 1M Tris 
0.7m1 P-mercaptoethanol 
20m1 10% SDS 
Distilled water to 100m1 
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2.9.3 Phenol/chloroform extraction and ethanol precipitation of 
DNA 
DNA was extracted and concentrated by adding an equal volume of 
phenol:chloroform to samples. Samples were vortexed and centrifuged at 10000g for 10 
minutes. The upper phase was then removed and 0.1 volumes of NaAc pH 6.5 and 2 
volumes of 100% ethanol added. Samples were then precipitated at -20 °C overnight before 
centrifuging at 13000g for 20 minutes. The DNA pellet was then washed with 70% ethanol 
and air-dried for 5 minutes before resuspending in an appropriate amount of MilliQ water. 
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CHAPTER 3. 
GM-CSF PROMOTER REMODELLING AND 
TRANSCRIPTION ARE DISTINCT PROCESSES. 
3.1 Introduction 
The induction of cytolcine gene expression is primarily controlled at the level of 
transcription, through the assembly of specific transcription factor complexes across gene 
regulatory regions. It is now evident that the transcriptional machinery must first access the 
relevant DNA binding sites within a repressive chromatin environment which provides an 
additional level of regulatory control (reviewed in Smale and Fisher, 2002; Holloway et al, 
2002). While it is well recognized that GM-CSF transcription is induced when stimulated 
by signals arising from T cell activation, (reviewed in Shannon et al, 1997; Jenkins et al, 
1995) the role of the pathways and factors activated downstream of TCR ligation in 
chromatin remodelling events at the GM-CSF gene remain largely unknown. 
The rapid increase in GM-CSF gene expression following T cell activation is 
regulated by a proximal promoter limited to 100 bp upstream of the transcription start site 
as well as an upstream enhancer (reviewed in Shannon et al, 1997). Earlier work by 
Cocker!! et al (1999) has identified an inducible DNase I hypersensitive site in the GM-
CSF promoter in response to stimulation with PMA and ionophore. The presence of this 
inducible DNase I hypersensitive site suggests that the chromatin structure of the GM-CSF 
promoter is altered following T cell stimulation. Indeed, a more detailed analysis by 
Holloway et al (2003) has revealed that GM-CSF gene expression is preceded by changes 
in chromatin structure across the proximal promoter region of the gene. While the GM-CSF 
promoter is slightly accessible to agents such as MNase and restriction enzymes in the 
resting T cell, immune stimulation promotes a dramatic rise in accessibility. Upon T cell 
stimulation changes in chromatin structure occur across the GM-CSF promoter in the 
region between -174 and +24, suggesting the targeted remodelling of a single nucleosome 
encompassing the proximal promoter (Holloway et al, 2003). 
Limited data is available regarding the activation of the endogenous GM-CSF 
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promoter, although a number of studies have considered the role of various transcription 
factors and signals in GM-CSF reporter driven expression (Jenkins et al, 1995; Shang et al, 
1999). An important role for NF-KB in GM-CSF gene activation has been identified as 
mutation of the NF-KB site in the human GM-CSF promoter reduces luciferase reporter 
expression by half (Jenkins et al, 1995). In addition, Shang et al (1999) demonstrated using 
gel shift assays, that NFAT binds the GM-CSF promoter to drive expression of a GM-CSF 
reporter construct in response to P/I signalling. 
While it is clear that inducible transcription factors play a major role in activating 
transcription from the GM-CSF promoter (Shang et al, 1999; Cakouros et al, 2001), 
activation of the endogenous GM-CSF gene is accompanied by remodelling of the 
proximal promoter region (Holloway et al, 2003) and the signals and factors responsible 
for increasing GM-CSF promoter accessibility have yet to be elucidated. However, 
previous work has implicated NF-KB proteins in GM-CSF promoter remodelling 
(Cakouros et al, 2001; Holloway et al, 2003). Mutation of the NF-KB/Sp 1 region in the 
GM-CSF promoter has been shown to drastically reduce GM-CSF expression, and this 
effect was only observed in a chromatin context and not in transiently transfected plasmids 
(Cakouros et al, 2001). Adding further support to a role for NF-K13 in GM-CSF promoter 
remodelling, Holloway et al (2003) stably transfected EL-4 T cells with a mutant IKE 
construct which prevented the nuclear translocation of NF-1(13 following T cell stimulation. 
T cells expressing this mutant construct failed to display the typical increase in promoter 
accessibility following T cell stimulation. This suggests that chromatin remodelling across 
the GM-CSF promoter region may be regulated by NF-x13 proteins. In contrast, NFAT 
family members have been implicated in remodelling of the GM-CSF enhancer region 
(Cockerill et al, 1993; Johnson et al, 2004), with inhibition of NFAT by the 
immunosuppressant, Cyclosporin A, preventing the appearance of an inducible DNase I 
hypersensitive site. 
While strong evidence for the NF-K.13 and NFAT transcription factors in regulating 
the GM-CSF promoter has been provided in the past, the precise role of individual factors 
in activating the endogenous GM-CSF gene have yet to be identified. This chapter aims to 
address how the GM-CSF gene is activated in a chromatin context. More precisely, roles of 
the PKC and calcium signalling pathways, along with the NP-KB and NFAT family 
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members were investigated. 
3.2 Results 
3.2.1 Distinct signals are required for chromatin remodelling 
and gene transcription at the GM-CSF promoter. 
In order to determine the transcription factor and signal requirements for GM-CSF 
promoter remodelling and gene transcription, these two events were examined following 
the activation of different intracellular signalling pathways in T cells. T cell receptor 
ligation activates two major signalling pathways involving the mobilization of PKC and the 
increase in free intracellular calcium levels (Altman et al, 1992). Phorbol esters and 
calcium ionophores are often used to activate T cells in vitro to mimic the activation of the 
PKC and calcium signalling pathways respectively (Takahama and Nakauchi, 1996). These 
agents are therefore able to trigger T cell activation and have previously been shown to 
induce the transcription of a number of cytokine genes including GM-CSF (Tsuboi et al, 
1994). 
Previous work by the author has demonstrated that both the PKC and calcium 
sigalling pathways are required for full transcriptional induction of GM-CSF gene 
expression (Brettingham-Moore, 2002, Honours Thesis). Little GM-CSF mRNA was 
detected in resting EL-4 T cells, however following the combined P/I treatment, GM-CSF 
mRNA levels increased approximately 200 fold (Figure 3.1a). In contrast I alone had 
minimal impact on GM-CSF transcription (approximately 4 fold increase) while treatment 
with P resulted in only a small (20 fold) increase. In addition these studies found using a 
real-time PCR based accessibility assay (CHART PCR, Rao et al, 2001) that a Hinfl site in 
the CK1 element in the GM-CSF promoter has an inherent basal accessibility of 
approximately 40% in non stimulated cells (Figure 3.1b). Following stimulation with P/I, 
Hint" accessibility increased to approximately 70%. Similar accessibility levels were 
observed at the GM-CSF promoter in P stimulated cells, while accessibility in I treated 
cells remained at basal levels (Brettingham-Moore, 2002, Honours thesis). 
Next it was necessary to determine whether accessibility changes observed at the 
Hinfl site were seen across the entire promoter and had the same signal requirements. 
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Figure 3.1. Distinct signals are required for GM-CSF gene transcription and 
promoter remodelling. (Brettingham-Moore, 2002, Honours thesis). (A) GM-
CSF mRNA levels were determined by real-time PCR analysis of cDNA prepared 
from EL-4 T cells either left untreated (NS) or stimulated for 4 hours with P and I, 
alone or in combination. Data is graphed as fold change in GM-CSF mRNA levels 
compared to non-stimulated. The mean and standard error of three replicate assays 
are shown. (B) Nuclei from NS EL-4 T cells or cells stimulated for 4 hours with P 
and I as indicated were incubated with Hinfl. Genomic DNA was analyzed by 
real-time PCR with primer set —I. The mean and standard error of three replicate 
assays are shown. 
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CK-I KB Sp I 	API NFAT/Ets 
-400 
Set -V 
Figure 3.2. Schematic representation of the GM-CSF promoter with 
transcription factor binding sites, the CD28RR, Hinfl cutting site and regions 
amplified by primer sets —V, -I, +I and +II. 
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Therefore the effect of the different stimuli on the accessibility of the promoter region to 
MNase digestion was assessed using primer sets mGM-I, mGM+I and mGM-V (Figure 
3.2). Primer set -I covers the CD28RR and the Hinfl recognition sequence, while primer set 
+I (-63 to +44) spans the transcription start site and the AN, NFAT/Ets transcription factor 
binding sites. In addition, accessibility at a site spanned by primer set —V, which binds 
further upstream of the transcription start site was analyzed (Figure 3.2). While Hinfl cuts 
at a specific site, MNase will cleave all internucleosomal sites. EL-4 T cells were left 
untreated or stimulated with P, I or P/I for 4 hours. Nuclei were then isolated and chromatin 
digested using MNase. Accessibility across the promoter region mirrored the results 
previously obtained using Hinfl. In unstimulated cells both the CD28RR (primer set -I, 
Figure 3.3a) and NFAT/AP-1 region (primer set +I, Figure 3.3b) showed an inherent 
accessibility to MNase of approximately 50%. Stimulation with P alone or P/I resulted in 
an increase in accessibility to approximately 75% across the entire promoter. I alone 
however was not able to increase accessibility above basal levels. Previous data (Holloway 
et al, 2003) has shown that changes in accessibility are confined to the GM-CSF promoter 
region. In agreement with this a lower basal accessibility was observed in the region 
amplified by primer set -V, located -422 to -347 base pairs upstream of the transcription 
start site. In addition stimulation with P, I and P/I failed to cause any change in 
accessibility in this region (Figure 3.3c). Put together, these data provide evidence for a 
role for factors activated downstream of PKC signalling in chromatin remodelling events at 
the GM-CSF promoter. However, full transcriptional induction of the GM-CSF gene 
requires factors activated downstream of the PKC and calcium signalling pathways. 
The GM-CSF promoter contains an array of transcription factor binding sites 
including sites for NF-x13 and NFAT proteins and these transcription factor families have 
been implicated in GM-CSF gene expression (Shang et al, 1999; Cakouros et al, 2001). In 
order to determine which transcription factors are likely to be involved in directing 
promoter remodelling compared to transcription, the presence of different transcription 
factors in the nucleus was correlated with different signalling events. Nuclear extracts were 
prepared from EL-4 T cells either left untreated (NS) or stimulated with P, I or P/I for 4 
hours. The presence of NF-K13 family members, c-Rel, Rel A along with NFAT family 
members, NFATc and NFATp in the nucleus was determined by western blotting. It is 
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Figure 3.3. PKC signalling is sufficient to induce GM-CSF promoter remodelling. 
Nuclei were isolated from non-stimulated (NS) EL-4 T cells or cells stimulated for 4 
hours with P and I as indicated and incubated with MNase. Genomic DNA was 
analyzed by real-time PCR with primer set -I (A), +I (B) and —V (C). The mean and 
standard error of three replicate assays are shown. 
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clear that while P can induce the nuclear translocation of c-Rel and Rel A, stimulation with 
P/I results in an increased accumulation of these proteins (Figure 3.4). Stimulation with P 
alone can induce the nuclear translocation of NFATc and once again stimulation with P/I 
results in an increase in nuclear accumulation. Combined P/I stimulation is required for the 
nuclear translocation of NFATp. I is capable of allowing a small amount of NFATc to enter 
the nucleus. Combined PKC (P) and calcium (I) signals ensures the nuclear translocation of 
all 4 factors. The blot was reprobed using an Sp 1 antibody to ensure even loading of all 
samples. From these results it is clear that the presence of c-Rel, Rel A and NFATc in the 
nucleus correlate with chromatin remodelling (Figure 3.3a-b) and suggest that these factors 
could play a role in increasing accessibility to the GM-CSF promoter in P treated cells. 
The PKC inhibitor, Ro-32-0432 (Wilkinson et al, 1993) was used to confirm the 
role of PKC signalling in GM-CSF promoter remodelling and gene transcription. To 
ascertain whether the PKC inhibitor had an effect on transcription factor activation EL-4 T 
cells were either left untreated or pre-treated with Ro-32-0432 for 1 hour before being 
stimulated with P/I for 4 hours. Nuclear extracts were then prepared and analyzed by 
western blotting (Figure 3.5). The inhibition of PKC signalling prevented the nuclear 
translocation of both NFATc and NFATp along with c-Rel and to a lesser extent Rel A. 
The blot was reprobed using an Spl antibody to ensure even loading of all samples. 
The effect of PKC inhibition on GM-CSF transcription was then determined by 
real-time PCR analysis of cDNA prepared from Ro-32-0432 treated EL-4 T cells. cDNA 
was analyzed by real-time PCR using the mGM+II primer set and primers designed to the 
"housekeeping" gene GAPDH (Table 2.2 chapter 2). PCR amplification was monitored by 
SYBR green incorporation and standard curves used to correlate Ct values with copy 
number. GM-CSF mRNA levels were then normalized to GAPDH. Cells activated in the 
absence of Ro-32-0432 showed an approximately 150 fold increase in GM-CSF expression 
(Figure 3.6a). In contrast pre-treatment with the PKC inhibitor markedly inhibited GM-
CSF transcription in response to T cell activation. To determine whether the reduction in 
GM-CSF activation was due to the inhibition of GM-CSF promoter remodelling, EL-4 T 
cells were either left untreated or pre-treated with Ro-32-0432 prior to incubating with or 
without P/I. Accessibility of the GM-CSF promoter to Hid.' was then determined using 
CHART-PCR. While control treated cells displayed a typical increase in accessibility 
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Figure 3.4. The nuclear translocation of NF-KB and NFAT proteins require 
distinct signals. Nuclear extracts from EL-4 T cells either left untreated (NS) or 
stimulated for 4 hours with P and I or P/I were subjected to SDS-PAGE and 
analyzed by western blotting with the indicated antibodies. 
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Figure 3.5. The inhibition of PKC signalling prevents the nuclear accumulation 
of NF-KB and NFAT proteins. Nuclear extracts from EL-4 T cells pre-treated with 
or without the PKC inhibitor Ro-32-0432 followed by stimulation with P/I for 4 
hours were subjected to SDS-PAGE and analyzed by western blotting with the 
indicated antibodies. 
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Figure 3.6. The PKC signalling pathway is required for transcription and 
GM-CSF promoter remodelling. (A) EL-4 T cells were either untreated or pre-
treated with Ro-32-0432, then incubated with or without P/I for 4 hours before 
isolating RNA. cDNA was then prepared and GM-CSF mRNA levels were 
determined by real-time PCR analysis. The mean and standard error of three 
replicate assays are shown. (B) Nuclei from EL-4 T cells as treated in A were 
incubated with HinfI and genomic DNA analyzed by real-time PCR using primer 
set -I. The mean and standard error of three replicate assays are shown. 
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across the GM-CSF promoter following T cell activation, chromatin remodelling was 
prevented in cells treated with the PKC inhibitor (Figure 3.6b). Therefore, the inhibition of 
the PKC signalling pathway prevented remodelling from occurring at the GM-CSF 
promoter in stimulated cells and confirms that PKC signalling is essential for remodelling. 
In order to verify the role of calcium signalling in GM-CSF gene transcription and 
remodelling the immunosuppressant cyclosporin A (CsA) was used to block this pathway. 
CsA binds cyclophillin and inhibits the action of the phosphatase calcineurin which is 
required to dephosphorylate NFAT for nuclear translocation (Liu et al, 1991). To 
determine the transcription factors affected by inhibition of calcium signalling by CsA 
nuclear extracts were prepared from control and CsA pre-treated EL-4 T cells either left 
unstimulated or P/I stimulated. Western analysis revealed that pre-treatment with CsA 
blocked the nuclear accumulation of NFATc and NFATp (Figure 3.7). In addition, CsA 
was also found to slightly inhibit the translocation of Rel A and c-Rel to the nucleus. 
To assess the role of NFAT proteins in GM-CSF promoter remodelling and gene 
transcription genomic DNA was analyzed by CHART-PCR. Nuclei isolated from EL-4 T 
cells either left untreated or treated with CsA before incubating with or without P/I for 4 
hours, were digested with HinfT and the accessibility of the GM-CSF promoter determined 
by real-time PCR analysis. Compared to the control treated cells, treatment with CsA did 
not alter the basal or stimulated levels of accessibility at the GM-CSF promoter (Figure 
3.8a). This result demonstrates that NFATc and NFATp are not required for chromatin 
remodelling events at the GM-CSF promoter in response to P/I. However, the reduction of 
NFATc and NFATp brought about by CsA pretreatment resulted in a dramatic decrease in 
GM-CSF mRNA levels (Figure 3.8b). While P/I induced a 300 fold increase in GM-CSF 
mRNA levels in control cells, only a 100 fold increase was detected in CsA treated cells. 
These data suggest that NFAT is required for transcription of the endogenous GM-
CSF gene. To confirm this, NFAT nuclear accumulation was specifically inhibited using 
the VIVIT peptide (Aramburu et al, 1999). In order to assess the role of NFAT further and 
in a more specific manner EL-4 T cells were transfected with a pEGFP-VIVIT expression 
construct. This peptide prevents the nuclear translocation of NFAT proteins by blocking the 
calcineurin binding site thereby preventing dephosphorylation (Aramburu et al, 1999). EL- 
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Figure 3.7. Cyclosporin A prevents the nuclear accumulation of NFAT proteins. 
Nuclear extracts from EL-4 T cells either left untreated or pre-treated with CsA before 
incubating with or without P/I for 4 hours were subjected to SDS-PAGE and analyzed 
by western blotting with the indicated antibodies. 
59 
%
 a
cc
es
si
bi
lit
y  
to
  H
in
fl 
B 
+ + 
400 
300 
200 
100 
Fo
ld
  c
ha
ng
e  i
n  
in
R
N
A
 le
ve
ls  
Figure 3.8. CsA inhibits GM-CSF gene transcription but not promoter 
remodelling in response to P/I. (A) Nuclei from EL-4 T cells either left untreated 
or treated with CsA before incubating with or without P/I for 4 hours were 
incubated with Hinfl and genomic DNA analyzed by real-time PCR using primer 
set -I. The mean and standard error of three replicate assays are shown. (B) cDNA 
prepared from EL-4 T cells as treated in A was analyzed by real-time PCR. The 
mean and standard error of three replicate assays are shown. 
60 
4 T cells were co-transfected with the K KII plasmid and the control pEGFP plasmid or the 
pEGFP-VIVIT plasmid. The KKII plasmid drives the expression of the mouse H-2K' 
receptor protein with a truncated cytoplasmic domain. This enables attachment of 
transfected cells to magnetic beads coated with a monoclonal antibody directed against the 
surface marker encoded by the KKII plasmid. The transfected cells were sorted 24 hours 
post transfection by virtue of expression of the H-2K k receptor. Cells were then either left 
untreated or stimulated for 4 hours before isolating RNA and analyzing by real-time PCR. 
While the cells transfected with the control plasmid showed a 160 fold increase in GM-
CSF expression following stimulation, transcription was reduced 5 fold in pEGFP-VIVIT 
transfected cells (Figure 3.9). Therefore, while not required for promoter remodelling, 
NFAT is essential for the optimal induction of GM-CSF transcription. 
To determine whether new protein synthesis is required for chromatin remodelling 
at the GM-CSF promoter and subsequent transcriptional activation, EL-4 T cells were 
treated with the protein synthesis inhibitor cyclohexamide (CHX). Nuclear translocation of 
the NF-KB and NFAT transcription factors in response to P/I was determined by western 
analysis. As seen previously Rel A, c-Rel, NFATp and NFATc were all absent from the 
nuclei of non-stimulated cells and all four factors translocated to the nucleus following 
stimulation with P/I (Figure 3.10a). CHX pre-treatment blocked the nuclear translocation of 
c-Rel and NFATc, while Rel A and NFATp were unaffected. This result is in keeping with 
Rel A and NFATp being retained in the cytoplasm of resting T cells and translocated to the 
nucleus in response to P/I (reviewed in Karin and Ben-Neriah, 2000; Northrop et al, 1994) 
but c-Rel and NFATc being newly synthesized in response to T cell activation. 
Interestingly, Rel A appeared in the nuclei of non-stimulated cells treated with CHX in 
keeping with the findings of Han and Brasier (1997) who demonstrated that this is due to 
the role of the CHX sensitive factor, IKB in the cytoplasmic retention of Rel A. Reprobing 
with the Spl antibody demonstrated equivalent loading in each lane. 
The effect of CHX pre-treatment on transcription and chromatin remodelling was 
then examined. EL-4 T cells were pre-treated with CHX for 30 minutes before being 
stimulated with P/I for 4 hours or left untreated. GM-CSF mRNA levels were then 
determined by real-time PCR. While cells untreated with CHX displayed a 350 fold 
increase in GM-CSF mRNA levels, T cells pretreated with the protein synthesis inhibitor 
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Figure 3.9. Inhibition of NFAT proteins reduces GM-CSF transcription. EL-4 T 
cells were co-transfected with the K KII and GFP or GFP-VIVIT plasinids prior to 
magnetically activated cell sorting before incubating with or without P/I for 4 hours. 
cDNA was prepared and levels of GM-CSF mRNA analyzed by real-time PCR. The 
mean and standard error of three replicate assays are shown. 
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Figure 3.10. New protein synthesis is required for GM-CSF promoter 
remodelling but not transciption. (A) Nuclear extracts from EL-4 T cells either 
untreated or pre-treated with cyclohexamide (CHX) before incubating with or 
without P/I for 4 hours were subjected to SDS-PAGE and analyzed by western 
blotting with the indicated antibodies. (B) cDNA prepared from EL-4 T cells as 
treated in A was analyzed by real-time PCR. The mean and standard error of three 
replicate assays are shown. (C) Nuclei prepared from EL-4 T cells as treated in A 
were digested with Hinfl and genomic DNA analyzed by real-time PCR with primer 
set -I. The mean and standard error of three replicate assays are shown. 
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displayed only a 100 fold increase in GM-CSF mRNA levels (Figure 3.10b). Next, the 
possibility that this reduction in transcription was due to inhibition of promoter remodelling 
was investigated. Nuclei were isolated from cells treated as above and promoter 
accessibility to Hinfl analyzed by CHART-PCR. As observed previously, non-stimulated 
cells displayed an inherent basal accessibility (-50%) which increased to 80% following T 
cell stimulation (Figure 3.10c). EL-4 T cells pre-treated with CHX, showed similar basal 
accessibility (50%) however remodelling of the promoter region following T cell 
stimulation was inhibited. These data suggest that chromatin remodelling requires new 
protein synthesis and implicates c-Rel or NFATc in this process, however previous results 
(Figure 3.8a) have ruled NFAT proteins out as contributing to remodelling. The results also 
demonstrate that some gene transcription can occur in the absence of promoter 
remodelling. 
3.2.2 GM-CSF gene transcription and promoter remodelling 
display distinct kinetics. 
The data outlined above demonstrate that the processes of chromatin remodelling 
across the GM-CSF promoter and gene transcription are distinct events. To determine 
whether the kinetics of these events were also distinct, each process was studied over time 
following T cell activation. EL-4 T cells were stimulated with P/I at various time points, up 
to 48 hours before extracting RNA and analyzing GM-CSF mRNA levels by real-time 
PCR. GM-CSF mRNA levels increased within 2 hours post stimulation and continued to 
increase to 600 fold at 6 hours (Figure 3.11a). Levels had decreased considerably by 24 and 
48 hours, however GM-CSF expression remained elevated for at least 48 hours following 
stimulation. In order to determine whether the kinetics of GM-CSF promoter remodelling 
were similar to transcription, accessibility to the promoter over time was analyzed. Nuclei 
from EL-4 T cells stimulated for 0, 2, 6, 24 and 48 hours with P/I were incubated with 
Hinfl before analyzing genomic DNA by real-time PCR. Accessibility of the Hinfl site in 
the GM-CSF promoter increased from 40% to 60% within 2 hours of the initial stimulation 
(Figure 3.11b) and continued to increase for at least 24 hours when accessibility reached 
maximal levels of approximately 80%. By 48 hours accessibility had begun to decline. To 
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Figure 3.11. GM-CSF promoter remodelling and gene transciption display 
distinct kinetics. (A) GM-CSF mRNA levels were determined by real-time PCR 
analysis of cDNA prepared from EL-4 T cells stimulated with P/I for the indicated 
time periods. The mean and standard error of 3 replicate assays are shown. Nuclei 
from cells stimulated with P/I for the indicated time periods were incubated with 
HinfT (B) or MNase (C). Genomic DNA was analyzed by real-time PCR using 
primer set -I. The mean and standard error of three replicate assays are shown. 
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determine whether similar kinetics were observed across the entire promoter nuclei were 
again isolated from EL-4 T cells stimulated with P/I for up to 48 hours before digesting 
with MNase and analyzing genomic DNA by real-time PCR. Analysis of accessibility 
across the GM-CSF promoter to MNase showed slightly different kinetics to accessibility 
at the single HinfI site. Within 2 hours following stimulation there was a dramatic increase 
in accessibility across the promoter region, reaching maximal levels of 80%, by 4 hours 
and this was maintained for at least 48 hours (Figure 3.11c). Thus while GM-CSF mRNA 
levels gradually increased following stimulation before peaking at 6 hours and declining by 
24 hours, chromatin changes at the GM-CSF promoter were relatively stable, being 
maintained in a highly accessible state for at least 48 hours. 
Next, the timing of transcription factor nuclear translocation was determined to 
correlate transcription factor presence with GM-CSF gene transcription and chromatin 
remodelling events. Nuclear extracts were prepared from EL-4 T cells stimulated at various 
time points over a 24 hour time period and analyzed by western blotting with Rel A, c-Rel, 
NFATp and NFATc antibodies. Rel A and NFATp showed similar nuclear translocation 
profiles (Figure 3.12). Both of these factors translocated to the nucleus within 30 minutes 
of T cell stimulation, and remained in the nucleus for at least 8 hours. By 16 and 24 hours 
post stimulation the levels of Rel A declined significantly, and NFATp was barely 
detectable in the nucleus. Meanwhile c-Rel entered the nucleus within 2 hours of 
stimulation and persisted for at least 24 hours. Similarly, NFATc translocated to the 
nucleus by 4 hours following stimulation and persisted for at least 24 hours. Thus NFATp 
and Rel A presence appears to correlate well with the transcriptional profile of GM-CSF, 
while the persistence of c-Rel and NFATc in the nucleus for a prolonged time period 
correlated with the more stable, longer term chromatin remodelling events at the promoter. 
While GM-CSF promoter remodelling appears to be a relatively stable event 
following T cell stimulation, transcription is a more transient process. To determine 
whether the remodelled state needed to be stably maintained by continued stimulation, 
stimulus withdrawal experiments were conducted. In order to determine whether stimulus 
withdrawal had an effect on GM-CSF transcription, EL-4 T cells were stimulated for 2 
hours before stimulus withdrawal. Cells were left for a further 4 or 22 hours before 
isolating RNA. EL-4 T cells were also stimulated with P/I in parallel for 0, 2, 6, and 24 
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Figure 3.12. The kinetics of NF-KB and NFAT nuclear translocation. Nuclear 
extracts prepared from EL-4 T cells stimulated with pn for the indicated time 
periods were subjected to SDS-PAGE and analyzed by western blotting with the 
indicated antibodies. 
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hours before isolating RNA. GM-CSF mRNA levels were then determined by real-time 
PCR analysis of cDNA. Cells treated with P/I displayed a transient increase in GM-CSF 
mRNA levels which peaked at 6 hours with a 500 fold induction before levels decreased to 
300 fold by 24 hours (Figure 3.13). In the stimulus withdrawal treatment GM-CSF mRNA 
levels at 6 hours only reached 40 fold. Following stimulus removal for 24 hours GM-CSF 
mRNA levels remained at basal levels. Thus in the absence of persistent stimulation GM-
CSF mRNA levels fail to reach the peak in expression seen in the control samples. 
The stability of GM-CSF promoter remodelling in the absence of persistent 
stimulation was then analyzed. EL-4 T cells were either left untreated or stimulated for 2 
hours with P/I at which time chromatin remodelling had occurred at the promoter (see 
Figure 3.11b and c). The stimulus was then withdrawn and cells were left for a further 4 or 
22 hours. Nuclei were then harvested from these samples along with cells stimulated for up 
to 24 hours and accessibility of the promoter Hinfl site examined by CHART-PCR. As 
seen before, stimulation resulted in an increase in GM-CSF promoter accessibility to 60% 
within 2 hours which increased further to 70% by 6 hours and was maintained for 24 hours 
(Figure 3.14a). Cells stimulated for 2 hours, followed by a 4 hour stimulus withdrawal only 
showed a slight decrease in accessibility (to approximately 65%). In comparison, promoter 
accessibility in EL-4 T cells stimulated for 2 hours followed by a 22 hour stimulus 
withdrawal decreased 20-25% compared to cells undergoing persistent stimulation for the 
same period (24 hours). However, even after stimulus removal for 22 hours accessibility 
had not returned to basal levels. 
In order to determine when accessibility returns to basal levels following stimulus 
withdrawal the effect of stimulus withdrawal over a longer time period was analyzed. EL-4 
T cells were either left untreated or stimulated with P/I for 24, 48 and 72 hours before 
isolating nuclei, digesting with MNase and analyzing by CHART-PCR. Nuclei from EL-4 
T cells treated for 2 hours to facilitate chromatin remodelling before stimulus withdrawal 
for 22, 46 and 70 hours were also isolated and analyzed by CHART-PCR in parallel. 
MNase accessibility across the GM-CSF promoter increased from a basal level of 
approximately 25% to 85% by 24 hours, remained at this level at 48 hours post stimulation 
(Figure 3.14b) and at 72 hours had decreased to 70%. In contrast, when the stimulus was 
withdrawn at 2 hours, promoter accessibility to MNase had decreased at 24 hours 
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Figure 3.13. The effect of brief versus continuous T cell stimulation on GM-
CSF gene transcription. EL-4 T cells were either left unstimulated or stimulated 
with WI for 2 hours, before the stimulus was withdrawn and the cells incubated for 
the indicated time periods. GM-CSF mRNA levels were determined by real-time 
PCR analysis of cDNA. The mean and standard error of three replicate assays are 
shown. 
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Figure 3.14. The effect of stimulus withdrawal on GM-CSF promoter 
remodelling. EL-4 T cells were incubated with P/I for 2 hours before the stimulus 
was withdrawn. In parallel, EL-4 T cells were stimulated with P/I for the indicated 
time periods. Nuclei were prepared and digested with Hinfi (A) or MNase (B). 
Genomic DNA was analyzed by real-time PCR using primer set -1. The mean and 
standard error of three replicate assays are shown. 
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compared to cells undergoing persistent stimulation and had returned to basal levels by 48 
hours. It is therefore clear that the remodelled GM-CSF promoter returns to its basal state 
following stimulus withdrawal although with significantly delayed kinetics compared to 
mRNA levels. 
Put together these data show GM-CSF transcriptional activation needs persistent 
stimulation while chromatin remodelling is relatively stably maintained. In order to 
determine how the nuclear translocation of transcription factors correlates with this, the 
effect of stimulus withdrawal on the nuclear accumulation of NF-K13 and NFAT was 
determined. Nuclear extracts were prepared from EL-4 T cells either left untreated, 
stimulated for 2, 6 and 24 hours or stimulated for 2 hours followed by a 4 or 22 hour 
stimulus withdrawal. Rel A was detected in the nucleus at 2 hours (Figure 3.15). At 6 hours 
post stimulation Rel A protein levels peaked but had dramatically decreased by 24 hours. 
However if stimulation was withdrawn after 2 hours, levels of Rel A decreased 
considerably by 4 hours and were undetectable by 22 hours. c-Rel nuclear translocation 
occurred within 2 hours post-stimulation and increased further at 6 and 24 hours. Stimulus 
withdrawal for 4 hours caused a slight decrease in c-Rel and by 22 hours the levels of c-Rel 
were barely detectable. In contrast NFATc and NFATp could not be detected in the nucleus 
following stimulus withdrawal. Therefore the more stable presence of NF-KB correlates 
with remodelling while the pattern of NFAT nuclear translocation correlates more closely 
with transcription. 
GM-CSF promoter remodelling is a stable event with chromatin accessibility 
remaining high for up to 72 hours post stimulation. In order to determine whether 
remodelling at the promoter is the rate limiting step in GM-CSF gene activation, 
subsequent reactivation of the gene was analyzed. EL-4 T cells were either left untreated or 
stimulated with P/I for 2 hours. The stimulus was then withdrawn and cells left for a further 
22 hours at which time mRNA levels return to basal but the promoter remains accessible 
(Figure 3.11). Cells were then restimulated with P, I or P/I. Stimulation with P alone had a 
minimal impact on GM-CSF transcription only causing a 20 fold increase in mRNA levels 
(Figure 3.16a). Restimulation with I caused no increase in transcription while restimulation 
with P/I resulted in a 300 fold increase in GM-CSF mRNA levels. These data suggest that 
while remodelling has already occurred in these previously stimulated cells, both PKC and 
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Figure 3.15. The stability of NF-KB and NFAT proteins in the nucleus. Nuclear 
extracts from EL-4 T cells which were either left unstimulated or stimulated with P/I 
for 2 hours, before the stimulus was withdrawn and the cells incubated for the indicated 
time periods, were subjected to SDS-PAGE and analyzed by western blotting with the 
indicated antibodies. 
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Figure 3.16. Restimulation of EL-4 T cells causes a more rapid and robust GM-
CSF transcriptional response. (A) GM-CSF mRNA levels were determined by 
real-time PCR analysis of cDNA prepared from EL-4 T cells stimulated for 2 hours 
followed by 22 hours of stimulus withdrawal. Cells were then left untreated (NS) or 
restimulated with P or I alone or in combination. The mean and standard error of 
three replicate assays are shown. (B) cDNA was prepared from EL-4 T cells either 
left untreated or stimulated with P/I over the indicated time periods. In parallel, 
cDNA was prepared from EL-4 T cells stimulated with P/I for 2 hours prior to 22 
hours of stimulus withdrawal. Cells were then restimulated over the indicated time 
periods. GM-CSF mRNA levels were determined by real-time PCR analysis. The 
mean and standard error of three replicate assays are shown. 
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calcium signalling pathways are still required for full transcriptional induction of GM-CSF. 
Next the effect of restimulation with P/I over time was analyzed. Following 
stimulation with P/I for 2 hours, stimulus was withdrawn for 22 hours before restimulating 
with P/I for 0 to 6 hours. cDNA was also prepared from EL-4 T cells stimulated for 0 to 6 
hours. Cells stimulated with P/I showed a typical profile of GM-CSF mRNA accumulation 
(Figure 3.16b) and levels reached approximately 400 fold by 6 hours. In contrast, in EL-4 T 
cells which were restimulated an approximately 800 fold increase in mRNA levels was 
detected by 6 hours. Restimulated cells showed a much more rapid induction of 
transcription. Therefore, cells in which remodelling has already occurred, due to prior 
stimulation, are capable of more rapid reactivation. 
3.3 DISCUSSION 
The data outlined in this chapter demonstrate that GM-CSF promoter remodelling 
and subsequent gene transcription are independent events. These two distinct events have 
different signal and transcription factor requirements. While remodelling of the GM-CSF 
promoter requires PKC activated factors, full transcriptional induction requires both the 
PKC and calcium signalling pathways. The PKC pathway may influence chromatin 
remodelling events at the GM-CSF promoter by activating transcription factors which bind 
to the GM-CSF promoter and recruit chromatin remodelling activities. In support of this 
NF-KB, which can be activated by PKC signalling alone, has been implicated in GM-CSF 
promoter remodelling (Cakouros et al, 2001; Holloway et al, 2003; Brettingham-Moore et 
al, 2005). Alternatively PKC signalling may lead to the activation of co-activators and 
remodelling complexes required for these remodelling events or may directly affect histone 
proteins. PKC has been found to directly phosphorylate a serine residue on histone H3 in 
vitro (Huang et al, 2004) which could directly influence chromatin accessibility at the 
promoter. Interestingly, remodelling of the GM-CSF promoter by PKC signalling alone 
caused a slight increase in transcription. This suggests that the increase in accessibility is 
sufficient to drive a low level of transcription, however other factors are clearly required 
for optimal gene expression. It is also interesting to note that the inhibition of PKC 
signalling caused a very slight increase in the basal accessibility of the promoter indicating 
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that perhaps a PKC activated factor is not only responsible for increasing promoter 
accessibility, but also necessary for maintaining the basal chromatin structure of the GM-
CSF promoter. 
While remodelling of the GM-CSF promoter can occur following PKC mobilization 
alone, other signals generated from the calcium signalling pathway are required to induce 
high levels of GM-CSF gene transcription. The requirement for both signalling pathways in 
full GM-CSF expression is supported by Jenkins et al (1995) whose work revealed that the 
activity of the human GM-CSF promoter attached to a luciferase reporter relies on both 
signals. The data presented in this chapter demonstrates that NFAT proteins are not 
essential for GM-CSF promoter remodelling, however, the nuclear translocation of NFAT 
appears to be critical for the optimal activation of transcription. CsA, which inhibits the 
nuclear translocation of NFAT, has previously been shown to inhibit endogenous GM-CSF 
gene transcription in Jurkat T cells (Tsuboi et al, 1994) and this finding was confirmed by 
specific inhibition of NFAT proteins using the VIVIT peptide. NFAT has previously been 
shown to play a role in GM-CSF enhancer remodelling (Cockerill et al, 1993), therefore 
the decrease in GM-CSF transcription due to the absence of NFAT may also be due to 
limited enhancer remodelling and activity. Another possibility is highlighted by the 
findings of Johnson et al (2004) who revealed that NFAT has the potential to cooperate 
with other co-activators at the GM-CSF enhancer. 
c-Rel has previously been implicated in GM-CSF induction in T cells (Himes et al, 
1996; Gerondakis et al, 1996). The results here clearly demonstrate that nuclear 
translocation of the NF-x13 family member c-Rel mirrors the increase in accessibility to the 
GM-CSF promoter across a range of treatments (Table 3.1). Remodelling of the GM-CSF 
promoter has been detected as early as 1 hour post stimulation (Holloway et al, 2003) and 
c-Rel has previously been detected in the nuclei of EL-4 T cells within 1 hour of 
stimulation (Rao et al, 2001). The delayed nuclear activation of c-Rel is concomitant with 
promoter remodelling and a large increase in protein binding to the CD28RR (Himes et al, 
1996; Shannon et al, 1995). Therefore it is possible that c-Rel is involved in the initial 
chromatin remodelling events at the GM-CSF promoter and/or maintaining increased 
accessibility at the remodelled promoter. The observation that CsA caused a slight 
reduction in c-Rel levels yet remodelling was not prevented would suggest that a certain 
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Chromatin 
Remodelling 
Table 3.1. Correlation between transcription factor presence in the nucleus 
and chromatin remodelling at the GM-CSF promoter. 
Treatment Rel A NFATc NFATp 
PMA 
4., 
X 
Ro-32-0432 X X 
CsA X X 
CHX X 
24 hour stim X 
24 hour stim removal X X X 
threshold of this NF-KB member is sufficient for chromatin remodelling. The role of c-Rel 
in chromatin remodelling events at the GM-CSF promoter is supported by findings that 
inhibition of c-Rel by Pentoxifylline inhibits the increase in GM-CSF promoter 
accessibility following T cell activation (Brettingham-Moore, 2002, Honours Thesis). In 
addition, Shannon and colleagues found that stimulation of c-Re1 4- T cells failed to induce 
GM-CSF promoter remodeling (Brettingham-Moore et al, 2005). It is interesting to note 
that NF-KB proteins have been found to have DNA bending properties in vitro (Schreck et 
al, 1990). This feature may help c-Rel to access DNA binding sites within the repressive 
chromatin environment and aid other factors in gaining access. 
Similar to the findings presented here for GM-CSF, c-Rel has also been identified 
as critical for IL-2 gene transcription in a reporter based system (Wang et al, 1997) and the 
accumulation of c-Rel has also been correlated with IL-2 promoter accessibility changes. 
Accessibility to the CD28RR in the IL-2 promoter upon stimulation was reduced in T cells 
from c-Rel -/- mice (Rao et al, 2003). In contrast, c-Rel does not play a role in IL-12 
promoter remodelling as increased accessibility in response to IFN-y and LPS stimulation 
was still observed in c-Re1 4- macrophages (Weinmann et al, 2001). However, c-Rel was 
found to be important for the transcription of IL-12. These differences highlight the 
specific way in which each gene is likely to be activated, with c-Rel playing different roles 
in different circumstances. 
This work also highlights the different roles played by different transcription factor 
family members. The CHX data demonstrated that while Rel A and NFATp are pre-
existing, both NFATc and c-Rel are newly synthesized, or require continual replacement. 
The appearance of Rel A in the nuclei of non stimulated CHX treated cells indicates that 
Rel A alone is incapable of remodelling the GM-CSF promoter. It is also evident from the 
CHX data that transcription of the GM-CSF gene can occur without any detectable changes 
in promoter accessibility. It is therefore possible that the transcriptional machinery can be 
assembled at the promoter and drive transcription at a low level in the absence of any 
changes to chromatin structure. This may be attributed to the inherent basal accessibility of 
the GM-CSF promoter or alternatively the influence of the enhancer element, either of 
which may allow low levels of transcription without full promoter remodelling. However, 
CHX has also previously been shown to block the appearance of an inducible DNase 
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hypersensitive site in the GM-CSF enhancer (Cockerill et al, 1993). 
Chromatin remodelling at the GM-CSF promoter is a relatively stable event while 
transcription is a transient event. The stability of GM-CSF promoter remodelling is 
biologically relevant in regard to the immune system as previously activated T cells may be 
able to respond more swiftly to subsequent attacks on the immune system. Restimulation of 
T cells results in a more rapid and robust GM-CSF transcriptional response suggesting that 
remodelling of the GM-CSF promoter is the rate limiting step for transcription. It also 
suggests that the altered structure of the promoter and stability of this event helps confer a 
type of "memory" to the cells. EL-4 T cells divide every 16 to 24 hours, thus the 
remodelled state would appear to be retained following cell division. It is possible that the 
stability of this increased accessibility is due to active maintenance of the remodelled state 
through cell division. The nuclear accumulation of c-Rel correlates with the stability of the 
remodelled promoter. Therefore it is possible that c-Rel may be involved in maintaining the 
increased accessibility. Alternatively, continuous signalling may allow the altered 
chromatin structure to be reset following cell division. In agreement with this, BAF 
remodelling complexes have been shown to be phosphorylated and inactivated during 
mitosis (Sif et al, 1998) indicating that remodelling is prevented during cell division and 
chromatin must be reset following division. Yet another possibility is the generation of 
transient, short-term epigenetic marks. Histone modifications in activated cells may help 
mark certain regions of the genome and impart memory to daughter cells (Smith et al, 
2002). 
It is also important to note, that as with any technique which studies cell 
populations rather than individual cells, an average value is obtained and thus it is 
impossible to determine whether the results from the CHART assay reflect the accessibility 
of all cells within the population or a small number within a heterogeneous population. For 
example an accessibility value of 50% may reflect a population in which 50% of the cells 
have 100% accessibility or alternatively a case in which 100% of cells have 50% 
accessibility. Therefore it is possible that accessibility remains at an increased level in 
some cells which have failed to divide over the time period examined. 
The data presented here are consistent with a two step model for GM-CSF 
activation in which remodelling precedes transcription. The first step in GM-CSF 
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activation being initiated by the activation of the PKC signalling pathway downstream of 
TCR ligation and resulting in chromatin remodelling and increased accessibility at the GM-
CSF promoter. This induces the nuclear translocation of NF-KB proteins. These 
transcription factors may then be able to bind to the promoter region due to the inherent 
basal accessibility of the GM-CSF promoter. c-Rel may then interact with chromatin 
remodelling factors to increase accessibility to the promoter region. This step ensures the 
second stage of activation can occur, by permitting other transcription factors and 
transcriptional machinery to access their relevant DNA binding sites. Only then, can GM-
CSF gene expression occur. 
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CHAPTER 4. 
BRG1 IS POISED AT THE GM-CSF PROMOTER IN T 
CELLS AND IS REQUIRED FOR GENE 
ACTIVATION. 
4.1 INTRODUCTION 
The data presented in the previous chapter and published reports have now clearly 
demonstrated that activation of the GM-CSF gene in T cells involves changes to the 
chromatin structure across its proximal promoter region (Cockerill et al, 1999; Holloway et 
al, 2003, Brettingham-Moore et al, 2005). However, very little is known about the 
mechanisms which underpin these chromatin remodelling events. Recent work by Chen et 
al (2005) has demonstrated using ChIP that total histone levels and histone acetylation at 
the GM-CSF promoter decrease following T cell activation, implying that remodelling 
involves the loss of histones from the promoter region. However, the complexes 
responsible for this chromatin remodelling and the mechanisms involved remain 
unidentified. 
The exact mechanism underlying the activation of inducible genes in a chromatin 
context has only been elucidated for a small number of mammalian genes. One of the best 
examples is the step by step assembly of an enhanceosome at the enhancer region of the 
IFN-I3 gene following viral infection (Agalioti et al, 2000). IFN-13 transcription is activated 
6 hours post infection, prior to which a highly ordered recruitment profile has occurred. 
This involves the binding of transcription factors to the nucleosome-free enhancer, 
followed by local increases in histone acetylation, subsequent SWI/SNF recruitment and 
finally remodelling of adjacent nucleosomes (Agalioti et al, 2000). During skeletal muscle 
differentiation a slightly different Brg I recruitment profile is observed at the myogenin 
promoter. A two-step mechanism was observed in which the homeodomain factor Pbxl is 
constitutively bound to the myogenin promoter and indirectly helps to recruit the 
transcription factor, MyoD. Following induction of myogenic differentiation increased H4 
80 
acetylation was observed followed by MyoD dependent binding of Brg 1 (de la Serna et al, 
2005). Brgl binding facilitates and strengthens MyoD binding even further and results in 
transcriptional induction of myogenin. 
Similar to the histone loss detected at the GM-CSF promoter (Chen et al, 2005) 
histone depletion has also been observed at the yeast PHO5 (Reinke and Horz, 2003; 
Korber et al, 2004) and PHO8 promoters (Adkins et al, 2004). In addition this histone loss 
has been shown to be dependent on SWI/SNF recruitment. While PHO8 activation requires 
SWI/SNF and GCN5 histone acetyltransferase activity (Gregory et al, 1999), the PHO5 
promoter is still remodelled in the absence of SWI/SNF and GCN5 but with delayed 
kinetics (Gadreau et al, 1997). The different requirements for PHO5 and PHO8 activation 
have recently been shown to be due to the inherent differences in chromatin structure, with 
the nucleosomes encompassing the PHO8 promoter being more stable than those at the 
PHO5 promoter (Hertel et al, 2005). Histone acetylation has also been demonstrated to 
precede promoter remodelling at the PHO5 promoter (Reinke and Horz, 2003) and this 
appears to be a common feature for gene activation (Agalioti et al, 2001; de la Serna et al, 
2005). 
Previous in vitro work by Holloway et al (2003) has suggested a role for the 
ATPase component of the SWI/SNF complex, Brgl, in GM-CSF gene activation. An 
immobilized GM-CSF promoter template was incubated with nuclear extracts from 
unstimulated and stimulated Jurkat T cells to demonstrate that Brg 1 could interact with the 
GM-CSF promoter in an NF-KB dependent manner (Holloway et al 2003). Brg 1 has 
previously been implicated in immune gene activation and, following T cell activation, the 
SWI/SNF complex has been found to associate with chromatin in a Brgl dependent manner 
(Zhao et al, 1998). However whether or not this ATPase interacts directly with the 
endogenous GM-CSF promoter is yet to be determined. 
Therefore, the role of Brgl in GM-CSF gene activation was analyzed and Brgl 
binding at the GM-CSF promoter was determined using the ChIP assay. In addition, the 
role of histone acetylation in GM-CSF activation was investigated. The basal state of the 
GM-CSF promoter in expressing and non-expressing cells was also analyzed to investigate 
whether the inherent chromatin environment determines GM-CSF expression capabilities. 
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4.2 RESULTS 
4.2.1 Brgl is required for GM-CSF gene activation 
In order to determine whether the Brgl-containing SWI/SNF complex is required 
for GM-CSF gene activation, GM-CSF expression was monitored in EL-4 T cells 
transfected with an ATPase mutant Brgl construct (pBJ5-brgl IC/R) in which lysine 774 has 
been mutated to an arginine (Khavari et al, 1993). This Brgl mutant protein has been found 
to assemble into the SWI/SNF complex, but is unable to remodel nucleosomes (de la Serna 
et al, 2000). The Brgl cDNA is cloned in frame with a C-terminal haemoglutanin (HA) tag 
which can be used to monitor expression of the mutant protein. To ensure the Brgl mutant 
protein was expressed in the transfected cells, EL-4 T cells were transfected with the 
control pBJ5 plasmid or pBJ5-brgl IC/R plasmid. Nuclear extracts were prepared, subjected 
to SDS-PAGE and analyzed by western blotting with the HA antibody. A band of over 180 
kDa was detected in the cells transfected with the pBJ5-brg1K/R plasmid but not in the 
control transfected cells (Figure 4.1a) confirming expression of the mutant Brgl protein in 
transfected cells. 
While the mutant protein can be expressed in EL-4 T cells, the transfection 
efficiency of these cells is relatively low (-15%) and therefore it was necessary to enrich 
for the transfected cells in order to monitor the functional effect of the Brgl mutant on 
GM-CSF gene activation. EL-4 T cells were therefore transfected with the pBJ5-brg1K/R 
plasmid or the empty pBJ5 control vector along with the K KII plasmid. This plasmid 
enables the expression of a truncated H-2K K receptor protein. Transfected cells expressing 
H-2K' can bind to magnetic beads coated with antibody directed against this cell surface 
marker to allow the transfected cell population to be enriched. Sorted cells were either left 
unstimulated or stimulated with P/I for 6 hours and GM-CSF expression monitored by real-
time PCR. GM-CSF mRNA levels increased approximately 500 fold following P/I 
stimulation in cells transfected with the control plasmid. In contrast, accumulation of GM-
CSF mRNA was reduced by 50% in cells expressing the Brgl ATPase mutant (Figure 
4.1b). This demonstrates that Brgl is required for optimal activation of the GM-CSF gene. 
It was hypothesised that the reduction in GM-CSF expression in cells transfected 
with the Brgl mutant could be due to the inability of the ATPase defective protein to 
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Figure 4.1. Brgl is required for efficient transcription of the GM-CSF gene. (A) 
Nuclear extracts prepared from EL-4 T cells transfected with either the pBJ5 or 
pBJ5-brg1K/R-HA plasmid were subjected to SDS-PAGE and analyzed by western 
blotting using an anti-HA antibody. (B) EL-4 T cells were co-transfected with the 
KKII and pBJ5 or pBJ5-brg1K/R plasmids prior to magnetically activated cell sorting 
before incubating with or without P/I for 6 hours. cDNA was prepared and levels of 
GM-CSF mRNA analyzed by real-time PCR. The mean and standard error of three 
replicate assays are shown. 
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remodel the GM-CSF promoter. To determine whether Brgl is involved in chromatin 
remodelling events at the GM-CSF promoter EL-4 T cells were transfected with either the 
pBJ5 or pBJ5-brg1K/R constructs along with the K KII plasmid. Following cell sorting 24 
hours post-transfection, cells were either left unstimulated or stimulated with P/I for 6 
hours. Nuclei were then isolated and incubated with or without MNase. Accessibility to the 
GM-CSF promoter was then determined by CHART-PCR analysis of genomic DNA using 
primer set —I which covers the proximal promoter. An inherent level of accessibility to 
MNase of approximately 50% was observed at the GM-CSF promoter in unstimulated cells 
transfected with the control plasmids (Figure 4.2) as seen previously at the GM-CSF 
promoter (Chapter 3). Accessibility to the promoter region increased to approximately 80% 
following stimulation. While a similar increased level of accessibility was detected in Brgl 
mutant expressing cells following stimulation, these cells displayed a slightly higher basal 
level of accessibility prior to stimulation in addition to increased variability. Surprisingly, 
these data suggest that Brgl is not required to generate the remodelled state across the 
promoter upon stimulation but may be involved in generating the basal chromatin structure. 
4.2.2 Brgl is enriched at the GM-CSF promoter in resting T 
cells and is lost from the promoter upon stimulation. 
Previous in vitro analysis of proteins recruited to the GM-CSF promoter has 
implicated Brgl in GM-CSF gene activation (Holloway et al, 2003). Therefore in order to 
determine whether Brgl is associated with the GM-CSF promoter in T cells, ChIP analysis 
was performed on EL-4 T cells with Brgl antibodies, before and after stimulation with P/I 
for 4 hours. Immunoprecipitated DNA was measured by real-time PCR using PCR primers 
designed to regions of the GM-CSF gene and the constitutively expressed GAPDH gene 
(Figure 4.3a). Brgl recruitment was calculated as a percentage of the DNA levels prior to 
immunoprecipitation (i.e. % total input). Using primer sets —I and +I which cover the GM-
CSF promoter, Brgl was found to be associated with the promoter in resting T cells 
however, Brgl levels at the promoter decreased upon T cell stimulation (Figure 4.3b). In 
contrast, there was little change in Brgl levels associated with distal 5' and 3' regions of 
the gene or the constitutively expressed GAPDH gene following stimulation (Figure 4.3b). 
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Figure 4.2. Brgl is not required for chromatin remodelling of the GM-CSF 
promoter. EL-4 T cells were co-transfected with the KKII and pBJ5 or pBJ5- 
brg1K/R plasmids prior to magnetically activated cell sorting before incubating with 
or without P/I for 6 hours. Nuclei were isolated and digested with MNase and 
genomic DNA analyzed by real-time PCR using primer set -I. The mean and 
standard error of three replicate assays are shown. 
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Figure 4.3. Brgl is bound to the GM-CSF promoter in resting T cells. (A) 
Schematic representation of the GM-CSF promoter with positions of primer 
sets 5', -I, +I and 3'. (B) EL-4 T cells were stimulated with P/I for 4 hours 
before performing ChIP with Brgl antibodies. Enrichment of Brgl at the GM-
CSF promoter, a 5' region, a 3' region and at the GAPDH gene was determined 
by real-time PCR. The mean and standard error of 3 replicate assays are shown. 
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In addition, in resting cells the relative levels of Brg 1 were considerably higher at the GM-
CSF promoter (primer sets —I and +I) than the 3' and 5' regions of the gene or the GAPDH 
gene suggesting enrichment of Brgl at the promoter region. These data therefore suggest 
that Brg 1 is enriched at the GM-CSF promoter in resting T cells and lost from the promoter 
region following T cell activation, concomitant with chromatin remodelling. Put together, 
these data suggest a role for Brg 1 in establishing the basal chromatin environment at the 
GM-CSF promoter that is conducive to gene activation. 
4.2.3 Increasing promoter acetylation facilitates Brgl 
recruitment and GM-CSF gene activation 
The data presented above demonstrate that Brg 1 is enriched at the GM-CSF 
promoter in resting T cells. This raises the question of how Brgl might be constitutively 
recruited to the GM-CSF promoter. The recruitment of Brg 1 has previously been linked to 
increased histone acetylation (Hassan et al, 2002). Therefore, to determine whether histone 
acetylation levels influence GM-CSF gene activation and chromatin remodelling, the effect 
of the histone deacetylase inhibitor, TSA on these two processes was examined. EL-4 T 
cells were pre-treated with TSA for 4 hours and left unstimulated or stimulated with P/I for 
4 hours. GM-CSF mRNA levels were then determined by real-time PCR analysis of cDNA. 
GM-CSF was induced 400 fold following stimulation with P/I (Figure 4.4). TSA pre-
treatment augmented GM-CSF expression in stimulated cells to approximately 1200 fold 
(Figure 4.4). Treatment of EL-4 T cells with TSA has been shown to increase global 
acetylated H3 levels and specifically increase acetylated histone H3 levels across the GM-
CSF gene (Chen and Shannon, personal communication). Therefore, increasing histone 
acetylation at the GM-CSF promoter results in increased gene transcription. 
In order to determine how increasing histone acetylation levels influenced 
chromatin remodelling events at the GM-CSF promoter, chromatin accessibility was 
monitored using CHART-PCR. EL-4 T cells were either left untreated or pre-treated with 
TSA for 4 hours prior to incubating with or without P/I for 4 hours. The GM-CSF promoter 
displayed an inherent accessibility to MNase of approximately 50% in the control treatment 
as expected, and following stimulation, this accessibility increased further to approximately 
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Figure 4.4. Increased acetylation increases GM-CSF gene transcription. 
EL-4 T cells were either left untreated or pre-treated with TSA prior to 
incubating with or without P/I for 4 hours. GM-CSF mRNA levels were 
determined by real-time PCR analysis of cDNA. The mean and standard error 
of 3 replicate assays are shown. 
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80% (Figure 4.5a). Cells which were pre-treated with TSA similarly displayed 
approximately 50% accessibility in untreated cells, increasing to 80% upon stimulation. 
Thus, despite enhancing GM-CSF gene transcription, TSA pre-treatment did not alter either 
basal or induced levels of accessibility at the GM-CSF promoter. This result failed to 
answer the question of how increasing histone acetylation augmented GM-CSF mRNA 
accumulation. Therefore to determine whether pre-treatment with TSA affected the kinetics 
of chromatin remodelling across the GM-CSF promoter. EL-4 T cells were either left 
untreated or pre-treated with TSA for 4 hours before incubating with P/I for 0, 0.5, 1 or 4 
hours. In the absence of TSA little change in chromatin accessibility across the GM-CSF 
promoter was observed 30 minutes following P/I stimulation and only a small increase in 
accessibility was observed 1 hour after P/I stimulation. As seen previously, a dramatic 
increase in accessibility was then observed 4 hours post stimulation with P/I (Fig 4.5b). In 
contrast, in cells pre-treated with TSA, increased chromatin accessibility was observed 
within 30 minutes post-stimulation and had almost reached maximal induced accessibility 
by 1 hour (Figure 4.5b) increasing only slightly further at 4 hours. These results suggest 
that increasing histone acetylation levels across the GM-CSF gene, while not affecting 
basal accessibility, allowed chromatin remodelling events to occur more rapidly following 
stimulation. 
To investigate the possibility that Brg 1 may be enriched at the GM-CSF promoter 
through association with acetylated histones, Brgl recruitment at the promoter was 
measured using the ChIP assay. EL-4 T cells were either left untreated or pre-treated with 
TSA for 16 hours before incubating with or without P/I for 4 hours. Chromatin was then 
crosslinked and immunoprecipitated with the Brg 1 antibody. Immunoprecipitated DNA 
was amplified by real-time PCR using primer set +I. As seen previously (Figure 4.3b), 
Brgl was enriched at the GM-CSF promoter in unstimulated T cells with levels decreasing 
upon stimulation (Figure 4.6). Treatment with TSA increased Brg 1 levels at the promoter 
by approximately 3 fold although the typical decrease in Brgl levels was not detected 
following P/I treatment in TSA treated cells. These data suggest that increasing acetylation 
at the GM-CSF promoter increases Brg 1 levels at the GM-CSF promoter, and are 
consistent with Brg 1 recruitment via acetylated histones. 
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Figure 4.5. Increased acetylation increases the rate of remodelling at the 
GM-CSF promoter. (A) EL-4 T cells were either left untreated or pre-treated 
with TSA prior to incubation with or without P/I for 4 hours. Nuclei were then 
isolated, incubated with MNase and accessibility at the GM-CSF promoter 
determined by real-time PCR analysis of genomic DNA using primer set —I. The 
mean and standard error of 3 replicate assays are shown. (B) EL-4 T cells were 
treated as in A prior to stimulating with P/I for the indicated times. Promoter 
accessibility was determined as in A. The mean and standard error of 3 replicate 
assays are shown. 
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Figure 4.6. TSA increases Brgl recruitment to the GM-CSF promoter. EL-4 
T cells were either left untreated or treated with TSA for 16 hours prior to 
incubating with or without P/I for 4 hours. Chromatin was then crosslinked and 
immunoprecipitated using Brgl antibodies. The relative enrichment of Brg 1 
compared to the unstimulated control was determined by real-time PCR analysis 
of DNA using primer set +I. The mean and standard error of 3 replicate assays 
are shown. 
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4.2.4 Chromatin remodelling at the GM-CSF promoter is 
inhibited in non-expressing cell types 
The data presented so far suggests that enrichment of Brg 1 at the GM-CSF 
promoter maybe a requirement of GM-CSF gene activation. To investigate this further, 
chromatin remodelling events were analyzed in B cells which do not normally express GM-
CSF. EL-4 T cells and A-20 B cells were either left untreated or stimulated with P/I for 4 
hours and GM-CSF mRNA levels determined by real-time PCR. As expected, GM-CSF 
was highly inducible in EL-4 T cells by P/I stimulation with an approximately 600 fold 
induction, while its expression was essentially uninducible in the B cell line (Table 4.1). In 
order to determine whether the difference in GM-CSF expression was due to disparity in 
chromatin accessibility across the GM-CSF promoter, non-stimulated and stimulated EL-4 
T cells and A-20 B cells were analyzed by CHART-PCR using primer set -I. As seen 
previously, EL-4 T cells displayed inherent basal accessibility to MNase which increased 
dramatically following stimulation with WI (Figure 4.7). While A-20 B cells displayed a 
similar level of basal accessibility, no increase in accessibility was observed upon 
stimulation with P/I (Figure 4.7). Therefore, chromatin analysis of the A-20 cells suggests 
that their inability to express GM-CSF maybe due to a blockage in chromatin remodelling 
events at the promoter. 
Brg 1 is associated with the GM-CSF promoter in T cells, and is required for GM-
CSF gene activation. Therefore ChIP assays were used to investigate whether there is a 
difference between the association of Brgl with the GM-CSF promoter in B cells compared 
to T cells. EL-4 T cells and A-20 B cells were either left untreated or stimulated with P/I 
for 4 hours before crosslinking chromatin followed by immunoprecipitation with Brg 1 
antibodies. hnmunoprecipitated DNA was then quantitated by real-time PCR analysis using 
primer set +I. As seen previously, Brg 1 was detected at the GM-CSF promoter in 
unstimulated T cells and levels decreased 2 fold upon stimulation (Fig 4.8). In contrast, 
very little Brgl was detected at the GM-CSF promoter in B cells in both resting and 
stimulated cells. Importantly, the Brg 1 levels detected in either unstimulated or stimulated 
B cells were lower than observed in T cells even following stimulation. Therefore it 
appears that Brgl is absent from the GM-CSF promoter in B cells. 
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Table 4.1. GM-CSF mRNA copy number in EL-4 T cells and A-20 B cells. EL-4 T 
cells and A-20 B cells were either left untreated or stimulated for 4 hours with P/I. 
cDNA was prepared and GM-CSF mRNA levels determined by real-time PCR. 
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Figure 4.7. The GM-CSF promoter is not remodelled in non expressing B 
cells. EL-4 T cells and A-20 B cells were either left untreated or stimulated 
with P/I for 4 hours. Nuclei were isolated and incubated with MNase prior to 
real-time PCR analysis of genomic DNA using primer set —I. The mean and 
standard error of 3 replicate assays are shown. 
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Figure 4.8. Brgl is not bound to the GM-CSF promoter in B cells. EL-4 T 
cells and A-20 B cells were incubated with or without WI for 4 hours before 
crosslinlcing chromatin and immunoprecipitating against Brgl. Recruitment of 
Brgl was then determined by real-time PCR analysis of DNA using primer set 
+I. The mean and standard error of three replicate assays are shown. 
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Figure 4.9. Increasing acetylation in B cells overcomes the block in GM-CSF 
expression by facilitating remodelling of the GM-CSF promoter. (A) A-20 B 
cells were either left untreated or treated with TSA prior to incubating with PII 
for 4 hours. GM-CSF mRNA levels were then determined by real-time PCR 
analysis of cDNA. The mean and standard error of 3 replicate assays are shown. 
(B) A-20 B cells were either left untreated or pre-treated with TSA before 
incubating with or without PII for 4 hours. Nuclei were then isolated and 
digested with MNase before analyzing genomic DNA by real-time PCR analysis 
using primer set -1. The mean and standard error of 3 replicate assays are shown. 
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Increasing histone acetylation levels was found to augment GM-CSF gene 
activation and increase the kinetics of chromatin remodelling events in T cells (Figure 4.5). 
Therefore to determine whether increasing histone acetylation could also alter the 
inducibility of the GM-CSF gene in B cells, A-20 B cells were pre-treated with TSA for 4 
hours. Cells were then either left untreated or stimulated with P/I for 4 hours before 
measuring GM-CSF mRNA levels using real-time PCR. As before, little GM-CSF mRNA 
was detected in B cells following stimulation with P/I. However, there was a dramatic 200 
fold increase in GM-CSF mRNA levels following stimulation with P/I in B cells pre-
treated with TSA (Figure 4.9a). Therefore, increasing acetylation of the GM-CSF promoter 
in B cells allows transcription to occur in response to P/I. However, it should be noted that 
while GM-CSF expression could be induced in B cells by pre-treatment with TSA, these 
levels are still much lower than those typically observed in T cells (Figure 4.4). 
In order to determine whether increasing histone acetylation levels by TSA 
treatment also facilitated chromatin remodelling events at the GM-CSF promoter, A-20 B 
cells were either left untreated or TSA pre-treated for 4 hours before incubating with or 
without P/I for 4 hours. Accessibility of the GM-CSF promoter to MNase was determined 
by CHART-PCR using primer set -I. As before, in non-stimulated B cells, the GM-CSF 
promoter displayed an inherent basal accessibility which remained unchanged following 
stimulation with P/I. Pre-treatment of B cells with TSA did not alter basal chromatin 
accessibility across the promoter, however it facilitated an increase in chromatin 
accessibility in response to P/I stimulation with levels increasing to 70% (Figure 4.9b), 
which is similar to levels observed in T cells upon stimulation. 
Collectively, these data indicate that Brg I is not associated with the GM-CSF 
promoter in B cells, which do not express GM-CSF in response to P/I stimulation. 
However chromatin remodelling events and GM-CSF gene expression can be induced by 
modification of the histone acetylation status of the gene. 
4.3 DISCUSSION 
Activation of the GM-CSF gene in T cells involves targeted chromatin remodelling 
events that result in increased accessibility across the promoter region (Holloway et al, 
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2003; Brettingham-Moore et al, 2005). Recently, this increased accessibility was shown to 
be due to the loss of histones from the GM-CSF promoter (Chen et al, 2005). The data 
presented in this chapter demonstrate that the ATPase component of the SWI/SNF 
remodelling complex, Brgl, is required for GM-CSF gene activation. Using a Brg 1 
dominant negative approach it was shown that Brgl is essential for the optimal activation 
of GM-CSF expression. ChIP analysis confirmed a direct role for Brgl in GM-CSF 
activation. Brgl is bound to the GM-CSF promoter in resting T cells and lost from the 
promoter region upon T cell activation. Combining this result with the findings of Chen et 
al (2005), it is evident that Brgl is poised at the GM-CSF promoter in resting T cells and 
lost concomitant with histone loss following T cell stimulation. 
The association of Brgl with the GM-CSF promoter in the resting state was 
somewhat unexpected, however Brgl has previously been found constitutively associated 
with a number of other promoters including the M-CSF (Lui et al, 2001), CIITA pIV 
promoter (Ni et al, 2005) and IFITM1 promoters (Cui et al, 2004). These genes are also 
rapidly activated, suggesting that the chromatin structure of these promoters is poised for 
swift transcriptional induction. The activation of the IFN responsive IFITM1 gene is 
remarkably similar to GM-CSF. It is expressed constitutively at low levels and induced 
rapidly following stimulation with IFNa or IFNy. In addition, the promoter has increased 
basal levels of H4 acetylation and the promoter is partially accessible to restriction 
digestion indicating that the nucleosome is partially disrupted in the basal state (Cui et al, 
2004). Brgl is constitutively bound to the nucleosome covering the IFITM1 promoter 
region. Therefore, the chromatin environment of the IF1TM1 gene suggests that it maybe 
prepared in anticipation of IFNa or IFNy signalling. 
Recently, Liang et al (2006) showed that the interleulcin-113 	gene is poised 
for rapid activation. Liang et al (2006) demonstrated that in resting monocytic cells capable 
of rapid transcriptional activation, the IL-1(3 promoter is assembled into a poised chromatin 
architecture, with the promoter nucleosome free in the basal state as determined by 
CHART-PCR and ChIP analysis of histone acetylation. In addition, it was demonstrated 
that promoter accessibility alone is not sufficient for transcription. Some promoters, such as 
those belonging to heat-shock genes exist in an open chromatin structure, sometimes with 
pre-initiated paused RNA polymerase II molecules. This indicates that not all genes require 
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nucleosome remodelling for transcriptional activation (Boehm et al, 2003). 
The constitutive recruitment of Brg 1 to the GM-CSF promoter may help establish a 
basal chromatin environment permissive to the rapid induction of transcription. Adding 
support to this hypothesis, the delayed recruitment of Brg 1 to the IFN-13 promoter 
correlates with the delayed up-regulation of transcription 6 hours post-infection (Agalioti et 
al, 2000). This slower transcriptional activation can be attributed to the requirement for 
histone acetylation and Brgl recruitment before the nucleosome covering the promoter can 
be remodelled. In contrast, histone loss is detectable across the GM-CSF promoter as early 
as 30 minutes after stimulation (Chen et al, 2005), with GM-CSF transcription increasing 
rapidly after this time and peaking at 6-8 hours (Chapter 3). It is possible that such rapid 
induction of GM-CSF gene expression can occur because the promoter is already primed 
for activation with an inherent basal level of acetylation and the presence of Brg 1. In the 
case of IFN-I3 activation, Brgl is associated with the promoter transiently, for only a few 
hours, while transcription continues for close to 24 hours (Agalioti et al, 2000). This 
suggests that Brg 1 functions within a short time frame to remodel the promoter region 
which remains in an accessible configuration for an extended period. The stability of the 
accessible state at the IFN-13 promoter is comparable to the stability of GM-CSF promoter 
remodelling (Chapter 3). 
Brgl may not only prime the GM-CSF gene for rapid activation by establishing a 
competent chromatin environment, it may also help to recruit other transcription factors to 
the GM-CSF promoter. Chromatin remodellers have been suggested to accelerate 
transcription factor interactions with non-specific DNA sites by speeding up genome wide 
scanning (Karpova et al, 2004). In fact, Brgl has been found to be responsible for the 
initial recruitment of the STAT1 co-activator to the CIITA promoter (Ni et al, 2005). It is 
therefore possible that Brgl enhances recruitment of the transcription factors required to 
drive GM-CSF expression. 
Adding further support to the hypothesis that Brg 1 recruitment is associated with 
priming genes for activation, Brgl was not detected at the promoter of non expressing B 
cells. While Brg 1 maintains a transcriptionally competent state in T cells it is possible that 
this signal can be overridden by increased histone acetylation in B cells. However, even 
though GM-CSF can be activated in TSA treated B cells the levels of activation are much 
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lower than those observed in T cells suggesting that Brgl binding is required for the 
optimal activation of transcription. This is supported by the reduction in GM-CSF 
transcription observed in T cells expressing the Brgl ATPase mutant. 
There are a number of possibilities to explain the mechanism behind the 
constitutive recruitment of Brgl at the GM-CSF promoter in T cells. In the case of the 
PHO5 promoter, chromatin remodelling and Brgl recruitment is dependent on prior 
histone hyperacetylation (Reinke and Horz, 2003). Similarly, a transient increase in histone 
acetylation occurs prior to Brgl recruitment to the IFN-0 promoter (Agalioti et al, 2000). 
Brg I is known to associate with acetylated histones via its bromodomain (Hassan et al, 
2002). This raises the possibility that Brg 1 is associated with the GM-CSF promoter via 
interactions with acetylated histones. In support of this, increasing histone acetylation by 
TSA treatment resulted in an associated increase in Brg 1 levels at the promoter and an 
increase in the rate of remodelling. It is important to note that the typical decrease in Brgl 
levels was not detected following P/I treatment in TSA treated cells. This may possibly be 
due to saturation of the nucleosome with Brgl and equilibrium between nucleosome 
assembly and disassembly. Alternatively, increasing histone acetylation may increase Brg 1 
recruitment across the entire gene and loss of Brg 1 did not occur on the neighbouring 
nucleosomes as detected in the ChIP assay. Acetylated histones are enriched at the GM-
CSF promoter (Chen and Shannon, unpublished data) and this may potentially enable the 
constitutive recruitment of Brgl. This would also explain why a transient increase in 
histone acetylation, as observed at the PHO5 and IFN-13 promoters (Reinke and Horz, 
2003; Agalioti et al, 2000), is not required at the GM-CSF promoter prior to chromatin 
remodelling (Chen et al, 2005). 
Alternatively, Brg 1 may be recruited to the GM-CSF promoter via an interaction 
with a constitutively expressed transcription factor. Liu et al (2002) have revealed that Spl 
binds Brg 1 and recruits SWI/SNF to the IFN-a responsive IFITM3 locus and perhaps a 
similar mechanism operates at the GM-CSF promoter. Indeed, Brgl has previously been 
shown to be recruited in a NF-KB/Spl dependent manner to the GM-CSF promoter in vitro 
(Holloway et al, 2003). This region has previously been shown as vital for GM-CSF 
promoter remodelling and transcription and thus makes it a potential candidate for the basal 
recruitment of Brgl. Alternatively, an unidentified, constantly bound transcription factor 
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may recruit Brgl. Whether Brgl is constitutively bound to the GM-CSF promoter in T cells 
throughout the cell cycle or if, following cell division, the basal state must be re-established 
remains to be elucidated. Interestingly, Brgl has previously been found to be excluded 
from condensed chromosomes during mitosis (Muchardt et al, 1996) suggesting that the 
basal chromatin state must be re-set following cell division. 
Unexpectedly, chromatin remodelling events across the GM-CSF promoter were 
still able to occur in the presence of the Brg 1 ATPase mutant. However, the basal 
accessibility of the GM-CSF was altered in Brgl mutant cells. This suggests that Brgl may 
be involved in maintaining a basal chromatin structure which is permissive to gene 
activation. In addition, it is possible that remodelling may occur less efficiently in the 
ATPase mutant cells, and this may have not been detected at the 6 hour time point 
examined. In support of this, chromatin remodelling can still occur at the PHO5 promoter 
in the absence of SWI/SNF but with delayed kinetics (Gaudreau et al, 1997; Barbaric et al, 
2001). In addition, wild type Brgl would still be operating in the transfected cells. It is also 
interesting to note that the ATPase domain of Brg 1 is not only required for its remodelling 
function but also for interactions with other factors (Bultman et al, 2005). Therefore the 
reduction in GM-CSF transcription in Brg 1 mutant cells may be attributed to interactions 
with other transcription factors being inhibited. Bultman et al (2005) generated a mutant 
Brgl in which the ATPase domain was mutated but ATPase activity was restored. They 
found that while the mutant Brgl is still recruited to the P-globin locus, remodelling and 
transcription were inhibited. By uncoupling ATPase activity and chromatin remodelling in 
this case it became evident that the ATPase domain is also essential for interactions with 
other co-activators 
GM-CSF is constitutively expressed at very low levels in resting T cells and rapidly 
induced in response to T cell activation signals. The promoter is relatively accessible in the 
resting state suggesting that the nucleosome is remodelled incompletely and constitutively. 
It is therefore conceivable that GM-CSF is a few steps further along in its activation 
profile. These data are in keeping with a model in which in resting T cells, Brgl is bound to 
the GM-CSF promoter due to increased basal acetylation, priming the gene for activation 
by establishing an inherent level of basal accessibility. Following stimulation an entire 
nucleosome is then lost from the promoter in a c-Rel dependent manner. c-Rel may drive or 
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Figure 4.10. Model for activation of the GM-CSF gene. Schematic 
representation of the GM-C SF promoter in the resting and activated state in B 
and T cells showing increased histone acetylation and Brg 1 recruitment in 
resting T cells. 
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maintain Brg 1 loss from the promoter thereby exposing DNA to the transcriptional 
machinery required for switching on gene expression (Figure 4.10). Many examples in the 
literature have demonstrated a delayed recruitment of Brgl to activated promoters. 
However, for immune genes such as GM-CSF which are rapidly activated, the basal 
recruitment of the SWI/SNF complex at sites which need to be remodelled may ensure the 
activating signal can operate much more efficiently. 
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CHAPTER 5. 
IFN-y, IL-4 AND IL-5 GENE ACTIVATION IN T 
CELLS IS BRG1 DEPENDENT. 
5.1 INTRODUCTION 
While a number of studies have investigated the role of Brgl in activating various 
genes, little work has been done to determine the role of Brgl in T cells (Yeh et al, 2002; 
Holloway et al, 2003; Gebuhr et al, 2003). To date, the involvement of Brgl during T cell 
activation is yet to be determined. The previous chapter highlighted a role for Brgl in GM-
CSF gene activation, raising the question of whether other genes are activated in a similar 
Brgl dependent manner in T cells. 
The role of Brg 1 in gene activation has been studied using a variety of different 
approaches. While knockout of the Brgl gene is embryonic lethal in mice (Bultman et al, 
2000) conditional Brgl knockouts have been used successfully in the past to elucidate Brgl 
function. Previous research has demonstrated that Brgl is vital for immune development 
and the immune response. The specific deletion of Brgl in thymocytes using the Cre-/oxP 
conditional mutagenesis system has revealed a role for this protein in T cell development 
(Gebuhr et al, 2003). Profound thymic abnormalities were observed in T cell specific Brgl 
deficient mice. Staining of these Brgl deficient cells with 5'-bromo-2'-deoxyuridine 
demonstrated that Brg 1 was required for thymocyte proliferation and survival. In 
agreement with Gebuhr et al (2003), Vradii et al (2006) recently demonstrated that Brgl is 
critical for haematopoietic cell maturation. A dominant negative Brg 1 mutant was stably 
expressed in myeloid cells. The forced expression of the mutant Brg 1 was found to inhibit 
G-CSF dependent differentiation of myeloid cells towards the granulocytic stage. 
Indeed, a vital role for Brgl in immune gene regulation has begun to emerge 
(reviewed in Chi, 2004). Cui et al (2004) revealed that the inhibition of Brgl reduces a 
cells ability to control viral growth by reducing the expression of IFN-P and other antiviral 
proteins. Cells were transfected with siRNA directed against the SWI/SNF component 
BAF47. The inhibition of BAF47 using this siRNA approach was shown to down-regulate 
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Brgl and its remodelling activity which in turn reduced the activity of IFN-f -3. In addition, 
Brgl appears to be essential for cytokine induced gene regulation and is responsible for the 
activation of IFN-a responsive genes (Huang et al, 2002). Brgl has also previously been 
shown to play an important role in T cell activation. Zhao et al (1998) found that T cell 
receptor signalling results in the rapid association of the Brgl complex with chromatin. 
This suggests that SWI/SNF might be involved in regulating the expression of genes 
typically activated following immune stimulation. This evidence strongly implicates Brgl 
in immune gene regulation and therefore highlights the importance of determining the 
targets of Brgl in T cells. 
A number of microarray studies investigating the role of Brgl have been conducted 
in the past. The ALAB, SW-13 and C33A cell lines all lack functional Brgl protein. These 
cell lines are derived from breast carcinoma, adenocarcinoma and cervical carcinomas 
respectively. The reintroduction of wildtype Brgl into these deficient cell lines has proved 
to be a useful means for elucidating the function of Brgl. In a study by Liu et al (2001) 
SW-13 cells were transfected with a wildtype Brgl construct. Brgl expressing cells were 
then enriched by FACS and differentially activated transcripts determined by microarray 
analysis. This group demonstrated that Brgl was involved in the activation of 
approximately 80 genes including the cytokine, M-CSF. 
Brgl has been shown to play a role in the regulation of cellular proliferation 
(Dunaief et al, 1994) and is frequently deleted or mutated in tumour cell lines (Wong et al, 
2000). It is therefore extremely important to determine the targets of this ATPase. Previous 
work by Hendricks et al (2004) used microarrays to identify novel Brgl targets in ALAB 
cells, a breast tumor cell line. This cell line lacks Brgl due to a premature stop codon 
mutation in exon 10. The adenovirus mediated reintroduction of Brgl into these cells 
resulted in the activation of numerous genes involved in cell adhesion, proliferation and 
motility. Targets included the protooncogenes, cJun and cMyc. Of greatest clinical 
relevance however, the reintroduction of Brgl into this tumor cell line was shown to induce 
growth arrest. In another microarray study, de la Sema et al (2005) used stably transfected 
myocytes capable of the inducible expression of a dominant negative Brgl protein for 
microarray analysis. This group found that the activation of one third of myoD induced 
genes were dependent on Brgl. Therefore, there are a variety of different ways which have 
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been used successfully in the past to elucidate targets of Brgl. 
Studies in yeast have shown that SWI/SNF is only required for the normal 
transcription of a small subset of genes. Expression studies have revealed that SWI/SNF 
regulates the transcription of 5-6% of the yeast genome (Sudarsanam et al, 2000). 
Furthermore, a genome wide study in yeast found that SWI/SNF dependent genes were 
scattered through out the genome suggesting that this complex controls transcription at the 
level of individual genes and not at the level of chromosomal domains (Sudarsanam et al, 
2000). Further complexity in Brgl function became evident as SWI/SNF has been found to 
have activating (DiRenzo et al, 2000; Liu et al, 2001) and repressive functions (Murphy et 
al, 1999; Pal et al, 2003). Thus, gene regulation by Brgl is extremely complex and is likely 
to be slightly different at each target gene. 
Very few direct targets of Brgl have been confirmed in mammalian cells. However, 
ChIP analysis has been successfully used to demonstrate that Brgl directly interacts with a 
number of promoters. Brgl has been shown to bind to the IFN-f3 promoter in HeLa cells 
following viral stimulation (Agalioti et al, 2000). ChIP analysis also revealed that Brgl is 
recruited to the myogenin promoter during myocyte differentiation (de la Serna et al, 2005) 
and Brg 1 has been found to be constitutively associated with the M-CSF promoter in the 
WI-38 fibroblast cell line (Liu et al, 2001). The P21 and metallothionein-1 promoters have 
also been identified as direct targets of Brg 1 (Hendricks et al, 2004; Datta et al, 2005). In 
each instance its recruitment appears to be cell type specific and requires different factors 
and signals. 
While the role of Brgl in regulating gene expression has been analyzed in a number 
of cell types, there is a lack of array studies investigating the role of Brgl in T cell 
function. The aim of this chapter is to identify T cell gene targets which rely on Brgl for 
activation. Gene targeting experiments in mice have demonstrated that while Brm is 
dispensable (Reyes et al, 1998) Brgl is essential for development (Bultman et al, 2000) 
and therefore the use of the Brgl knockout is not possible for studying the function of Brgl 
in T cells. Hence, the transient introduction of a dominant negative ATPase mutant (K—>R) 
Brgl followed by cell sorting was used to assess the effect of Brgl on gene activation in 
EL-4 T cells. Microarrays were used here for the first time to identify a subset of Brgl 
dependent inducible T cell genes. 
105 
5.2 RESULTS 
5.2.1 Experimental design 
To determine the set of inducible genes in T cells which are dependent on Brgl for 
their activation, EL-4 T cells in which Brgl activity is disrupted were generated and 
subsequently analyzed using microarrays. SWI/SNF function was disrupted by over-
expression of the ATPase defective Brgl K774R mutant (Khavari et al, 1993). Cells 
expressing this mutant have previously been used to determine Brgl target genes in mouse 
NIB 3T3 fibroblasts (de la Serna et al, 2000). 
Attempts were made at generating stably transfected pBJ5-brglIC/R EL-4 T cells. 
However, while the stable transfection of the pBJ5 control was successful, the cells 
transfected with the Brgl mutant failed to grow (Ray and Holloway, personal 
communication). Therefore cells were transiently transfected with the Brgl mutant 
construct and the transfected cell population purified and analyzed using microarrays since 
this strategy had been used successfully to investigate the role of Brgl in GM-CSF gene 
activation (Figure 4.1b, Chapter 4). In addition Liu et al (2001) used a similar technique to 
demonstrate a role for Brgl in M-CSF activation by transient transfection followed by 
FACS. Liu and co-workers transfected Brgl deficient SWI 13 cells with a GFP tagged 
Brgl expression vector. Transfected cells were then enriched by FACS 24 hours post 
transfection and gene expression changes determined by microarray analysis. 
EL-4 T cells were transfected with either the pBJ5 parent vector or pBJ5-brg1K/R 
plasmids along with the KKII plasmid which expresses a truncated form of the KKII 
receptor (as described in Material and Methods and Chapter 4). After 24 hours transfected 
cells were purified by virtue of expressing the K KII receptor and incubated with or without 
P/I for 6 hours. RNA was then extracted from each of these four cell samples for 
microarray analysis (Table 5.1). The experiment was then repeated to generate a second 
replicate set of RNA. 
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Table 5.1 RNA samples generated for microarray analysis. 
Sample I.D. Transfection WI (hrs) 
NS-pBJ5 -1 pBJ5 0 
PI-pBJ5- 1 pBJ5 6 
NS-Brgm- 1 pBJ5-brgIK/R 0 
PI-Brgm- 1 pBJ5-brgIK/R 6 
NS-pBJ5 -2 pBJ5 0 
PI-pBJ5 -2 pBJ5 6 
NS-Brgm-2 pBJ5-brg 1 IC/R 0 
PI-Brgm-2 pBJ5-brglIC/R 6 
5.2.2 Quality Assurance 
5.2.2.1 RNA quality 
The quality of data generated from microarray experiments is to a large extent a 
reflection of sample quality. Therefore the RNA was subjected to a number of quality 
assurance assessments before the microarray experiments were undertaken. RNA quality 
was verified using the Agilent 2100 BioAnalyzer which can accurately determine sample 
integrity. This chip based capillary electrophoresis system was used to determine the ratio 
of the 28S ribosomal peak to the 18S ribosomal peak. All samples were within an 
acceptable range of 1.6 to 1.9 (Table 5.2) which confirmed that the starting RNA was of 
high quality. Sample concentration and A260/280 ratios were determined using the 
NanoDropa Each ratio was within the acceptable range of 1.8-2.1 suggesting the RNA 
was relatively pure (Table 5.2). 
5.2.2.2 Confirmation of functional depletion of Brgl 
Since disruption of Brg 1 function is known to affect GM-CSF gene activation 
(Chapter 4) GM-CSF mRNA levels were analyzed in the RNA samples in order to confirm 
a functional effect from the introduction of the Brgl mutant. An aliquot of each RNA 
sample was converted to cDNA and analyzed by real-time PCR to determine GM-CSF 
mRNA levels. In cells transfected with the control pBJ5 plasmid a greater than 500 fold 
increase in GM-CSF mRNA was detected following stimulation with P/I for 6 hours 
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Table 5.2. The A260/280 and 28S/18S rRNA ratios of the microarray 
samples. The integrity of RNA isolated from KKII and pBJ5 or pBJ5-brg1K/R 
co-transfected cells was determined using the Agilent 2100 BioAnalyzer and 
RNA purity determined using the NanoDrop®. 
A260/2440 28Si18S rRNA 
ratio 
NS PB,J5 :=I 2.11 
PI ppJ5 1 1.96 1.7 
NS13r 2! 1 6 
PI B 2.13 1 6 
iNS::01315,2 2, 1.7 
P1 pB.15-2 2:07 1.7 
NS B rgm-2 2:03 
PI Brgm-2 2.09 1.6 
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Figure 5.1. Brgl is required for transcription of the GM-CSF gene. EL-4 T cells 
were co-transfected with the KKII and pBJ5 or pBJ5-brg1K/R plasmids prior to 
magnetically activated cell sorting before incubating with or without P/I for 6 hours. 
cDNA was prepared and levels of GM-CSF mRNA analyzed by real-time PCR. The 
data for replicate 1 (A) and replicate 2 (B) are shown. 
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(Figure 5.1; 500 fold in replicate 1, 600 fold in replicate 2). As seen previously (Chapter 4) 
GM-CSF activation in response to WI was reduced almost 50% in cells transfected with the 
pBJ5-brgliC/R plasmid (Figure 5.1) with cells expressing the mutant construct only capable 
of producing a 300 (replicate 1) or 250 fold (replicate 2) induction in GM-CSF mRNA 
upon T cell activation. This demonstrated that Brg 1 function had been disrupted in the cells 
containing the Brg 1 mutant protein, and that this translated into reduced expression of a 
known Brg 1 candidate gene, and suggested that these samples would be useful to screen for 
novel Brgl targets. 
5.2.2.3 Sample processing and array quality 
5.2.2.3.1 Test Arrays 
Affymetrix GeneChip@ Test3 arrays were used as a verification of sample quality 
and sample processing from total RNA through to the hybridization. These test arrays 
provide an accurate means of determining the quality of the labelled target prior to analysis 
on the GeneChip@ Mouse Genome 430 2.0 arrays. The test arrays comprise probes 
representing a subset of characterised genes from various organisms. For each gene 
represented, probes derived from the 5', middle and 3' portions of the gene are represented 
thereby enabling the identification of samples containing degraded RNA or inefficiencies 
in cDNA synthesis which would lead to poor experimental results. The control 
hybridization probes are identical to those used on the GeneChip@ Mouse Genome 430 2.0 
arrays and include a subset of mouse housekeeping genes. Briefly, RNA was converted to 
fragmented cRNA and hybridized to the Test3 arrays overnight before scanning. The 5' to 
3' ratios of two housekeeping genes were analyzed. This ratio is an indication of sample 
integrity, input, the number of full length transcripts and cDNA reaction efficiency. For 
each experiment 3'15' ratios for the housekeeping genes (3 -actin  and GAPDH were close to 
1, ranging from 0.74 to 1.37 (Table 5.3), indicating efficient cDNA synthesis. 
Background values reflect the autofluorescence of the array and non-specific 
binding of target or stain molecules. Typical background values on arrays analyzed through 
the JCSMR Biomolecular Resource Facility are approximately 45 (S. Rao, personal 
communication) and should be similar within the one experiment to ensure accurate 
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comparisons can be made. High background levels result in an overall loss of sensitivity in 
the experiment. The test arrays had an average background of approximately 45, ranging 
from 34.33 to 53.93 (Table 5.3). Together, these data suggested that the 8 samples were of 
high quality and therefore were hybridized to the GeneChip@ Mouse Genome 430 2.0 
arrays to screen for Brgl target genes. 
5.2.2.3.2 Affymetrix Mouse Genome 430 2.0 Array Quality 
The Affymetrix Mouse Genome 430 2.0 arrays allow the analysis of over 39,000 
transcripts and variants, including 34,000 well characterized mouse genes. Oligonucleotide 
probes (11 pairs of 25-mers) including perfect match and mismatch probes are used to 
measure the level of transcription for each gene represented on the array. Before analyzing 
the data generated from the Mouse Genome 430 2.0 Arrays, the quality of sample 
processing and hybridization was confirmed. As seen with the Test3 Arrays, the 5' to 3' 
ratio for the housekeeping genes (3 -actin and GAPDH were close to 1 (Table 5.4) and the 
arrays had an average background of 45 ranging from 41.67 to 54.34 for the 8 arrays 
indicating consistency across the arrays (Table 5.5). 
Each Affymetrix array represents a separate experiment therefore data must be 
normalized to account for variability in starting amounts of RNA, sample procesing, 
staining and scanning. Arrays must be scaled or normalized to one target intensity to allow 
comparison between experiments. The signal intensities were imported into GeneChip@ 
Operating Software version 1.2 (GCOS; Affymetrix) and all arrays were normalized using 
the MAS 5.0 algorithm for comparison purposes to a target intensity (TGT) of 150. 
Optimally, scale factors should be very close to one another (within three-fold) indicating 
that minimal scaling of the data is required. The scale factor for the 8 arrays in this 
experiment ranged from 1.1 to 2.1 which indicated that the scaling due to background 
across the arrays was minimal (Table 5.5). 
The number of probe sets called "present" relative to the entire number of probe 
sets on the array is dependent on the type of cell, stimuli and overall RNA quality. The call 
of "presence" or "absence" was determined by signal intensity above or below background 
respectively. Extremely low percentage of genes present values are often an indication of 
poor sample quality or hybridization. The percentage of genes present or absent was similar 
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Table 5.3. Efficiency of cDNA synthesis and levels of non specific binding on the 
Affymetrix Test3 arrays. RNA from EL-4 T cells co-transfected with the pBJ5 or 
pBJ5-brg1K/R and KKII plasmids was processed and hybridized to the Affymetrix 
Test3 arrays. Signal intensities were measured and 5' to 3' ratio for 2 housekeeping 
genes generated. Background signal levels were also measured on the test arrays. 
Array Beta actin 
signal 
375' 
GAPDH 
signal 
3:6' 
Background 
N 1.13 0.78 34.33 
PI pBJ5-1 1.26 0.86 
NS8ighl 1.16 , 0.81 36.01 
PI Brgm- L37 0.77 
074 
41.08 
115 ;ili:;85 NS45815:-2 
P1 pBJ5-2 1.16 0.90 46.15 
8rgrtv.:_ 1. 	 0;78 
PI Brgm-2 1.24 45.89 
Table 5.4. Efficiency of cDNA synthesis for the Affymetrix Mouse Genome 430 
2.0 arrays. RNA from EL-4 T cells co-transfected with the pBJ5 or pBJ5-brg1K/R 
and KKII plasmids was processed and hybridized to the Affymetrix GeneChip@ 
mouse genome 430 2.0 arrays. The arrays were scanned and signal intensities were 
measured to calculate the 5' to 3' ratio for 2 housekeeping genes. 
Array Beta-actin 
sigaal (3'/57) 
GAPDH 
signal (375.) 
NS pB15-1 1.14 0.78 
PI pl3J5-1 1.26 0.82 
Nw tli-1 113 as3 
PI Brgm-I 1.20 0.79 
,,.: .... _. 
NS OBJ5-2 1.15 QM 
PI OBJ5-2..: 1.14 0:4P 
Ns iyito-2 115 0.78 
PI Brgin- 2 _ 	 1.19 q Vii§ ,.....$,.0A 
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CO - 
CO - • IP Nol gm III 
Table 5.5. Relative hybridization efficiency, non specific binding and % genes 
present on the arrays. Following sample hybridization and scanning, the signal 
intensities of each array were used to generate the scale factor, background and 
percentage of genes present using GCOS. 
Array Scale Factor Average 
background 
% genes 
present 
NS pBJ5-1 1.474623561 42.44 45.4 
PI pBJ5-1 1.773011446 54.34 40.0 
NS Brgm-1 2.098287106 41.67 42.6 
PI Brgm-1 1.551655054 41.79 44.] 
NS pBJ5-2 1.158938408 50.61 46.1 
PI pBJ5-2 1.895966768 44.09 42.4 
NS Brgm-2 1.10244453 44.39 46.3 
PI Brgm-2 1.63254261 	_ 41.95 43.3 
— 
E 
sample 
Figure 5.2. Box plots of the log 2 Affymetrix signal values for all the samples as 
output by Bioconductor. 
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across the replicate arrays with the % present ranging between 40.0 to 46.3% (Table 5.5). 
This result is typical of array experiments which have been conducted in the JCSMR 
Biomolecular Resource Facility (S. Rao, personal communication). Together these analyses 
confirmed that the 8 RNA samples and hybridizations were of high quality. 
Statistical analysis was initially - carried out by Dr. Stephen Ohms of the 
Biomoleeular Resource Facility. Plots of the log 2 CEL file intensities were generated using 
the box plot function in the base package R (Bioconductor version 1.8.0) with all input 
parameters set to default values. The 8 arrays were found to be highly reproducible with 
background equivalent among all samples as demonstrated in Figure 5.2. Using unbiased 
statistical analysis it was shown that all arrays had performed with equal efficiency. 
Therefore it was concluded that all 8 arrays were of good quality and suitable for 
comparison across samples. 
5.2.3 Microarray data analysis 
5.2.3.1 Absolute analysis 
Once the quality of the samples and arrays had been confirmed absolute data 
analysis was performed using the computational analysis program GCOS. Since GM-CSF 
is known to be regulated by Brgl and this had been confirmed in the samples prior to array 
analysis GM-CSF data was extracted to confirm that changes in expression could be 
detected on the arrays and the target intensity values (TGTs) are shown in Table 5.6. For 
both replicates an increase in GM-CSF expression was detected following stimulation to a 
TGT of 1600 and 1100 for replicates 1 and 2 respectively. In the mutant transfected cells 
TGTs of approximately 800 were detected (Table 5.6). This demonstrated that expression 
of the Brg 1 mutant resulted in reduced GM-CSF expression in both replicates (Figure 5.3) 
confirming the real-time PCR analysis of these samples (Figure 5.1). 
5.2.3.2 Comparative analysis 
Normalized data was transferred to GeneSpring 7.2 (Silicon Genetics) for 
comparative analysis. The extremely defined aim of this analysis was to identify inducible 
T cell genes which, like GM-CSF, were Brgl dependent. The loss of Brgl was found to 
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Table 5.6. GM-CSF TGTs for the two replicate experiments. EL-4 T cells 
were co-transfected with either the pBJ5 or pBJ5-brg1K/R and KKII plasmids 
prior to magnetically activated cell sorting and incubation with or without P/I for 
6 hours. Fragmented cRNA was prepared and hybridized to the Affymetrix 
GeneChip@ mouse genome 430 2.0 arrays. The arrays were scanned and signal 
intensities (TGTs) used to determine the relative levels of GM-CSF mRNA. 
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Figure 5.3. GM-CSF TGTs for the two replicate experiments. EL-4 T cells 
were co-transfected with either the pBJ5 or pBJ5-brglIUR and KKII plasmids 
prior to magnetically activated cell sorting and incubation with or without P/I for 6 
hours. Fragmented cRNA was prepared and hybridized to the Affymetrix 
GeneChip@ mouse genome 430 2.0 arrays. The relative levels of GM-CSF mRNA 
were determined by scanning signal intensities (TGTs). The mean and standard 
error of the two replicate assays are shown. 
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disrupt the activation of 0.3% of genes in EL-4 T cells. Altered basal expression in the 
mutant transfected cells was also determined. Upregulated basal levels of 2 fold or greater 
were observed in 32 genes (data not shown). In addition, 47 genes were down-regulated 2 
fold or greater in the Brgl mutant cells (both replicates). 
Data was filtered to determine the genes differentially expressed between the 
control and Brg 1 mutant samples. The Advanced Filter tool in GeneSpring was used to 
generate a list of inducible genes which had a reduction in activation in the Brgl mutant 
expressing cells compared to the control cells (i.e. genes with flags present in P/I control 
AND genes induced greater than 2 fold in P/I control compared to the NS control NOT 
genes induced greater than 1.4 fold in the P/I control compared to the P/I mutant). The 
stringency of the filters set was adapted to generate a list of genes with similar profiles to 
GM-CSF. In replicate 1, 1071 genes were affected according to the filters set and 2570 
genes were affected in replicate 2 (Figure 5.4). The difference betweent the genes identified 
in each replicate can be explained by slight variations in signal intensity across replicate 
arrays. A number of genes may be excluded from replicate 1 as they fall just outside the 2 
or 1.4 fold cutoffs. The gene lists generated for each experimental replicate were combined 
and genes common to both lists and therefore reproducibly differentially expressed 
identified. Of the genes induced greater than 2 fold in response to P/I stimulation, 101 
displayed reduced expression in the pBJ5-brg1K/R cells compared to the control stimulated 
cells and are listed in Appendix A. A subset of "known" genes is displayed in Table 5.7. 
These genes were then grouped according to functional classification by using the 
"Build Ontology" function in GeneSpring. It was evident that genes involved in a wide 
range of processes were affected by the Brgl mutant including a large number of genes 
involved in cell communication (Figure 5.5). As GM-CSF was not included in the 
combined data (Table 5.7) a less stringent means of identifying Brg 1 targets was used. The 
cytokine and immune genes which fell into the cell communication category for replicate 1 
were identified and are listed along with signal intensity values in Table 5.8. This group 
included M-CSF, IL-4, IL-5, IL-25, GM-CSF, and IFN-y. Genes differentially expressed in 
both replicates included IL-4 and IFN-y. 
115 
Replicate 2 
2,570 genes 
Replicate 
1,071 genes 
1 111111111111111111111111111111111111111111H1111111111111  	
Figure 5.4. Venn diagram of genes identified as inducible Brgl targets in EL-
4 T cells for replicate 1 and 2. 
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Table 5.7. Genes with reduced activation in the Brgl mutant cells. Data from 
the microarray experiments was imported into GeneSpring and inducible genes 
which were downregulated in the presence of the Brgl mutant in both replicates 
identified using the advanced filter. Only a subset of genes are shown. 
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0 Other 
Figure 5.5. Functional classification of genes differentially expressed in the 
pBJ5-brglIUR transfected cells. Data from the microarray experiments was 
imported into GeneSpring and inducible genes which were downregulated by the 
expression of the Brg 1 mutant were grouped according to function using the build 
ontology tool. 
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Table 5.8. Immune genes with reduced activation in the Brgl mutant. Data 
from the microarray experiments was imported into GeneSpring and inducible 
genes which were downregulated in the presence of the Brgl mutant (m) in 
replicate 1 identified using the advanced filter. Genes were then sorted according 
to ontology and immune genes which fell into the "cell communication" category 
are listed. 
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5.2.4 Expression of the cytokines M-CSF, IFN-y, IL-4 and IL-5 is 
dependent on Brgl 
Of the genes found to be dependent on Brgl for activation in T cells, a number were 
cytokines, including M-CSF, IFN- y, IL-4 and IL-5. To validate the Brg 1 dependence of 
these genes, EL-4 T cells were again co-transfected with KKII and pBJ5 or the pBJ5- 
brg1K/R mutant plasmids and transfected cells purified 24 hours later. Cells were then left 
unstimulated or stimulated with P/I for 6 hours before isolating RNA. M-CSF, IFN- y, IL-4 
and IL-5 mRNA levels were then determined by real-time PCR analysis of cDNA. The 
disruption of Brgl function in EL-4 T cells reduced M-CSF mRNA accumulation (Figure 
5.6a). An 11 fold increase in M-CSF mRNA levels was observed in control transfected 
cells following stimulation with P/I. In contrast, M-CSF mRNA only increased 7 fold in P/I 
stimulated cells expressing the Brgl mutant. Stimulation of control transfected cells 
produced a 1500 fold increase in IFN-y mRNA levels, however the response to stimulation 
in the mutant transfected cells was reduced to 500 fold (Figure 5.6b). The Brgl mutant also 
inhibited IL-4 expression (Figure 5.6c). Control transfected cells displayed an 
approximately 60 fold increase in IL-4 mRNA levels following stimulation, while the Brgl 
mutant transfected cells exhibited only a 10 fold increase in IL-4 expression. IL-5 
expression was almost completely abolished by Brgl mutant expression. While control 
transfected cells displayed a 60 fold induction in IL-5 mRNA levels, IL-5 transcription was 
inhibited in cells transfected with the Brgl mutant (Figure 5.6d). These data validated the 
microarray results and confirmed that Brgl is involved in the expression of M-CSF, IFN-y, 
IL-4 and IL-5. M-CSF has previously been identified as a target of Brgl by Liu et at (2000) 
and the identification of a known Brgl target therefore confirms the validity of data 
generated from the microarrays. 
5.2.5 IFN-y, IL-4 and IL-5 display distinct activation profiles 
As M-CSF has previously been identified as a direct target of Brg 1 (Lui et al, 
2001), the remaining candidates IFN-y, IL-4 and IL-5 were chosen for further analysis. In 
order to determine the activation profiles of the IFN-y, IL-4 and IL-5 genes in response to 
WI stimulation in EL-4 T cells, RNA was isolated from EL-4 T cells stimulated with P/I for 
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Figure 5.6. Induction of M-CSF, IFN-y, IL-4 and IL-5 genes is Brgl dependent. 
EL-4 T cells were transfected with the pBJ5 or pBJ5-brg1K/R plasmids. Transfected 
cells were purified before incubation with or without WI for 6 hours. cDNA was 
prepared and levels of M-CSF (A), IFN-y (B), 11,-4 (C) and IL-5 (D) mRNA 
determined by real-time PCR. The results for a single assay are shown. 
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0, 0.5, 2, 4, 6 and 24 hours. cDNA was prepared and IFN-y, IL-4 and IL-5 mRNA levels 
determined by real-time PCR. An increase in IFN-y mRNA levels was detected within 30 
minutes of stimulation and peaked at 6 hours with a 300 fold induction before returning to 
near basal levels by 24 hours (Figure 5.7a). The IL-4 gene was induced more rapidly with 
mRNA levels peaking at 4 hours post-stimulation with levels reaching approximately 60 
fold basal levels, declining after this time and returning to basal levels by 24 hours post-
stimulation (Figure 5.7b). The IL-5 mRNA time course displayed distinctly different 
kinetics with little increase in mRNA levels detected before 6 hours of stimulation but had 
significantly increased by 24 hours to 30 fold basal levels (Figure 5.7c). Thus while the 
IFN-y and IL-4 genes, like GM-CSF are rapidly activated in response to P/I, the IL-5 gene 
showed a more delayed activation profile. 
5.2.6 The IFN-y, IL-4 and IL-5 promoters display distinct 
remodelling profiles 
To determine whether the different activation profiles of the IFN-y, IL-4 and IL-5 
genes reflected differences in basal chromatin structure and remodelling kinetics chromatin 
accessibility across their promoters was examined prior to and following stimulation. EL-4 
T cells were either left untreated or stimulated with P/I for 4 and 24 hours. Nuclei were 
then isolated and digested with MNase. Accessibility was determined by real-time PCR 
analysis of genomic DNA using primer sets designed to the IFN-y, IL-4 or IL-5 promoters. 
A low level of basal accessibility was detected at the IFN-y promoter (20%) which 
increased to 30% at 4 hours post-stimulation and by 24 hours had decreased to 
approximately 25% (Figure 5.8a). The IL-4 promoter had a higher inherent level of basal 
accessibility, with accessibility in the non-stimulated cells at 45% (Figure 5.8b). 
Stimulation for 4 hours resulted in increased promoter accessibility with levels increasing 
to 60% and remained at this level for 24 hours. The IL-5 promoter was relatively 
inaccessible in resting T cells with basal accessibility at approximately 20%. Accessibility 
remained at this level at 4 hours post stimulation, however at 24 hours post stimulation the 
promoter had opened up to approximately 50% (Figure 5.8c). Chromatin accessibility 
changes at the IFN- y, IL-4 and IL-5 promoters reflected the transcriptional activation 
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Figure 5.7. The IFN-y, IL-4 and IL-5 genes show distinct activation profiles. 
cDNA was prepared from EL-4 T cells stimulated with P/1 for the indicated time 
periods. IFN-y (A) IL-4 (B) and IL-5 (C) mRNA levels were then analyzed by real-
time PCR. The mean and standard error of three replicate assays are shown. 
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Figure 5.8. The IFN-y, IL-4 and IL-5 promoters display different remodelling 
profiles. Nuclei isolated from EL-4 T cells stimulated for the indicated time periods 
were digested with MNase before analyzing genomic DNA by real-time PCR with 
primers designed to the IFN-y (A) IL-4 promoter (B) and 1L-5 promoter (C). The 
mean and standard error for two replicate assays are shown 
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kinetics of these genes. 
5.2.7 Brgl is bound to the IFN-y promoter in resting cells and is 
recruited to the IL-4 promoter following stimulation 
IFN-y, IL-4 and IL-5 expression in activated T cells, like GM-CSF, is dependent on 
Brgl. To determine whether Brgl is directly involved in the activation of these genes, ChIP 
assays were used to investigate whether Brgl is associated with the 'gene promoters. EL-4 
T cells were left unstimulated or stimulated for 4 hours with P/I before cross linking and 
immunoprecipitating chromatin using a Brgl antibody. ChIP revealed that Brgl is enriched 
at the IFN-y promoter in resting T cells, and Brgl levels decrease following stimulation 
(Figure 5.9a). In contrast only relatively low levels of Brgl were detected at the IL-4 
promoter in resting cells, however following stimulation Brgl levels increased 3 fold 
(Figure 5.9b). In contrast, little Brgl was detected at the IL-5 promoter in resting and 
stimulated cells (Figure 5.9c). Therefore, IFN-y shows a similar Brgl recruitment profile to 
GM-CSF with Brgl bound to the resting promoter and lost following stimulation. In 
contrast, while IL-4 has a similar activation profile to GM-CSF and IFN- y, Brgl is not 
present at the IL-4 promoter in the resting state but is recruited following stimulation. Brgl 
could not be detected at the IL-5 promoter at the time points analyzed. 
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Figure 5.9. Brgl binding at the IFN-y, IL-4 and IL-5 promoters. EL-4 T cells 
were either left untreated or stimulated for 4 hours with P/I before 
immunoprecipitating chromatin using a Brgl antibody. Enrichment of Brgl was 
determined by real-time PCR analysis using primers designed to the IFN-y (A) IL-4 
(B) and IL-5 (C) promoter regions. The mean and standard error of three replicate 
assays are shown 
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5.3 DISCUSSION 
Microarray experiments have proved to be incredibly powerful tools for 
determining the function of Brgl (Liu et al, 2001; Hendricks et al, 2004; de la Serna et al, 
2005). Here, tnicroarray analysis was used to address the extremely focussed question of 
whether other immune genes are regulated by Brgl in a similar manner to GM-CSF in 
response to T cell activation. This study identified 101 targets of Brgl from 34,000 known 
mouse transcripts which were reproducibly differentially expressed. Other studies have 
found similarly small sets of genes regulated by Brgl. Hendricks et al (2004) found 70 
genes induced 2 fold or more following the restoration of Brgl in SW-13 and ALAB cells 
and 65 genes repressed 2 fold or greater, out of 40,000 genes screened. While Liu et al 
(2001) found 80 genes induced 3 fold or greater and 2 repressed 3 fold or more out of 
22,000 genes in SW-13 cells following reintroduction of Brgl. The data mining techniques 
used differ between research groups and depend on the aim of the experiment. The number 
of genes identified is therefore restricted by the cut-offs used in data analysis and of course 
the cell type, experimental system and treatments used. In this case GM-CSF, a previously 
identified target of Brgl, was actually omitted from the gene list generated for replicate 2. 
It is therefore clear that less stringent filtering could be used to identify more Brgl 
dependent genes. Thus, Brgl targets which are activated via different signalling cascades 
would be omitted from this study along with genes which failed to meet the restrictions set 
during data analysis. 
The microarray data presented in this chapter demonstrates that Brgl is essential for 
the activation of a number of cytolcine genes in T cells. M-CSF, IFN-y, IL-4 and IL-5 were 
all identified as targets of Brgl. The fact that M-CSF has previously been identified as a 
Brgl target in a past microarray study validates the data presented in this chapter (Liu et al, 
2001). IFN-y expression is associated with Th 1 cells, while IL-4 and IL-5 are Th2 
cytokines. EL-4 T cells have Th 1 and Th2 expression capabilities and are thus considered 
Th0 like. It is therefore interesting to note that both Th1 and Th2 cytokines were identified 
as targets of Brgl. 
This is not the first time a role for Brgl in cytokine signalling has been identified. 
Pattenden et al (2002) have previously shown that Brgl is linked to immune surveillance as 
Brgl interacts with the CIITA promoter in an IFN-y inducible manner. Recent evidence has 
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pointed to a role for Brg 1 in immune regulation (Zhao et al, 1998; Huang et al, 2002; Cui 
et al, 2004) and Brg 1 has previously been identified as playing a major role in the immune 
response due to its requirement in inducing IFN-y and IFN-a responsive genes (Pattenden 
et al, 2002; Ni et al, 2005). The findings presented in this chapter add further support to the 
role of Brgl in immune regulation. 
While IFN-y, IL-4 and IL-5 were all identified as Brg 1 targets, each has a distinct 
activation profile. IFN-y is rapidly activated, with an increase in promoter accessibility 
detected within a short time frame. In addition, Brg 1 was found to be constitutively 
associated with the IFN-y promoter. These features suggest that IFN-y gene is poised for 
activation in a similar manner to GM-CSF. The data presented in this chapter supports the 
very recent findings of Zhang and Boothby (2006) in which Brgl was shown to be 
constitutively associated with the IFN-y promoter in mouse primary Th 1 cells. Their work 
demonstrated that, like GM-CSF, the rapid activation of IFN-y is associated with basal 
recruitment of Brgl. Three days following differentiation under Thl or Th2 conditions 
Brgl was found to be associated with the IFN-y promoter in Th 1 but not Th2 cells with 
recruitment therefore being associated with locus activation. The association of Brg 1 with 
the promoter region was also linked to increased accessibility and transcriptional 
competence. Similar to the findings for GM-CSF and IFN-y, Brgl has also been found 
constitutively associated with the M-CSF promoter in SW-13 and WI38 cells (Liu et al, 
2001), suggesting a similar mechanism for gene activation. It is also interesting to note 
however, that unlike GM-CSF, the IFN-y promoter is relatively inaccessible in its basal and 
activated state. It would therefore be important to study remodelling of the IFN-y gene over 
a series of time points and at a number of different sites. 
Precisely which factor is responsible for anchoring Brg 1 to the promoter region 
remains unclear. Constitutively expressed factors or basal histone acetylation may be 
involved in the basal recruitment of Brgl to the IFN-y and GM-CSF promoters. Indeed, the 
data presented in Chapter 4 indicates that the basal recruitment of Brgl to the GM-CSF 
promoter may be attributed to increased basal histone acetylation. In support of this 
hypothesis de la Serna et al (2005) have shown that histone H4 hyperacetylation precedes 
Brg 1 recruitment to the myogenin promoter. Recently, it has been suggested that Brg 1 
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association with the IFN-y promoter in Thl cells is dependent on NFAT members as Brgl 
recruitment is CsA sensitive and Brgl can co-immunoprecipitate with NFAT (Zhang and 
Boothby, 2006). This hypothesis may be flawed however, as NFAT only translocates to the 
nucleus following T cell activation. In addition, this study failed to address whether basal 
histone acetylation of the IFN-y promoter influences Brgl recruitment. Increased histone 
acetylation has previously been observed at the IFN-y locus in Thl cells (Avni et al, 2002), 
which correlates with the basal Brgl recruitment identified by Zhang and Boothby (2006). 
However, the role of histone acetylation in Brgl recruitment needs to be studied in more 
detail. 
Unlike GM-CSF and IFN-y, which share a common mechanism of activation with 
promoter priming by basal Brgl recruitment, the IL-4 gene is activated using a different 
Brg 1 dependent mechanism. Intriguingly, while the IL-4 gene displayed a slightly more 
rapid activation profile than IFN-y and GM-CSF, Brgl recruitment was delayed. However, 
the peak in IL-4 expression and promoter remodelling did occur concomitant with Brgl 
recruitment highlighting the importance of Brgl in 11,4 activation. While Brgl was not 
detected at the IL-4 promoter in resting cells, it may be recruited to the IL-4 promoter 
relatively quickly, at a time point omitted from the ChIP experiment. Alternatively, the 
delay in Brgl binding may be due to a more central role for histone acetylation in IL-4 
activation. The IL-4 promoter in naive and Th2 cells is modified in the basal state, with the 
promoter region immunoprecipitating with acetylated H3 (Grogan et al 2003). This basal 
chromatin modification may help to establish a permissive chromatin environment and 
prime the gene for rapid induction as IL-4 transcription is dependent on hyperacetylation of 
the promoter region (Valapour et al, 2002; Grogan et al, 2003). Thus, it appears that the IL-
4 promoter is primed for activation in a manner distinct to GM-CSF, with increased basal 
accessibility and histone acetylation playing a primary role in rapid activation with 
SWI/SNF binding occurring with more delayed kinetics. Perhaps this permissive chromatin 
environment helps mark the IL-4 promoter for rapid recruitment of Brgl. 
In comparison to GM-CSF, IFN- y and IL-4, the IL-5 gene is significantly delayed 
in its activation with levels elevated only at 24 hours post stimulation. It is therefore 
surprising that IL-5 was identified as a target of Brgl in the microarray experiments as 
these cells only received 6 hours of P/I stimulation. This appears to be due to IL-5 being 
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more responsive to WI in transfected cells as this result was validated by replicate real-time 
PCR experiments. The IL-5 promoter is highly compacted with basal accessibility 
extremely low with only a slight increase observed 24 hours post stimulation concomitant 
with transcriptional induction. This is supported by the findings of Siegel et al, (1995) who 
found that the IL-5 promoter region is protected from DNase I digestion. In addition 
increased sensitivity to DNase I was observed in regions bordering this site suggesting that 
like GM-CSF, the IL-5 proximal promoter is covered by a nucleosome (Cousins et al, 
2000). The delayed activation of IL-5 may therefore be attributed to the highly compacted 
promoter region. It is also possible that other co-activators are delayed in their nuclear 
translocation. In support of this, the activation of an IL-5 promoter-driven luciferase 
reporter in EL-4 T cells has previously been observed to take approximately 9 to 12 hours 
to become fully activated post stimulation (Wang et al, 2006). It is clear that activation in a 
chromatin context would be considerably slower due to the chromatin remodelling 
requirement. The delay in IL-5 activation may also be attributed to the delay in Brgl 
recruitment. At the two time points analyzed, Brg 1 was not detected at the IL-5 promoter, 
however it would be interesting to analyze Brgl recruitment over 24 hours to correlate 
gene activity and the presence of Brgl. Alternatively, IL-5 may be a secondary target of 
Brgl. 
It is evident that Brg 1 is involved in the activation of genes switched on rapidly and 
others which are activated with more delayed kinetics. Previous work in macrophages in 
which the ATPase was disrupted through the retroviral delivery of siRNA hairpins directed 
against Brgl found that Brgl is involved in the activation of late primary and secondary 
response genes (Ramirez-CatTozzi et al, 2006). Brg 1 was also found to be constitutively 
associated with the promoter regions of early primary response genes which parallels the 
findings presented here for the rapidly activated GM-CSF and IFN-y genes, although Brg 1 
did not appear to be required for their subsequent activation. 
The data presented in this chapter highlight a role for Brgl in immune regulation. 
Microarray analysis was successfully used to identify T cell genes dependent on Brgl for 
their activation. A number of cytokine genes were identified as Brgl targets including IFN-
y, IL-4 and IL-5. While each of these cytokines requires Brgl for optimal expression, there 
is some distinction between the transcription and chromatin remodelling profiles for each 
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gene. The divergent regulation of IFN-y, IL-4, IL-5 and GM-CSF suggests that although 
each gene requires Brg 1 for activation, IL-4 and IL-5 adopt a slightly different mechanism 
to GM-CSF and IFN-y for transcriptional induction. The inaccessible nature of the IL-5 
promoter and absence of Brg 1 recruitment may contribute to delayed transcription of the 
IL-5 gene. While the rapidly activated IL-4 gene exhibits increased basal promoter 
accessibility, IL-4 is not primed for activation by basal recruitment of Brgl. IFN-y was 
found to share a similar activation profile to GM-CSF and data presented here suggests it 
may be regulated by a common mechanism. As observed for GM-CSF, Brg 1 is 
constitutively poised at the IFN-y promoter in resting EL-4 T cells and lost from the 
promoter concomitant with gene activation. 
131 
CHAPTER 6 
CONCLUSIONS AND FUTURE DIRECTIONS 
Activation of the GM-CSF gene following immune stimulation has been studied 
extensively in the past however the mechanism underlying activation of the GM-CSF gene 
in a chromatin context has remained largely unstudied. The data presented in this thesis 
clearly demonstrate that GM-CSF promoter remodelling and gene transcription are distinct 
events. Each process can occur independently of the other and has different signalling and 
transcription factor requirements and different kinetics. While GM-CSF gene transcription 
relies on PKC and calcium signalling pathways, GM-CSF promoter remodelling requires 
the action of PKC alone. In addition the transcription factors activated downstream of T 
cell stimulation are involved in different processes. NFAT members are required for the 
optimal induction of GM-CSF gene transcription but are dispensable for promoter 
remodelling and this may be attributed to the requirement of NFAT in enhancer 
remodelling (Cockerill et al, 1993; Johnson et al, 2004). In contrast, NF-KB members, in 
particular c-Rel, are essential for chromatin remodelling events at the GM-CSF promoter. It 
is also clear that GM-CSF gene transcription and promoter remodelling show quite 
different kinetics. While transcription displays a transient profile, peaking within several 
hours of T cell activation, remodelling events at the GM-CSF promoter were relatively 
stable, being maintained over several days. The stability of promoter remodelling was 
closely correlated with the nuclear translocation of c-Rel, suggesting this factor may be 
involved in maintaining the remodelled state. The stability of remodelling also raises the 
question of whether increased accessibility to the GM-CSF promoter is maintained through 
cell division or reset at the beginning of the cell cycle and this would be interesting for 
further investigation. 
The precise mechanism involved in remodelling the GM-CSF promoter remains 
largely unknown. However, recently Chen et al (2005) demonstrated that the increase in 
GM-CSF promoter accessibility, observed during T cell activation, is due to loss of 
histones from the promoter. Here, an important role for the ATPase component of the 
SWI/SNF complex, Brg 1 was identified in GM-CSF transcriptional activation. Brg 1 is 
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essential for the optimal transcriptional activation of the GM-CSF gene, as a reduction in 
GM-CSF mRNA production was detected in T cells expressing a Brg 1 mutant protein. 
While Brgl defective T cells were still capable of GM-CSF promoter remodelling upon T 
cell stimulation, basal levels of accessibility were slightly increased and displayed more 
variability suggesting Brg 1 may be involved in maintaining the basal state of the promoter. 
Interestingly, the PI105 promoter can still be remodelled in the absence of SWI/SNF, 
however with delayed kinetics (Gadreau et al, 1997) thus it is possible that the kinetics of 
GM-CSF promoter remodelling was affected in a similar manner which was not detectable 
at the time point analyzed. 
A direct role for Brg 1 in GM-CSF gene activation was confirmed using the ChIP 
assay, which unexpectedly demonstrated that Brg 1 was constitutively recruited to the GM-
CSF promoter in resting T cells and lost from the promoter concomitant with histone loss, 
following T cell activation. Analysis of Brgl enrichment at the GM-CSF promoter in non-
expressing B cells demonstrated that Brg 1 is absent, providing further support for a role for 
Brg 1 in GM-CSF activation in T cells. This raised the question as to how Brgl is 
constitutively associated with the GM-CSF promoter in T cells. Evidently, the classic 
model in which SWI/SNF is recruited to gene regulatory elements by inducible 
transcription factors (eg. Agalioti et al, 2000, de la Serna et al, 2005) does not hold true in 
this case. It is possible that a constitutively expressed factor helps tether Brgl to the GM-
CSF promoter and this has been demonstrated in the case of the IFITM3 gene with Spl 
recruiting Brgl (Liu et al, 2002). Alternatively, Brg 1 may bind to the resting GM-CSF 
promoter via an interaction with acetylated histones as Brg 1 contains a bromodomain 
capable of such an interaction (Hassan et al, 2002). The data presented here suggest that the 
basal recruitment of Brg 1 may in fact be due to increased basal levels of histone acetylation 
as increasing the levels of acetylation lead to increased Brgl recruitment at the promoter 
and increased the rate of remodelling. In support of this increased histone acetylation has 
been detected across the GM-CSF promoter in T cells (Chen and Shannon, personal 
communication). 
The signal that drives histone loss and remodelling of the GM-CSF promoter 
remains unclear. Combining the Brg 1 data with the findings from Chapter 3 it is possible 
that the NF-KB family member, c-Rel, which is associated with GM-CSF promoter 
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remodelling, interacts with Brgl following T cell activation to drive histone loss. 
Confirmation of a role for c-Re! in GM-CSF promoter remodelling could be provided by 
determining Brg 1 recruitment and histone loss in c-Re14- or PTX treated T cells. A role for 
PKC signalling in chromatin remodelling at the GM-CSF promoter was also highlighted in 
Chapter 3. Previous work by Rando and colleagues (2002) found that phosphatidylinositol, 
activated downstream of PKC signalling, interacts with Brg 1 in vitro and enhances its 
affinity for chromatin. In addition, Zhao et al, (1998) also found that SWI/SNF binding 
after T cell activation was dependent on phosphoinositol. Therefore, it is possible that PKC 
signalling helps to increase the activity of Brg 1 and its affinity with chromatin to drive the 
loss of the nucleosome encompassing the GM-CSF promoter. PKC has also been found to 
directly phosphorylate a serine residue on histone H3 in vitro (Huang et al, 2004) and this 
ability to modify histone marks may influence the docking of other factors which direct 
nucleosome loss. Determining the role of histone chaperones in the loss of histones from 
the GM-CSF promoter would help to elucidate how this process occurs. 
The constitutive basal recruitment of Brg 1 to the GM-CSF promoter in T cells may 
be involved in generating a poised state with increased basal acetylation and increased 
Brg 1 recruitment priming the gene for rapid activation. Work by Ramirez-Carrozzi et al 
(2006) supports this hypothesis as Brgl was found to be constitutively associated with a 
number of early response genes including Cxcl2, Tnf and Ptgs2 in macrophages which are 
activated within minutes of LPS stimulation. However, in this case Brg I was not found to 
be essential for the transcriptional activation of these genes. 
The data presented in this thesis is consistent with a model in which GM-CSF is 
primed for rapid activation in T cells (Figure 6.1). An enrichment of acetylated histones is 
evident at the resting GM-CSF promoter (Chen and Shannon, unpublished data). This 
histone mark may potentially act as a docking site for the constitutive basal recruitment of 
Brg 1 . The enrichment of Brgl at the promoter may then help to establish a competent 
chromatin environment which can be remodelled rapidly. In response to T cell activating 
signals the nuclear translocation of c-Rel may direct the loss of histones from the GM-CSF 
promoter creating a highly accessible promoter region capable of binding the 
transcriptional machinery. Nucleosome loss is stably maintained potentially via prevention 
of nucleosome reassembly by c-Rel (Figure 6.1). Future work investigating the role of Brgl 
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Figure 6.1. Model for activation of the GM-CSF gene. Schematic 
representation of the GM-CSF promoter in the resting and activated state. 
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in remodelling the GM-CSF enhancer and the precise order of transcription factor 
recruitment events at the promoter would help to further clarify this model. 
In order to determine whether this mechanism is common to immune genes 
microarray analysis of Brg 1 defective T cells was used to identify Brg 1 targets. Transcripts 
from resting and activated T cells expressing a Brg 1 mutant construct were analyzed 
following hybridization to Affymetrix mouse genome arrays. An extremely defined 
question was asked in order to identify immune genes which were activated in a Brg 1 
dependent manner similar to GM-CSF. The cytokines IFN-y, IL-4 and IL-5 were identified 
as potential Brg 1 targets and chosen for futher analysis as these genes share a similar role 
in immune regulation as GM-CSF. It is important to note that only a small portion of the 
microarray data was used in this study and therefore these data could be further analyzed to 
consider the role of Brgl in other aspects of T cell activation. Analysis of the activation and 
remodelling profiles for each of the candidate genes demonstrated that while IL-4 and IFN-
y shared similar activation profiles to GM-CSF, the IL-5 gene was relatively delayed in its 
activation and promoter remodelling. Brgl recruitment was found to be different at each of 
these promoters. Brg 1 was bound to the IFN-y promoter in resting T cells and lost 
following T cell activation. In contrast, recruitment of Brgl to the IL-4 promoter required T 
cell activating signals. Brg 1 was not detected at the IL-5 promoter in resting T cells or 
those which had been activated for 4 hours and therefore could not be confirmed as a direct 
Brg 1 target. Future work should define Brg 1 recruitment over an extended time course in 
order to determine whether Brgl is recruited to the IL-4 promoter rapidly and the IL-5 
promoter in a more delayed manner. 
IL-4 and IFN-y have similar activation and remodelling profiles and ChIP 
demonstrated they are direct targets of Brgl. The constitutive recruitment of Brgl to the 
IFN-y and GM-CSF promoters suggests they may share a common model of activation. 
Perhaps IFN-y is poised in a similar manner to GM-CSF with increased levels of basal 
acetylation acting as a docking site for Brg 1 recruitment. Following T cell activation, the 
nucleosome covering the IFN-y promoter is rapidly remodelled, allowing the 
transcriptional machinery to assemble at a much faster rate. The delayed recruitment of 
Brgl to the IL-4 promoter is consistent with a number of published reports detailing a more 
traditional model of transcription factor mediated recruitment of remodelling activities 
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(Agalioti et al, 2000; de la Serna et al, 2005). In the case of IL-4, the promoter is relatively 
accessible in the basal state perhaps with slightly increased levels of histone acetylation. T 
cell activation signals are then required to trigger relatively rapid Brg 1 binding. Brg 1 can 
then further increase accessibility to the IL-4 promoter and enhance binding of the 
transcriptional machinery. The IL-5 gene is activated with much more delayed kinetics and 
this may be attributed to the requirement for histone acetylation and Brgl recruitment 
before chromatin remodelling can occur. 
It is possible that both the IFN-y and IL-4 promoters have slightly increased levels 
of histone acetylation to enhance Brg 1 recruitment. During Thl differentiation the IFN-y 
locus undergoes extensive H3 and H4 acetylation (Morinobu et al, 2004) and it is therefore 
possible that the constitutive recruitment of Brg 1 is via histone acetylation in Th 1 cells. 
Meanwhile, the IL-4 promoter is associated with acetylated H3 in Th2 cells (Grogan et al, 
2003) which could serve to mark the gene for rapid Brg 1 recruitment following T cell 
activation. 
The mechanisms involved in remodelling cytokine promoters to facilitate gene 
activation are known for only a small number of genes, however a common theme appears 
to be emerging. At the IFN-P promoter, NF-KB is bound first, within 2 hours of viral 
infection, followed by recruitment of the HAT, GCN5 at 5 hours. Brg 1 is then recruited at 
6 hours, at which point mRNA levels increase (Agalioti et al, 2000). The data presented in 
this thesis suggests that there may be a unifying theme in cytolcine gene regulation. While 
each gene is activated in a very specific, tightly co-ordinated manner, there appear to be 
some common features. The delay in IL-5 activation may be attributed to delays in histone 
acetylation and Brg 1 recruitment. Thus, transcription following T cell activation is slower, 
taking up to 24 hours for mRNA to accumulate. IFN-13 is potentially a few steps further 
along the activation profile, with acetylation and Brg 1 recruitment occurring more rapidly 
to ensure mRNA accumulates within 6 hours of viral infection (Agalioti et al, 2000). GM-
CSF and IFN-y activate even more rapidly, with increased transcription detected within less 
than an hour. This faster activation profile could be attributed to promoter priming, with 
increased levels of basal histone acetylation and Brgl recruitment. Even faster activation is 
observed at the IL-113 gene in macrophages, with transcription increasing within a matter of 
minutes of activation with LPS and peaking within three to four hours (Liang et al, 2006). 
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Figure 6.2. An emerging theme for the activation of cytokine genes. Schematic 
representation of the IL-5, IFN-13, IFN-y, GM-CSF and IL-10 promoters, their 
remodelling requirements and transcriptional profiles showing the role of histone 
acetylation and Brg 1 in activation. 
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The IL-113 promoter is nucleosome free in the basal state with high levels of accessibility. 
This means that the only rate limiting step in transcription in this case is the assembly of 
the transcriptional machinery (Figure 6.2). 
The role of Brgl in the activation of early versus delayed response immune genes is 
interesting to consider. A clear example of a role for Brgl in activating immune genes is 
provided by studies on the IL-12b promoter. Brg 1 is required for IL-12b promoter and 
enhancer remodelling as depletion of Brgl by siRNA in macrophages inhibits LPS induced 
increases in accessibility (Ramirez-Carrozzi et al, 2006). Similar to GM-CSF, IL-12b 
mRNA accumulates approximately 2 hours post stimulation, however unlike GM-CSF, 
Brgl is recruited to the IL-12b promoter following LPS stimulation of macrophages. The 
loss of Brgl did not impact on expression of early primary response genes (activated within 
minutes of stimulation) however while Brgl was found to be recruited to late primary 
response and secondary response genes in an LPS induced manner, Brgl was actually 
found to be constitutively associated with the early primary response promoters. This 
suggests that Brgl may establish or maintain a poised chromatin environment for rapidly 
activated genes in macrophages (Ramirez-Carrozzi et al, 2006). 
The link between Brg 1 and DNA methylation in priming genes for activation is also 
interesting to consider. Banine et al (2005) found that the restoration of Brg 1 to deficient 
cells lead to demethylation of target promoters. Aberrant DNA methylation has long been 
established as a feature of cancerous cells (reviewed in Baylin, 2005) and therefore the loss 
of Brgl and its role in cancer requires further study. Indeed, a number of published reports 
have revealed that Brg 1 is mutated in cancerous cell lines (Wong et al, 2000; Reisman et 
al, 2002) and primary tumors (Medina et al, 2004). Therefore, in terms of the clinical 
implications of this work, it will be important to screen myeloid leukemias in which GM-
CSF is aberrantly expressed for mutations in Brg 1 and investigate how Brg 1 impacts the 
methylation status of the GM-CSF gene. Investigating changes in the methylation status of 
the GM-CSF gene in cells transfected with the Brg 1 mutant could provide further insight 
into the mechanisms involved in GM-CSF gene activation. Indeed, the GM-CSF promoter 
has found to be methylated in Brg 1 deficient C33A cells and is demethylated in expressing 
EL-4 T cells (Sprod and Holloway, personal communication). 
By defining the molecular events in GM-CSF gene activation, some insight has 
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been gained into the mechanisms operating to activate immune genes in a chromatin 
context. Highly ordered and specific signals and recruitment events are required to drive 
remodelling and transcription of the GM-CSF gene. Most importantly, all these features 
contribute to the most important aspect of GM-CSF induction, its rapid and transient 
nature. In addition, from these data, together with studies emerging in the literature, 
common themes underlying activation of immune genes are beginning to emerge. 
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APPENDIX A 
Combined gene list for replicate 1 and 2 for genes with reduced activation in Brgl 
mutant expressing cells. 
Gene Name 
1445937_at 
1446082_at 
1445521_at 
1446430_at 
1445097_at 
1448039_at 
1449235_at 
1449298_a_at 
1447087_at 
1447135_at 
1447041_at 
1447647_at 
1447374_at 
1441298_at 
1441044_at 
1442178_at 
1441662_at 
1440716_at 
1440893_at 
1441738_at 
1440742_at 
1440558_at 
1443474_at 
1443919_at 
Description 
Transcribed sequences 
15 days embryo head cDNA, RIKEN full-length enriched 
library, clone:D930048E06 product:unknown EST, full insert 
sequence 
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 
(Hu antigen R) 
RIKEN cDNA A630025009 gene 
L0210E07-3 NIA Mouse Newborn Ovary cDNA Library Mus 
musculus cDNA clone L0210E07 3', mRNA sequence. 
ujO4e02.xl Sugano mouse liver mlia Mus musculus cDNA clone 
IMAGE: 1890938 3' similar to gb:M29281 Mouse complement 
receptor (MOUSE);, mRNA sequence. 
tumor necrosis factor (ligand) superfamily, member 6 
phosphodiesterase 1A, calmodulin-dependent 
Transcribed sequences 
Transcribed sequences 
BB124417 RIKEN full-length enriched, adult male urinary 
bladder Mus musculus cDNA clone 9530097L15 3', mRNA 
sequence. 
wingless-related MMTV integration site 7A 
0 day neonate lung cDNA, RIKEN full-length enriched library, 
clone:E030033D05 product:weakly similar to DNA-BINDING 
PROTEIN [Rattus norvegicus], full insert sequence 
spectrin beta 3 
16 days embryo head cDNA, RIKEN full-length enriched 
library, clone:C130002M15 product:unknown EST, full insert 
sequence 
Transcribed sequences 
cytochrome P450, family 4, subfamily x, polypeptide 1 
Adult male spinal cord cDNA, RIKEN full-length enriched 
library, clone:A330051C14 product:unknown EST, full insert 
sequence 
RIO kinase 1 (yeast) 
CO502C08-3 MA Mouse E13.5 VMB Dopamine cell cDNA 
Library Mus musculus cDNA clone CO502C08 3', mRNA 
sequence. 
Transcribed sequences 
ATPase, class II, type 9B 
Transcribed sequences 
RIKEN cDNA B230206N24 gene 
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Gene Name 	Description 
1442550_at Transcribed sequences 
1442600_at 	0 day neonate cerebellum cDNA, RIKEN full-length enriched 
library, clone:C230008G15 product:unknown EST, full insert 
sequence 
1457423_at 	Transcribed sequence with moderate similarity to protein 
pdb:1LBG (E. coli) B Chain B, Lactose Operon Repressor 
Bound To 21-Base Pair Symmetric Operator Dna, Alpha 
Carbons Only 
1457608_at 	BB236014 RIKEN full-length enriched, 3 days neonate thymus 
Mus musculus cDNA clone A630056003 3', mRNA sequence. 
1456847_at 	Transcribed sequence with strong similarity to protein sp:P00722 
(E. coli) BGAL_ECOLI Beta-galactosidase 
1456564_at 	 RIKEN cDNA CO30046101 gene 
1459447_at Transcribed sequences 
1460271_at 	 triggering receptor expressed on myeloid cells 3 
1460088_at AV209518 RIKEN full-length enriched, adult male testis Mus 
musculus cDNA clone 1700120A01 3', mRNA sequence. 
1460104_at 	 vacuolar protein sorting 4b (yeast) 
1458025_at Transcribed sequences 
1452309_at 	RIKEN cDNA 4933421H10 gene 
1451837_at adaptor-related protein complex 3, beta 2 subunit 
1452028_a_at 	cadherin 23 (otocadherin) 
1449864_at interleukin 4 
1449903_at 	cytotoxic and regulatory T cell molecule 
1449900_at 601776377F1 NCI_CGAP_Lu29 Mus musculus cDNA clone 
IMAGE:4017906 5', mRNA sequence. 
1449988_at 	 immunity-associated protein 
1449652_at AV318995 RIKEN full-length enriched, 13 days embryo male 
testis Mus musculus cDNA clone 6030403F05 3', mRNA 
sequence. 
1450716_at 	 a disintegrin-like and metalloprotease (reprolysin type) with 
thrombospondin type 1 motif, 1 
1450869_at 	 fibroblast growth factor 1 
1450829_at tumor necrosis factor, alpha-induced protein 3 
1450375_at 	 persephin 
1455186_a_at RIKEN cDNA 1190003J15 gene 
1453075_at 	 RIKEN cDNA 1600012P17 gene 
1453210_at Mus musculus 8 days embryo whole body cDNA, RIKEN full- 
length enriched library, clone:5730507C01 product:similar to 
ZINC FINGER PROTEIN 125 (FRAGMENT) [Mus musculus], 
full insert sequence. 
1453874_at 	 RIKEN cDNA 4933401B06 gene 
1453437_at RIKEN cDNA A230020K05 gene 
1425071_s_at 	neurotrophic tyrosine kinase, receptor, type 3 
1424376_at CDC42 effector protein (Rho GTPase binding) 1 
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Gene Name 	Description 
1424647_at gamma-aminobutyric acid (GABA-A) receptor, pi 
1425569_a_at 	signaling lymphocytic activation molecule family member 1 
1425471_x_at Mus musculus cDNA clone MGC:6439 IMAGE:3601769, 
complete cds. 
1425720_at 	CDNA clone MGC:12025 IMAGE:3603243, complete cds 
1425225_at Fc receptor-like 3 
1423061_at 	armadillo repeat gene deleted in velo-cardio-facial syndrome 
1422397_a_at interleulcin 15 receptor, alpha chain 
1427828_at 	Mus musculus murine retrovirus readthrough RNA sequence. 
1426632_at Similar to hypothetical protein MGC2376 (L0C233529), mRNA 
1425947_at 	 interferon gamma 
1426180_a_at submaxillary gland androgen regulated protein 2 
1426176_a_at 	prokineticin 2 
1426071_at progressive ankylosis 
1419431_at 	epiregulin 
1418900_at RIKEN cDNA 1810045K17 gene 
1418018_at 	carboxypeptidase D 
1417496_at BB332449 RIKEN full-length enriched, 6 days neonate medulla 
oblongata Mus musculus cDNA clone B730048G11 3', mRNA 
sequence. 
1419651_at 	RIKEN cDNA 2610200G18 gene 
1419628_at C. elegans ceh-10 homeo domain containing homolog 
1420593_a_at 	TEA domain family member 3 
1420888_at Bc12-like 
1420887_a_at 	Bc12-like 
1420700_s_at folate receptor 4 (delta) 
1420532_at 	activin receptor interacting protein 1 
1435523_s_at 11 days embryo head cDNA, RIKEN full-length enriched 
library, clone:6230415F21 product:unknown EST, full insert 
sequence 
1435508_x_at 	RIKEN cDNA 0610009D07 gene 
1439043_at RIKEN cDNA 1500010G04 gene 
1438927_x_at 	Similar to 60S ribosomal protein L23a (L0C270584), mRNA 
1439110_at RIKEN cDNA A930012016 gene 
1439816_at 	Transcribed sequences 
1439485_at RIKEN cDNA 4932417D18 gene 
1437937_at 	chemokine binding protein 2 
1438570_at Transcribed sequences 
1437360_at 	RIKEN cDNA B530002L05 gene 
1430070_at RIKEN cDNA 1500035N22 gene 
1430843_at 	RIKEN cDNA 1110027M19 gene 
1428943_at RIKEN cDNA 4933433B15 gene 
1429657_at 	 UI-M-BH1-anr-b-02-0-UI.s1 NIH BMAP M S2 Mus musculus 
cDNA clone UI-M-BH1-anr-b-02-0-UI 3',—mR1\1— A sequence. 
1433573_x_at 	protease, serine, 2 
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Gene Name 	Description' 
143297 l_at Adult male testis cDNA, RIKEN full-length enriched library, 
clone:4921518B13 product:unclassifiable, full insert sequence 
1432891_at 	 dehydrogenase/reductase (SDR family) member 7 
1432888_at Adult male testis cDNA, RIICEN full-length enriched library, 
clone:4930455M05 product: unclassifiable, full insert sequence 
1432864_at 	 10 days lactation, adult female mammary gland cDNA, RIKEN 
full-length enriched library, clone:D730050C22 
product:unclassifiable, full insert sequence 
1432959_at 	 Adult male testis cDNA, RIKEN full-length enriched library, 
clone:4930447122 product:unknown EST, full insert sequence 
1431626_at 	Adult male testis cDNA, RIKEN full-length enriched library, 
clone:4933429K18 product:unclassifiable, full insert sequence 
1432795_at 	Adult male tongue cDNA, RIKEN full-length enriched library, 
clone:2310058F05 product:unclassifiable, full insert sequence 
1432155_at 	Wiskott-Aldrich syndrome-like (human) 
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